
<html lang="en"     class="pb-page"  data-request-id="60cd29f4-dfd8-4569-9da4-3370749a8bfc"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2012.55.issue-6;article:article:10.1021/jm201454n"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis" /></meta><meta name="dc.Creator" content="Anthony D.  William" /></meta><meta name="dc.Creator" content="Angeline C.-H.  Lee" /></meta><meta name="dc.Creator" content="Anders  Poulsen" /></meta><meta name="dc.Creator" content="Kee Chuan  Goh" /></meta><meta name="dc.Creator" content="Babita  Madan" /></meta><meta name="dc.Creator" content="Stefan  Hart" /></meta><meta name="dc.Creator" content="Evelyn  Tan" /></meta><meta name="dc.Creator" content="Haishan  Wang" /></meta><meta name="dc.Creator" content="Harish  Nagaraj" /></meta><meta name="dc.Creator" content="Dizhong  Chen" /></meta><meta name="dc.Creator" content="Chai Ping  Lee" /></meta><meta name="dc.Creator" content="Eric T.  Sun" /></meta><meta name="dc.Creator" content="Ramesh  Jayaraman" /></meta><meta name="dc.Creator" content="Mohammad Khalid  Pasha" /></meta><meta name="dc.Creator" content="Kantharaj  Ethirajulu" /></meta><meta name="dc.Creator" content="Jeanette M.  Wood" /></meta><meta name="dc.Creator" content="Brian W.  Dymock" /></meta><meta name="dc.Description" content="Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within the JAK family and FLT3 kinase. Following a multiparameter optimizati..." /></meta><meta name="Description" content="Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within the JAK family and FLT3 kinase. Following a multiparameter optimizati..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 6, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm201454n" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm201454n" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm201454n" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm201454n" /></link>
        
    
    

<title>Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm201454n" /></meta><meta property="og:title" content="Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0011.jpeg" /></meta><meta property="og:description" content="Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within the JAK family and FLT3 kinase. Following a multiparameter optimization of a key aryl ring of the previously described SB1518 (pacritinib), the highly soluble 14l was selected as the optimal compound. Oral efficacy in the murine collagen-induced arthritis (CIA) model for rheumatoid arthritis (RA) supported 14l as a potential treatment for autoimmune diseases and inflammatory disorders such as psoriasis and RA. Compound 14l (SB1578) was progressed into development and is currently undergoing phase 1 clinical trials in healthy volunteers." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within the JAK family and FLT3 kinase. Following a multiparameter optimization of a key aryl ring of the previously described SB1518 (pacritinib), the highly soluble 14l was selected as the optimal compound. Oral efficacy in the murine collagen-induced arthritis (CIA) model for rheumatoid arthritis (RA) supported 14l as a potential treatment for autoimmune diseases and inflammatory disorders such as psoriasis and RA. Compound 14l (SB1578) was progressed into development and is currently undergoing phase 1 clinical trials in healthy volunteers." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0011.jpeg" /></meta><meta name="twitter:title" content="Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm201454n"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm201454n">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm201454n&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm201454n&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm201454n&amp;href=/doi/10.1021/jm201454n" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2623-2640</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm2014259" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm2014698" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of the Macrocycle (9<i>E</i>)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony+D.++William">Anthony D. William</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Angeline+C.-H.++Lee">Angeline C.-H. Lee</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anders++Poulsen">Anders Poulsen</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kee+Chuan++Goh">Kee Chuan Goh</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Babita++Madan">Babita Madan</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Hart">Stefan Hart</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Evelyn++Tan">Evelyn Tan</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Haishan++Wang">Haishan Wang</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Harish++Nagaraj">Harish Nagaraj</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dizhong++Chen">Dizhong Chen</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chai+Ping++Lee">Chai Ping Lee</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eric+T.++Sun">Eric T. Sun</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ramesh++Jayaraman">Ramesh Jayaraman</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mohammad+Khalid++Pasha">Mohammad Khalid Pasha</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kantharaj++Ethirajulu">Kantharaj Ethirajulu</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeanette+M.++Wood">Jeanette M. Wood</a></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+W.++Dymock">Brian W. Dymock</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">S*BIO Pte. Ltd., 1 Science Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore 117528</span></div><div class="corresp-info"><strong>*</strong>Tel: +65 62195443. E-mail: <a href="/cdn-cgi/l/email-protection#a2d5c3ccd6cacdccdb9393e2dbc3cacdcd8cc1cdcf"><span class="__cf_email__" data-cfemail="3443555a405c5b5a4d0505744d555c5b5b1a575b59">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm201454n&amp;href=/doi/10.1021%2Fjm201454n" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2623â2640</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 17, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 October 2011</li><li><span class="item_label"><b>Published</b> online</span>6 March 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 March 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm201454n" title="DOI URL">https://doi.org/10.1021/jm201454n</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2623%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAnthony%2BD.%2BWilliam%252C%2BAngeline%2BC.-H.%2BLee%252C%2BAnders%2BPoulsen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D6%26contentID%3Djm201454n%26title%3DDiscovery%2Bof%2Bthe%2BMacrocycle%2B%25289E%2529-15-%25282-%2528Pyrrolidin-1-yl%2529ethoxy%2529-7%252C12%252C25-trioxa-19%252C21%252C24-triaza-tetracyclo%255B18.3.1.1%25282%252C5%2529.1%252814%252C18%2529%255Dhexacosa-1%252824%2529%252C2%252C4%252C9%252C14%252826%2529%252C15%252C17%252C20%252C22-nonaene%2B%2528SB1578%2529%252C%2Ba%2BPotent%2BInhibitor%2Bof%2BJanus%2BKinase%2B2%252FFms-LikeTyrosine%2BKinase-3%2B%2528JAK2%252FFLT3%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BRheumatoid%2BArthritis%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2640%26publicationDate%3DMarch%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm201454n"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3547</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">29</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm201454n" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;D. William&quot;},{&quot;first_name&quot;:&quot;Angeline&quot;,&quot;last_name&quot;:&quot;C.-H. Lee&quot;},{&quot;first_name&quot;:&quot;Anders&quot;,&quot;last_name&quot;:&quot;Poulsen&quot;},{&quot;first_name&quot;:&quot;Kee&quot;,&quot;last_name&quot;:&quot;Chuan Goh&quot;},{&quot;first_name&quot;:&quot;Babita&quot;,&quot;last_name&quot;:&quot;Madan&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Hart&quot;},{&quot;first_name&quot;:&quot;Evelyn&quot;,&quot;last_name&quot;:&quot;Tan&quot;},{&quot;first_name&quot;:&quot;Haishan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Harish&quot;,&quot;last_name&quot;:&quot;Nagaraj&quot;},{&quot;first_name&quot;:&quot;Dizhong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Chai&quot;,&quot;last_name&quot;:&quot;Ping Lee&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;T. Sun&quot;},{&quot;first_name&quot;:&quot;Ramesh&quot;,&quot;last_name&quot;:&quot;Jayaraman&quot;},{&quot;first_name&quot;:&quot;Mohammad&quot;,&quot;last_name&quot;:&quot;Khalid Pasha&quot;},{&quot;first_name&quot;:&quot;Kantharaj&quot;,&quot;last_name&quot;:&quot;Ethirajulu&quot;},{&quot;first_name&quot;:&quot;Jeanette&quot;,&quot;last_name&quot;:&quot;M. Wood&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;W. Dymock&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;2623-2640&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm201454n&quot;},&quot;abstract&quot;:&quot;Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within the JAK family and FLT3 kinase. Following a multiparameter optimization of a key aryl ring of the previously described SB1518 (pacritinib), the highly soluble 14l was selected as the optimal compound. Oral efficacy in the murine collagen-induced arthritis (CIA) model for rheumatoid arthritis (RA) supported 14l as a potential treatment for autoimmune diseases and inflammatory disorders such as psoriasis and RA. Compound 14l (SB1578) was progressed into development and is currently undergoing phase 1 clinical trials in healthy volunteers.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201454n&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201454n" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201454n&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201454n" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201454n&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201454n" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm201454n&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201454n&amp;href=/doi/10.1021/jm201454n" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm201454n" /></input><a href="/doi/pdf/10.1021/jm201454n" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm201454n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm201454n%26sid%3Dliteratum%253Aachs%26pmid%3D22339472%26genre%3Darticle%26aulast%3DWilliam%26date%3D2012%26atitle%3DDiscovery%2Bof%2Bthe%2BMacrocycle%2B%25289E%2529-15-%25282-%2528Pyrrolidin-1-yl%2529ethoxy%2529-7%252C12%252C25-trioxa-19%252C21%252C24-triaza-tetracyclo%255B18.3.1.1%25282%252C5%2529.1%252814%252C18%2529%255Dhexacosa-1%252824%2529%252C2%252C4%252C9%252C14%252826%2529%252C15%252C17%252C20%252C22-nonaene%2B%2528SB1578%2529%252C%2Ba%2BPotent%2BInhibitor%2Bof%2BJanus%2BKinase%2B2%252FFms-LikeTyrosine%2BKinase-3%2B%2528JAK2%252FFLT3%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BRheumatoid%2BArthritis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D6%26spage%3D2623%26epage%3D2640%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292588" title="Partition coefficient">Partition coefficient</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=291163" title="Macrocycles">Macrocycles</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/6" title="Go to Volume 55, Issue 6"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jmcmar.2012.55.issue-6/production/jmcmar.2012.55.issue-6.largecover.jpg" alt="Go to Volume 55, Issue 6"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within the JAK family and FLT3 kinase. Following a multiparameter optimization of a key aryl ring of the previously described SB1518 (pacritinib), the highly soluble <b>14l</b> was selected as the optimal compound. Oral efficacy in the murine collagen-induced arthritis (CIA) model for rheumatoid arthritis (RA) supported <b>14l</b> as a potential treatment for autoimmune diseases and inflammatory disorders such as psoriasis and RA. Compound <b>14l</b> (SB1578) was progressed into development and is currently undergoing phase 1 clinical trials in healthy volunteers.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61254" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61254" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">An estimated 1% of the worldâs population is afflicted by rheumatoid arthritis (RA), a chronic, systemic inflammatory disorder leading to the destruction of articular cartilage and ankylosis of the joints.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> RA is a disabling and painful condition, which leads to substantial loss of functioning and mobility if not adequately treated. Nonpharmacological treatment includes physical, occupational, and nutritional therapy, but these do not stop the progression of joint destruction. Analgesic and anti-inflammatory drugs, including steroids, are used to suppress the symptoms, while disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, hydroxychloroquin, and sulfasalazine, modify the underlying immune process in an effort to prevent long-term damage.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Although many patients derive benefit from DMARDs, few achieve remission, and there are many adverse events related to the liver, bone marrow, and renal toxicity, allergic skin reactions, autoimmunity and infections. More recently, the advent of biological agents targeted at pro-inflammatory cytokines, such as the anti-TNFÎ± drugs etanercept, infliximab, and adalimumab, have successfully suppressed inflammation in many individuals with rheumatoid arthritis (RA).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> However, these and other biologics are expensive drugs with significant side effects, and the majority of patients relapse when treatment is withdrawn.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Inhibition of protein kinases implicated in cytokine signaling networks has emerged as a potential new treatment paradigm for RA.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The hematopoietin family of cytokines, which includes several postulated to have roles in RA (e.g., interferons, IL-2, IL-6, IL-7, IL-12, and IL-15), bind to Type I and II cytokine receptors and signal through the janus kinase-signal transducer and activator of the transcription (JAK-STAT) pathway.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> There are 4 members of the JAK kinase family (JAK1, JAK2, JAK3, and TYK2 (tyrosine kinase 2)) which play essential roles in several important physiological processes such as hematopoiesis and lipid homeostasis.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> JAK inhibitors with a range of selectivity profiles have been described with many now in clinical trials for treatment of various cancers (JAK1/2) and for immunosuppressive disorders (JAK3).<a onclick="showRef(event, 'ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17">(8-17)</a> However, the immunosuppressive effects of inhibiting JAK3 may cause severe combined immunodeficiency syndrome (SCID); hence, targeting selected JAK proteins is thought to be desirable. JAK2 plays an essential role in the signaling of pro-inflammatory cytokines involved in the pathogenesis of RA.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Hence, JAK2 specific inhibitors may be differentiated from other JAK inhibitors and produce therapeutic benefits in inflammatory autoimmune diseases without immunosuppression. TYK2 is involved in Type I IFN signaling, and mice with a mutation in TYK2 have reduced susceptibility to collagen-induced arthritis.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> FLT3 (fms-like tyrosine kinase 3), a class III receptor tyrosine kinase, has been implicated in RA through high levels of expression of FLT3-ligand at the site of inflammation in RA patients.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In a mouse antigen-induced arthritis (AIA) model treatment with the FLT3 inhibitor sunitinib reduced the intensity of synovitis and the incidence of bone destruction.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p">Given the above evidence for therapeutic intervention via blockade of kinase signaling pathways implicated in RA, a specific JAK2/FLT3/TYK2 antagonist may have therapeutic potential.</div><div class="NLM_p">We have recently reported the discovery of pacritinib (SB1518, (<b>2</b>, where R<sub>2</sub> = <i>N</i>-pyrrolidinylethoxy, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), a unique macrocyclic JAK2/FLT3/TYK2 inhibitor currently in clinical development for myelofibrosis, lymphoma, and other cancers,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and SB1317/TG02 (<b>3</b>, R<sub>1</sub> = Me, R<sub>2</sub> = H), a CDK/JAK2/FLT3 inhibitor for the treatment of advanced leukemias and multiple myeloma.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Herein, we describe the discovery of a further series of macrocycles targeting JAK2, FLT3, and TYK2 kinases, a compelling profile for the treatment of rheumatoid arthritis (RA).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0013.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Modulating the macrocycle phenyl ring system.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i2" class="anchor-spacer"></div><h3 class="article-section__title" id="_i2"> Chemistry</h3><div class="NLM_p">We were inspired to continue to evolve the macrocycle theme aiming to develop a compound with higher selectivity, particularly against JAK3, a higher therapeutic window for nononcology applications, and improved solubility (lower cLogP), hence improving and differentiating from the first generation series.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> We set ourselves the challenge of fine-tuning various aspects of both series described above, searching for a higher selectivity for JAK2 within the janus kinase family, while achieving our solubility goals. We set out to explore a wide range of heterocyclic rings, both saturated and unsaturated, as well as, monocyclic and bicyclic, in the biaryl-pyrimidine system (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).</div><div class="NLM_p">Synthesis of the macrocycles via the Ring Closing Metathesis (RCM) reaction pioneered by Grubbs was carried out as previously reported employing either Grubbs second generation catalyst ((C<sub>46</sub>H<sub>65</sub>Cl<sub>2</sub>N<sub>2</sub>PRu), [1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro(phenylmethylene)(tricyclohexylphosphine)ruthenium), or Zhan-1B catalyst ((RuCl<sub>2</sub>[C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>][C<sub>12</sub>H<sub>17</sub>NO<sub>3</sub>S]), 1,3-Bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene[2-(isopropoxy)-5-(<i>N</i>,<i>N</i>-dimethylaminosulfonyl)phenyl]methylene ruthenium(II) dichloride).<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> Most products were isolated as predominately trans isomers, with a minority as inseparable mixtures of geometrical isomers. Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a> illustrate the synthetic routes for construction of the left-hand and right-hand fragments, respectively.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0014.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) 3-piperidinemethanol, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 93%. (b) Allyl bromide, NaH (60% in mineral oil), â78 Â°Cârt, 52%. (c) Pd(dppf)Cl<sub>2</sub>Â·CH<sub>2</sub>Cl<sub>2</sub> (1:1), Na<sub>2</sub>CO<sub>3</sub>, 1,2-dimethoxyethane, water, 80 Â°C, 58â92%. (d) 4-Bromobut-1-ene/allyl bromide, NaH (60% in mineral oil), DMF, rt, 62â77%. (e) NaBH<sub>4</sub>, THF, MeOH, 0 Â°C, 70â94%. (f) Allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 46â84%.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0001.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) <i>N</i>-Allylmethyl amine, Na(OAc)<sub>3</sub>BH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 75â95%. (b) SnCl<sub>2</sub>Â·2H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1), rt, 64â98%. (c) Allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 55â78%. (d) 2-Bromoethyl methyl ether, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 Â°C, 86%. (e) 1,2-Dichloroethane, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 Â°C, 72%. (f) NaBH<sub>4</sub>, THF, water, 0 Â°C, 94%. (g) Pyrrolidine, DMA, 90 Â°C, 75â78%.</p></p></figure><div class="NLM_p">Herein, we have introduced both saturated and unsaturated ring systems to the left-hand fragments: commercially available 2,4-dichloropyrimidine (<b>1a</b>) reacted readily with 4-piperidinemethanol under mild basic conditions to afford primary alcohol <b>4a</b>. Sodium hydride-assisted displacement with allyl bromide furnished allylether <b>5a</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Suzuki coupling of <b>1a</b> with heterocyclic boronic acids or esters <b>3a</b>â<b>h</b> gave rise to a diverse range of intermediates. Indolylpyrimidines <b>4b</b> and <b>4q</b> were subsequently alkylated with either 4-bromo-1-butene, giving <b>5b</b>, or allyl bromide to give <b>5c</b> and <b>5j</b>. Thiophenes <b>4h</b> and <b>4j</b>, furans <b>4c</b>, <b>4l</b>, and <b>4n</b>, and 3-pyridyl <b>4f</b> aldehyde Suzuki products were readily reduced to alcohols by sodium borohydride, and alkylation of the alcohols was achieved under phase transfer conditions with allyl bromide, giving allylethers <b>5d</b>â<b>i</b> in moderate to good yield (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).</div><div class="NLM_p">Methods for preparing right-hand fragments <b>10a</b>â<b>e</b> have been previously reported for analogous compounds.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> Reductive amination of 3-nitrobenzaldehye (<b>6a</b>) with <i>N</i>-methyl-allylamine followed by tin chloride reduction of the nitro group gave aniline <b>10a</b>. In a similar reduction/allylation/reduction sequence, <b>10b</b> was formed from <b>6b</b> following an initial alkylation with bromoethylmethyl ether. Alternatively, alkylation of <b>6b</b> with 1,2-dichloroethane gives versatile intermediate <b>6d</b>, which was reductively aminated, as for <b>8a</b>, then aminated with pyrrolidine before nitro reduction to furnish <b>10c</b>. Allylation of <b>7a</b> gave <b>9a</b> in moderate to good yield, followed by nitro reduction to give anline <b>10d</b>. Facile reduction of <b>6d</b> to <b>7d</b> followed by allylation, pyrrolidine displacement, and nitro reduction furnished aniline <b>10e</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).</div><div class="NLM_p">Terminal alkenes <b>10a</b>â<b>e</b> were coupled with the left-hand fragments <b>5a</b>â<b>j</b> in a high yielding acidic displacement using hydrochloric acid (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). Ruthenium catalyzed RCM directly formed macrocycles <b>13a</b>â<b>c</b>, <b>13e</b>â<b>h</b>, <b>14a</b>â<b>d</b>, and <b>14f</b>â<b>n</b> (Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Following coupling of 2-fluoropyridyl biaryls <b>4e</b> and <b>4p</b> with <b>10a</b> and <b>10c</b>, fluoride displacement with 3-buten-1-ol, under basic conditions, produced the desired dienes in moderate yields. Macrocyclisation with Grubbs second generation catalyst, using hydrochloric acid as an addictive, to neutralize the basic center, provided macrocyclic 2-pyridyl ethers <b>13d</b>, <b>14d</b>, and <b>14e</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0002.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) 4 M HCl, <i>n</i>-butanol, 80â100 Â°C, 81â86%. (b) 3-Buten-1-ol, NaH (60% in mineral oil), THF, 0 Â°C, 36â48%. (c). Grubbs second generation or Zhan catalyst, HCl, CH<sub>2</sub>Cl<sub>2</sub>, 45 Â°C, 36â76%.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of Macrocycles with Hetero-Atomic Ring Bi-Aryl to Pyrimidine</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0003.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All compounds were isolated as c.95:5 trans/cis mixtures.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">All IC<sub>50</sub> values are the mean Â± SD of at least two independent experiments.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Study of Aromatic Ring Substitutions with Small Groups for Fine Tuning Selectivity and Solubility</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0004.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0005.gif" alt="" id="GRAPHIC-d1327e752-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">All compounds were isolated as c.95:5 trans/cis mixtures.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">All IC<sub>50</sub> values are the mean Â± SD of at least two independent experiments.</p></div></div><div></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14480" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14480" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Preliminary Study of HeterocycleâLinker Combinations</h3><div class="NLM_p">Linkers of 8 atoms in length between the meta positions of both aryl groups were previously found to be optimal in a series of phenyl-pyrimidine compounds.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> A selection of those linkers combined with (i) saturated; (ii) 5- or 6-membered; and (iii) bicyclic heterocycles were installed in some initial exploratory compounds. We rapidly lost interest in saturated compounds given the complete lack of activity of <b>13a</b>. However, other saturated series, with shorter linkers, were more active and will be reported in a future publication. Focusing on heteroaromatic rings, we decided to maintain the macrocycle ring size at either 17 or 18 atoms, which was found to be optimal for JAK2 activity in the phenyl series.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Incorporation of a bicyclic indole into the structure was possible with these restrictions giving <b>13b</b> and <b>13c</b>. Both compounds were potent against FLT3 and selective against JAK3, two key aspects of our target profile. However, only <b>13c</b> was potent against JAK2, the observed 10-fold JAK2 potency difference may be explained by the larger ring size of <b>13b</b> leading to some unfavorable clashes with the protein (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). More importantly, both compounds were active against CDK2 in the same concentration range as FLT3, a critical selectivity issue. Given this negative aspect and the generally greater challenges of synthesizing the indole macrocycles, we focused our attention on monocyclic rings. Pyridyl rings with the basic linker, such as <b>13d</b>, retained their high potency for CDK2 as expected but unfortunately lost JAK2 potency as compared to the corresponding phenyl ring (CDK2 IC<sub>50</sub> 0.013 Î¼M and JAK2 IC<sub>50</sub> 0.073 Î¼M).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> CDK2 selectivity can be increased by exchanging the basic center in the linker for an ether oxygen, as in <b>13e</b>, but surprisingly, JAK2 potency was completely abolished. This appears to be due to the placement of the pyridyl nitrogen, which is in a highly unfavorable location with regard to Asp994. Since the pyridyl is not protonated, the opportunity to interact with Asp994 is lost, and instead, a repulsive interaction forces the ligand out of the binding site (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). This is significantly reversed on changing the nature of the linker to a neutral ether group (<b>13f</b>), although selectivity for JAK1 and 3 has been achieved, CDK2 potency is high, whereas JAK2 and FLT3 activity is weak. The smaller furan ring, with its hydrogens projecting externally from the macrocycle, was then explored with the same two linker types for comparison. Basic <b>13g</b> was a generally uninteresting moderately potent CDK2 inhibitor, but <b>13h</b> was much more interesting with submicromolar JAK2, TYK2, and FLT3 potency, as well as selectivity for JAK1 and 3. CDK2 potency is still a major issue (see Figure S2, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>), but we felt this series was worthy of further work to attempt to improve potency against the key targets and eliminate CDK2 activity.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Compound <b>13c</b> docked into JAK2. Hydrogen bonds are shown in magenta dashed lines and close contacts in orange dashed lines. The only close contact between <b>13c</b> and JAK2 is between the backbone carbonyl of Glu930 and the free hydrogen next to the pyrimidine nitrogen of <b>13c</b>. This is an attractive interaction and may be described as a weak hydrogen bond. (B) Compound <b>13b</b> docked into JAK2. The macrocyclic linker of <b>13b</b> is more bulky than that of <b>13c</b>, and consequently <b>13b</b> has several close contacts to the protein. The reduced JAK2 activity of <b>13b</b> may be due to slight clashes with the protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Sitemap analysis of JAK2 with <b>13e</b> docked into the ATP-binding site. White dots indicate positions where it is favorable to place ligand atoms. The yellow, blue, and red grids are hydrophobic and hydrogen bond acceptor and donor areas of the binding site, respectively. The pyridine nitrogen falls into the hydrogen bond donor area around the carboxylic acid group of Asp994. The interaction with Asp994 will be repulsive (distance 3.7 Ã) unless the pyridine is protonated. The pyridine p<i>K</i><sub>a</sub> is calculated by Epik to be 3.6, which indicates it is not protonated; hence, the negative interaction of the pyridine forces the compound out of the binding site leading to a lower IC<sub>50</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Study of HeterocycleâLinker Combinations with Solubilizing Side Chains</h3><div class="NLM_p">From our earlier work,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> we had identified a robust solubilizing side chain which conferred good JAK2 and FLT3 potency as well as physicochemical properties. Given the similarities between this reported series and the heterocyclic series discussed herein, we decided to install the same side chain in a selection of heterocyclic macrocycles from Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> to understand if the same benefits were transferred. Adding the preferred side chain to <b>13c</b> gave <b>14a</b>, which did experience a slight improvement in JAK2 potency; however, its FLT3 potency was increased by an order of magnitude giving a single digit nanomolar IC<sub>50</sub> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Although CDK2 potency of <b>14a</b> dropped by 3-fold, JAK3 potency had become significant. Addition of a 5â²-methyl group to the pyrimidine ring has been previously found to boost JAK2 (and, undesirably, JAK3) potency in the phenyl series.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> However, when the same change is installed in the indole, giving <b>14b</b>, JAK2 potency is actually reduced, and surprisingly, JAK3 activity is abolished. CDK2 potency of <b>14b</b> dropped by 10-fold compared to that of <b>14a</b>, but the high cLogP and disappointing JAK2 activity prompted us to move our focus to monocyclic rings. Comparing 3-pyridyl <b>14c</b> with <b>13f</b>, we observed a trend similar to that of the indole series: a modest improvement in JAK2 potency, good FLT3 activity, and much improved CDK2/JAK2 selectivity. However, JAK3/JAK2 selectivity had dropped significantly. In general, 3-pyridyl compounds do not benefit fully from the addition of the pyrrolidinylethoxy side chain most likely due to repulsive forces between the unprotonated lone pair and amino acid residues (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). However, this is not the case with the 4-pyridyl compounds typified by <b>14d</b>, which has an IC<sub>50</sub> of 18 nM against JAK2. In addition, <b>14d</b> has good activity against TYK2 and FLT3 and over 10-fold selectivity for CDK2 and over 50-fold selectivity for JAK1 and JAK3. The direct comparator without the side chain was not prepared, but clearly this profile is much improved over <b>13d</b> and moving toward our target profile. As discussed above for <b>14b</b>, previous studies had shown that a 5â²-methyl pyrimidine group could boost JAK2 potency. When <b>14e</b> was prepared and tested, we found that JAK2 potency remained unchanged, but we were pleasantly surprised to see much increased selectivity for CDK2 (CDK2/JAK2 = 278-fold for <b>14e</b>); however, the extra methyl had increased cLogP to 4.8. For this reason, we did not extend the study of the 5â²-pyrimidyl substituents. Such good potency of pyridyl analogues <b>14d</b> and <b>14e</b> may be explained by a potential water-mediated H-bond to Asp981 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>14d</b> docked into JAK2. There is room for a water molecule which may mediate a hydrogen bond between the pyridine nitrogen and the side chain of Asp981. This may explain the increased JAK2 activity of pyrimidine analogues like <b>14d</b> and <b>14e</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">5-Membered heterocycles were also investigated with the preferred pyrrolidinyl-ethyloxy side chain. Furan and thiophene analogues <b>14f</b> and <b>14g</b> with the basic N-methyl linker were moderately potent against JAK2 but the latter exhibited good activity for TYK2 and FLT3. An alternative side chain, methoxyethoxy (compounds <b>14h</b> and <b>14i</b>), showed that the pyrrolidine enhances JAK2 potency by 3â5-fold (compare <b>14f</b> with <b>14h</b> and <b>14g</b> with <b>14i</b>). Again, as for <b>14f</b> and <b>14g</b>, the thiophene was more active than furan. This may be explained by the highly lipophilic nature of the binding site where the thiophene is interacting (Figure S1, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Significant JAK2 potency gains were achieved with the combination of thiophene, diether linker, and pyrroidine side chain: <b>14j</b> exhibited a JAK2 IC<sub>50</sub> of 7 nM with 32 and 24 nM for TYK2 and FLT3, respectively. Furthermore, this compound was 400-, 57-, and 89-fold selective for CDK2, JAK1, and JAK3, respectively. Although cLogP was a little high, we were encouraged to progress the profiling of <b>14j</b> due to its excellent potency and selectivity profile.</div><div class="NLM_p last">When the thiophene sulfur is moved to a regioisomeric position at the exterior of the macrocycle (<b>14k</b>), the in vitro potency profile was quite similar to that of <b>14j</b>, but cLogP rises significantly. Constraints on the molecular conformation of the macrocycles clearly have the potential to result in significantly different physicochemistry lending another dimension to the SAR and opportunities to tune the structure to a preferred profile. The analogous furan to <b>14j</b> was less active against JAK2 (see Figure S1, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) but did have a very positive selectivity profile: <b>14l</b> has a JAK2 IC<sub>50</sub> of 46 nM and selectivity of 152-, 58-, and 93-fold for CDK2, JAK1, and JAK3, respectively. Its potency against FLT3 is in the same concentration range as JAK2 with 5-fold selectivity against TYK2. cLogP is lower for <b>14l</b> than for <b>14j</b>, but both compounds were selected for further assessment along with <b>14k</b>. Another compound selected for further profiling was <b>14m</b>, the furan comparator of <b>14k</b>. In this case, the cLogP is reduced to 3.6 with the polar oxygen atom more exposed to solvent. The overall potency profile of <b>14m</b> is similar to that of <b>14l</b> but with improved CDK2 selectivity (<b>14m</b> CDK2 IC<sub>50</sub> >10 Î¼M). Moving the oxygen atom in the furan to the remaining ortho position (<b>14n</b>), with respect to the pyrimidine, results in a further drop in JAK2 and FLT3 activity below 100 nM, although the excellent CDK2 selectivity was retained.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Further In Vitro Profiling of Selected Compounds</h3><div class="NLM_p">Selected inhibitors which met our criteria of JAK2 and FLT3 potency with selectivity against CDK2, JAK1, and JAK3 were further profiled in vitro (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). A few potent compounds with higher cLogPs (<b>14e</b> and <b>14k</b>) are compared for information purposes. Even the higher cLogP compounds had acceptable solubility, but <b>14l</b> and <b>14m</b> were superior in this important respect. CYP3A4 and 2D6 were not an issue with the tested compounds with the exception of the high cLogP <b>14e</b>, which inhibited CYP3A4 with an IC<sub>50</sub> of 0.97 Î¼M. Human microsomal stabilities were remarkably good, as has been previously noted with these macrocyclic compounds. Stability was lower in mouse microsomes but still acceptable for further preclinical evaluation in mouse models. On-target cellular potency was evaluated in a cell proliferation assay using two cancer cells lines: Ba/F3 (driven by the JAK2 V617F mutant) and HL60 (driven by FLT3). Cell proliferation data (GI<sub>50</sub>) vary about 5-fold between the selected compounds (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). As a measure of cell inhibition efficiency, GI<sub>50</sub>/IC<sub>50</sub> shows that <b>14k</b> and <b>14l</b> were the most efficient compounds in Ba/F3 cells (JAK2 driven) and that <b>14j</b> was the best performing compound, relative to its enzyme IC<sub>50</sub>, in HL60 cells. Compounds <b>14k</b>, <b>14l</b>, and <b>14m</b> were similarly efficient in HL60 cells. Apart from solubility, there did not appear to be any significant differences in vitro between high and low cLogP compounds. Of the preferred lower cLogP compounds <b>14j</b>, <b>14l</b>, and <b>14m</b>, we were concerned about the metabolites of furan compounds. Furans can be metabolized to 1,4-<i>cis</i>-butendials, which are toxic.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> However, it is reported that 2,5-disubstitued furans, such as ranitidine, are quite stable in vivo;<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> hence, we felt that <b>14l</b>, being 2â5-disubstituted, posed less of a risk than <b>14m</b>. Highly potent <b>14j</b> was an attractive compound from most respects but only moderately soluble. Selection of a preferred single candidate was aided by hERG screening (binding assay). In general, the pyridyl derivatives were moderately potent with IC<sub>50</sub>s in the 1â5 Î¼M range. We were aiming to eliminate hERG activity as a concern; hence, <b>14l</b> was preferred over <b>14j</b> (>10 Î¼M (14% at 10 Î¼M) and 7.2 Î¼M, respectively). Taken together, this complex set of data supported <b>14l</b> as the preferred candidate. Although <b>14l</b> was not always the best compound in each test category, it did, however, meet our minimum target profile in all areas with a balanced compromise between the criteria. Hence, <b>14l</b> was selected as the preferred drug candidate and went forward into more advanced profiling studies.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Further in Vitro Profiling of Preferred Compounds Leading to Selection of in Vivo Candidate 14l</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd</th><th class="colsep0 rowsep0" align="center">JAK2 IC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CDK2/JAK2<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">JAK1/JAK2<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">JAK3/JAK2<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">TYK2/IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">FLT3 IC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">Solubility (Î¼g/mL)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">cLogP</th><th class="colsep0 rowsep0" align="center">CYP3A4 IC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">CYP2D6 IC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">HLM <i>t</i><sub>1/2</sub>(min)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">MLM <i>t</i><sub>1/2</sub>(min)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">hERG IC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a></th><th class="colsep0 rowsep0" align="center">Ba/F3 GI<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">GI<sub>50</sub>/IC<sub>50</sub><a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">HL60 GI<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">GI<sub>50</sub>/IC<sub>50</sub><a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14e</b></td><td class="colsep0 rowsep0" align="left">0.014</td><td class="colsep0 rowsep0" align="left">278</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">0.072</td><td class="colsep0 rowsep0" align="left">0.031</td><td class="colsep0 rowsep0" align="left">243Â Â±Â 5</td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" align="left">0.97Â Â±Â 0.19</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"><i>2</i> (<i>Est</i>.)<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">0.13Â Â±Â 0.036</td><td class="colsep0 rowsep0" align="left">9.3</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14j</b></td><td class="colsep0 rowsep0" align="left">0.0073</td><td class="colsep0 rowsep0" align="left">397</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="left">0.032</td><td class="colsep0 rowsep0" align="left">0.024</td><td class="colsep0 rowsep0" align="left">154Â Â±Â 16</td><td class="colsep0 rowsep0" align="left">4.1</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">7.2</td><td class="colsep0 rowsep0" align="left">0.055Â Â±Â 0.007</td><td class="colsep0 rowsep0" align="left">7.5</td><td class="colsep0 rowsep0" align="left">0.20Â Â±Â 0.042</td><td class="colsep0 rowsep0" align="left">8.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14k</b></td><td class="colsep0 rowsep0" align="left">0.017</td><td class="colsep0 rowsep0" align="left">400</td><td class="colsep0 rowsep0" align="left">88</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">0.047</td><td class="colsep0 rowsep0" align="left">0.045</td><td class="colsep0 rowsep0" align="left">218Â Â±Â 18</td><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">0.080Â Â±Â 0.028</td><td class="colsep0 rowsep0" align="left">4.7</td><td class="colsep0 rowsep0" align="left">0.64Â Â±Â 0.049</td><td class="colsep0 rowsep0" align="left">14.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14l</b></td><td class="colsep0 rowsep0" align="left">0.046</td><td class="colsep0 rowsep0" align="left">152</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">0.23</td><td class="colsep0 rowsep0" align="left">0.060</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.25Â Â±Â 0.19</td><td class="colsep0 rowsep0" align="left">5.4</td><td class="colsep0 rowsep0" align="left">0.85Â Â±Â 0.34</td><td class="colsep0 rowsep0" align="left">14.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14m</b></td><td class="colsep0 rowsep0" align="left">0.067</td><td class="colsep0 rowsep0" align="left">>149</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left">131</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.048</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">0.71Â Â±Â 0.18</td><td class="colsep0 rowsep0" align="left">14.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">All IC<sub>50</sub> and GI<sub>50</sub> values are means of at least two independent experiments.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">High throughput solubility in PBS buffered at pH 7.0.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">CYP activity determined in the human liver microsome system, see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for details.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">One determination.</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Ba/F3 GI<sub>50</sub>/JAK IC<sub>50</sub>.</p></div><div class="footnote" id="t3fn6"><sup>f</sup><p class="last">HL60 GI<sub>50</sub>/JAK IC<sub>50</sub>.</p></div><div class="footnote" id="t3fn7"><sup>g</sup><p class="last">Dofetalide binding, single determination carried out by MDS Pharma Services.</p></div><div class="footnote" id="t3fn8"><sup>h</sup><p class="last">Estimated value; <b>14e</b> was not tested but pyridyl analogue <b>14d</b> had a hERG binding IC<sub>50</sub> of 2.4 Î¼M as did other pyridyl analogues. ND denotes not determined.</p></div></div></div><div class="NLM_p">In silico, <b>14l</b> meets all accepted drug-like guidelines for an orally absorbed small molecule with molecular weight less than 500, a cLogP less than 5, numbers of H-bond donors and acceptors less than 5 and 10, respectively, and a polar surface area of less than 120 Ã<sup>2</sup>. Compound <b>14l</b> is highly soluble, >250 Î¼g/mL, in the kinetic experiment and 0.88â1.43 mg/mL in the thermodynamic experiment buffered to pH 7.0. This solubility compares very well to that of <b>2</b> (where R<sub>2</sub> = <i>N</i>-pyrrolidinylethoxy, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), which is 150 Î¼g/mL at pH 7.0. In the Caco-2 bidirectional permeability assay, <b>14l</b> showed high permeability with an efflux ratio of 1.1, which indicated that <b>14l</b> is probably not a substrate for <i>p</i>-glycoprotein in humans and thus may show high intestinal absorption. Compound <b>14l</b> was found to be stable in liver microsomal stability studies with HLM, MLM, RLM, and DLM <i>t</i><sub>1/2</sub> > 60 min and was moderately stable in MoLM with <i>t</i><sub>1/2</sub> of 23 min (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Compound <b>14l</b> did not inhibit the major drug metabolizing human CYP450s 1A2, 3A4, 2D6, and 2C9 at below 10 Î¼M but did inhibit 2C19 (IC<sub>50</sub> â¼1.4 Î¼M), suggesting that it may not have the potential to cause drugâdrug interactions in vivo. In vitro plasma protein binding of <b>14l</b> was high and similar in humans and monkeys and was significantly lower in mouse, dog, and rat plasma.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Physicochemical Properties and in Vitro ADME of <b>14l</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">property</th><th class="colsep0 rowsep0" align="center">value</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mol.wt</td><td class="colsep0 rowsep0" align="left">463</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of HDB</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of HBA</td><td class="colsep0 rowsep0" align="left">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogP</td><td class="colsep0 rowsep0" align="left">3.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i> (pH 7.4)</td><td class="colsep0 rowsep0" align="left">1.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PSA (Ã<sup>2</sup>)</td><td class="colsep0 rowsep0" align="left">82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">thermodynamic solubility pH 7.0 (mg/mL)</td><td class="colsep0 rowsep0" align="left">0.88â1.43<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">permeability (<i>P</i><sub>app,Â AâB</sub>,Â ÃÂ 10<sup>â6</sup> cm/sec)</td><td class="colsep0 rowsep0" align="left">24.8, efflux ratio = 1.1 (low)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver microsomes (<i>t</i><sub>1/2</sub>, min)</td><td class="colsep0 rowsep0" align="left">>60<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MoLM (<i>t</i><sub>1/2</sub>, min)</td><td class="colsep0 rowsep0" align="left">23<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human CYP inhibition IC<sub>50</sub> (Î¼M)</td><td class="colsep0 rowsep0" align="left">>10<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a>; 1.4<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP450 phenotyping</td><td class="colsep0 rowsep0" align="left">cleared by 3A4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP450 induction</td><td class="colsep0 rowsep0" align="left">negative for 3A4 and 1A2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding (%)<a class="ref internalNav" href="#t4fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">99.0 (H); 98.7(Mo), 87.3â87.5(M, R, D)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Two determinations of two different batches of <b>14l</b>.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Caco-2 bidirectional permeability assay.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Human, dog, rat, and mouse.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">Rhesus monkey microsomes.</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last">Human CYP3A4, 1A2, 2D6, 2C9Â·CYP3A4, and 2D6; fluorescence detection.</p></div><div class="footnote" id="t4fn6"><sup>f</sup><p class="last">2C19.</p></div><div class="footnote" id="t4fn7"><sup>g</sup><p class="last">Equilibrium dialysis assay at 1000 ng/mL. H = human, Mo = monkey, M = mouse, R = rat, and D = dog.</p></div></div></div><div class="NLM_p last">Testing against a panel of kinases revealed that <b>14l</b> is approximately 20-fold selective against a cross-section of other kinases with the exception of c-fms receptor kinase (IC<sub>50</sub> 69 nM) and CDK9 (IC<sub>50</sub> 36 nM). Elevated levels of c-fms ligand, macrophage colony stimulating factor (M-CSF), are observed in the joints of RA patients; hence, due to its pivotal role in the pathogenesis of RA, the blockade of the M-CSF/c-fms axis has been shown to inhibit the progression of arthritis.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> CDK9 promotes RNA synthesis for cell growth and differentiation and has been identified as a potential target for therapeutic intervention in oncology, virology, and cardiology.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Pharmacokinetics of <b>14l</b> in Multiple Species</h3><div class="NLM_p">The pharmacokinetic properties of <b>14l</b> are sumarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Compound <b>14l</b> showed rapid to moderately fast absorption (<i>t</i><sub>max</sub> ranged between 0.5 to â¼2.3 h) in mice, rats, and monkeys and was relatively slower in dogs.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Oral Pharmacokinetic Parameters (Mean Â± SD) of <b>14l</b> in Mouse, Rat, Dog, and Rhesus Monkey</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">mouse<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">rat (<i>n</i>Â =Â 3)</th><th class="colsep0 rowsep0" align="center">dog (<i>n</i>Â =Â 3)</th><th class="colsep0 rowsep0" align="center">monkey(<i>n</i>Â =Â 3)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">doseÂ (mg/kg)</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">1227</td><td class="colsep0 rowsep0" align="left">231Â Â±Â 85</td><td class="colsep0 rowsep0" align="left">27Â Â±Â 7</td><td class="colsep0 rowsep0" align="left">1976Â Â±Â 575</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">2.3Â Â±Â 1.5</td><td class="colsep0 rowsep0" align="left">3.0Â Â±Â 1.0</td><td class="colsep0 rowsep0" align="left">2.0Â Â±Â 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">3.6Â Â±Â 1.4</td><td class="colsep0 rowsep0" align="left">1.5Â Â±Â 0.5</td><td class="colsep0 rowsep0" align="left">1.1Â Â±Â 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0-â</sub>(ngÂ·h/mL)</td><td class="colsep0 rowsep0" align="left">2020</td><td class="colsep0 rowsep0" align="left">1499Â Â±Â 192</td><td class="colsep0 rowsep0" align="left">96Â Â±Â 33</td><td class="colsep0 rowsep0" align="left">7590Â Â±Â 2958</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oral bioavailability (F%)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">32</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Estimated from mean concentration time data (<i>n</i> = 3 mice per time point).</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Mean.</p></div></div></div><div class="NLM_p last">The terminal <i>t</i><sub>1/2</sub> was moderate in mice, dogs, and monkeys (ranged between 0.8 and 1.5 h) and longer in rats (3.6 h). The oral bioavailability was moderate in mice and monkeys (32â34%) and poor in rats and dogs (6%). Exposures achieved in mice at 50 mg/kg exceeded the pharmacological concentrations (JAK2 IC<sub>50</sub> = 46 nM and FLT3 IC<sub>50</sub> = 62 nM).</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Modulation of JAK2 Signaling Pathways</h3><div class="NLM_p">The effects of <b>14l</b> on JAK2 signaling were investigated in 4 different cellular contexts: a cell line expressing constitutively activated mutant JAK2 (SET2, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>A);<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> a cell line expressing constitutively activated wild-type JAK2 (MDA-MB-231, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B); a cell line requiring exogenous ligand to activate wild-type JAK2 (HEK293, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>C); and primary human T cells (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>D). JAK2 signaling was dose-dependently inhibited by <b>14l</b> treatment in all four cell systems. Note that <b>14l</b> inhibited cell proliferation in SET2 cells with an IC<sub>50</sub> of 0.246 nM.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>14l</b> blocks JAK2 signaling pathways in multiple cellular contexts.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Following cell incubation with <b>14l</b>, 30 Î¼g of cell lysates were resolved on SDSâPAGE, transferred onto PVDF membranes, and probed with the respective antibodies. (A) SET2 cells were treated with various concentrations of <b>14l</b> for 4 h. (B) MDA-MB-231 cells were treated with various concentrations of <b>14l</b> for 4 h. (C) HEK293 cells were incubated with various concentrations of <b>14l</b> for 3 h followed by treatment with 1000 U/mL IFN-Î³. (D) Human CD4<sup>+</sup> T cells were incubated with various concentrations of <b>14l</b> for 3 h followed by treatment with 10 ng/mL interleukin-12.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Treatment with <b>14l</b> is Efficacious in the Murine Collagen Induced Arthritis Model</h3><div class="NLM_p">The murine CIA model recapitulates the clinical and histological development of human rheumatoid arthritis and has been useful in evaluating the effects of clinically used agents.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> After the onset of collagen induced arthritis, mice were administered twice daily with doses of 105 mg/kg or 210 mg/kg (free base equivalent) of <b>14l</b>, and the treatment was continued for 10 days. In the vehicle group, the clinical arthritic score of mice increased rapidly from day 0 to disease day 11 (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). Treatment with <b>14l</b> led to a dose-dependent inhibition of arthritis, with a 23% and 59% reduction in the AUC in the mice administered 105 mg/kg and 210 mg/kg <b>14l</b>, respectively. Treatment effects at the higher dose were comparable to the mice treated with dexamethasone with a 63% reduction in the AUC. This reduction in the clinical arthritis scores was also accompanied by substantial improvement in the histopathology of the drug-treated mice (data not shown). This data shows that inhibition of JAK2 signaling, which is involved in the pathological responses of inflammatory and autoimmune diseases, could be an efficacious new paradigm for the treatment of rheumatoid arthritis.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>14l</b> attenuates clinical symptoms of arthritis in a mouse CIA model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Arthritis was induced in mice by immunization with type II collagen emulsified in Freundâs Complete Adjuvant. Following the disease onset (day 0), the mice were enrolled into treatment groups of 10 and were orally administered with <b>14l</b> (105 or 210 mg/kg b.i.d, free base equivalent) or dexamethasone (0.1 mg/kg); naÃ¯ve group had 4 mice. Clinical arthritis scores were evaluated daily for 10 days. The graph represents the analysis of clinical arthritis scores with area under the dosing curve calculation, *<i>p</i> â¤ 0.05, MannâWhitney U test to vehicle.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43442" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43442" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">This article provides a further demonstration that conformationally constrained macrocycles can be potent and selective inhibitors of kinases. This research has general applicability to kinase inhibitors since the macrocyclic linkage is distinct from the hinge binding region of the inhibitor. Using this simple paradigm, we demonstrate that a significant degree of kinase selectivity is, in fact, achievable starting from rather unpromising N-aryl pyrimidines. Ring-closing metathesis chemistry has been successfully employed to construct relatively rigid ATP-competitive heterobiaryl macrocycles, with significantly reduced degrees of conformational freedom over typical nonmacrocyclic kinase inhibitors. In addition to being potent inhibitors of JAK2, FLT3, and TYK2, this series has good physicochemical properties explaining the good translation of potency to the cell. Exchange of the previously described phenyl system<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> for heteroaryls was found to be fruitful with SAR studies leading to the 5-membered thiophene and furan rings as preferred motifs. Following extensive in vitro and in vivo profiling, highly soluble <b>14l</b>, with negligible hERG binding inhibition, was shown to inhibit its targets in cells and in vivo. Tolerable twice daily oral doses of <b>14l</b> in the mouse CIA model led to efficacy similar to that of dexamethasone; hence, <b>14l</b> was therefore selected for further development. Compound <b>14l</b> (SB1578) is currently being evaluated in phase 1 clinical trials in healthy volunteers.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry</h3><div class="NLM_p">Purity was >95% for all tested compounds except those indicated in their respective synthesis descriptions. For detailed HPLC analytical methods and general chemistry, refer to our earlier publication.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> [1-(2-Chloro-pyrimidin-4-yl)-piperidin-3-yl]-methanol (<b>4a</b>)</h4><div class="NLM_p last">To a solution of 2,4-dichloropyrimidine <b>1a</b> (1.86 g, 12.5 mmol), 3-piperidinemethanol (1.59 g, 13.8 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (80 mL) was added Et<sub>3</sub>N (2.0 mL, 14.4 mmol), and the resulting mixture was stirred at room temp for 2 h. Aqueous Na<sub>2</sub>CO<sub>3</sub> was added, and the product was extracted with CH<sub>2</sub>Cl<sub>2</sub> thrice. After workup, a solid (2.67 g; yield, 94%) was obtained as a mixture of title compound and isomer (i.e., [1-(4-chloro-pyrimidin-2-yl)-piperidin-4-yl]-methanol) in a ratio of 87:13 as determined by <sup>1</sup>H NMR. The crude mixture was taken forward for the next step without any further purification. The title compound (the major product): LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 228 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) selected peaks: Î´ 8.00 (d, 1H, <i>J</i> = 6.2 Hz), 6.76 (d, 1H, <i>J</i> = 6.3 Hz), 4.67 (t, 2H, <i>J</i> = 5.2 Hz); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) Î´ 162.0, 159.6, 157.1, 102.1, 63.3, 47.0, 44.1, 38.3, 26.7, 23.9.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 6-(2-Chloro-pyrimidin-4-yl)-1<i>H</i>-indole (<b>4b</b>)</h4><div class="NLM_p last">To a prestirred mxiture of 2,4-dichloropyrimidine <b>1a</b> (0.83 g, 5.5 mmol), 1<i>H</i>-indol-6-yl boronic acid (0.83 g, 5.0 mmol) in 1,2-dimethoxyethane (40 mL) and saturated aqueous solution of NaHCO<sub>3</sub> (4 mL) was added Pd(PPh<sub>3</sub>)<sub>4</sub> (0.30 g, 0.26 mmol). The solution was heated to 85 Â°C for 6 to 8 h. After the reaction was completed, the solution was cooled down and filtered through Celite. The filtrate was added to ethyl acetate (40 mL) and water (20 mL), and the organic layer was separated, washed with water (3Ã) and brine (3Ã), and concentrated. The residue was purified by flash chromatography (silica, EtOAc/hexanes from 1:5 to 1:2) to afford the title compound (0.76 g, yield 66%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 9.74 (s, 1H), 9.23 (d, 1H, <i>J =</i> 1.2 Hz), 8.83 (d, 1H, <i>J =</i> 5.3 Hz), 8.01 (dd, 1H, <i>J =</i> 5.3, 1.2 Hz), 7.60â7.65 (m, 1H), 7.35 (t, 1H, <i>J =</i> 8.2 Hz), 6.94â6.99 (m, 1H). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 230 ([M + H])<sup>+</sup> .</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 5-(2-Chloro-pyrimidin-4-yl)-furan-2-carbaldehyde (<b>4c</b>)</h4><div class="NLM_p">To a degassed (nitrogen) solution of 2,4-dichloropyrimidine <b>1a</b> (3.8 g, 25.51 mmol) and 5-formyl-2-furan boronic acid (3 g, 21.44 mmol) in 1,2-dimethoxy ethane [DME] (100 mL) were added aq. Na<sub>2</sub>CO<sub>3</sub> (5.5 g in 10 mL of H<sub>2</sub>O, 51.0 mmol) and Pd(dppf)Cl<sub>2</sub> CH<sub>2</sub>Cl<sub>2</sub> [1:1] (0.87 g, 1.07 mmol). The reaction mixture was stirred to 80 Â°C for 4 h. It was cooled to rt and poured into water and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 Ã 40 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to obtain the crude residue. The crude material was purified by column chromatography (EtOAc/Hexane 1:2) to afford <b>4c</b> (3.01 g; yield, 67%) as an off-white solid. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 209 ([M + H]<sup>+</sup>).</div><div class="NLM_p last">Following a procedure similar to that of <b>4c</b>, the following intermediates were synthesized.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 2-Chloro-4-(2-fluoro-pyridin-4-yl)-pyrimidine (<b>4e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>1a</b> and 2-fluoro-4-pyridine boronic acid <b>3c</b> (yield, 61%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 210 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>): Î´ 8.85 (d, 1H), 8.47 (d, 1H), 7.87 (dt, 1H), 7.75 (d, 1H), 7.67â7.68 (m, 1H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 5-(2-Chloro-pyrimidin-4-yl)-pyridine-3-carbaldehyde (<b>4f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>1a</b> and 5-formyl-3-pyridine boronic acid pinacol ester <b>3a</b> (yield, 80%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 220 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 5-(2-Chloro-pyrimidin-4-yl)-thiophene-2-carbaldehyde (<b>4h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>1a</b> and 5-formyl-2-thiophene boronic acid <b>3e</b> (yield, 84%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 225 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 10.64 (s, 1H), 8.68 (d, 1H), 7.66 (m, 2H), 7.57 (d, 1H).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-(2-Chloro-pyrimidin-4-yl)-thiophene-2-carbaldehyde (<b>4j</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>1a</b> and 2-formyl-4-thiophene boronic acid <b>3f</b> (yield, 92%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 225 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4-(2-Chloro-pyrimidin-4-yl)-furan-2-carbaldehyde (<b>4l</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>1a</b> and 2-formyl-4-furan boronic acid <b>3g</b> (yield, 61%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 209 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 5-(2-Chloro-pyrimidin-4-yl)-furan-3-carbaldehyde (<b>4n</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>1a</b> and 4-formyl-2-furan boronic acid <b>3h</b> (yield, 70%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 209 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-Chloro-4-(2-fluoro-pyridin-4-yl)-5-methyl-pyrimidine (<b>4p</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2,4-dichloro-5-methylpyrimidine <b>1b</b> and 2-fluoro-4-pyridine boronic acid <b>3c</b> (yield, 58%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 224 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 6-(2-Chloro-5-methyl-pyrimidin-4-yl)-1<i>H</i>-indole (<b>4q</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2,4-dichloro-5-methylpyrimidine <b>1b</b> and 6-indole boronic acid <b>3a</b> (yield, 77%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 244 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> [5-(2-Chloro-pyrimidin-4-yl)-furan-2-yl]-methanol (<b>4d</b>)</h4><div class="NLM_p">To a solution of <b>4c</b> (2.25 g, 10.79 mmol) in THF (40 mL), cooled at 0 Â°C, was added NaBH<sub>4</sub> (0.82 g, 21.58 mmol), followed by MeOH (10 mL) dropwise, maintaining the temperature at 0 Â°C. The resulting mixture was brought to rt and stirred for 30 min. The reaction mixture was quenched with H<sub>2</sub>O and extracted with EtOAc (3 Ã 25 mL). The combined organic extracts were washed with H<sub>2</sub>O, followed by brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to furnish without purification 2.14 g of compound <b>4d</b> (yield, 94%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 211 ([M + H]<sup>+</sup>).</div><div class="NLM_p last">Following a procedure similar to that of <b>4d</b>, the following intermediates were synthesized.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> [5-(2-Chloro-pyrimidin-4-yl)-pyridin-3-yl]-methanol (<b>4g</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4f</b> (yield, 75%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 222 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> [5-(2-Chloro-pyrimidin-4-yl)-thiophen-2-yl]-methanol (<b>4i</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4h</b> (yield, 70%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 227 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 8.62 (d, 1H), 7.55 (m, 2H), 7.25 (d, 1H), 4.83 (s, 2H), 4.68 (bs, 1H).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> [4-(2-Chloro-pyrimidin-4-yl)-thiophen-2-yl]-methanol (<b>4k</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4j</b> (yield, 80%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 227 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> [4-(2-Chloro-pyrimidin-4-yl)-furan-2-yl]-methanol (<b>4m</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4l</b> (yield, 93%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 211 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> [5-(2-Chloro-pyrimidin-4-yl)-furan-3-yl]-methanol (<b>4o</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4n</b> (yield, 78%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 211 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 4-(3-Allyloxymethyl-piperidin-1-yl)-2-chloro-pyrimidine (<b>5a</b>)</h4><div class="NLM_p last">A solution of <b>4a</b> (1.12 g, 4.91 mmol) in anhydrous THF (40 mL) was added allyl bromide (1.5 mL, 17.3 mmol) and cooled in an acetone/dry ice bath. Sodium hydride (60% in mineral oil, 0.910 g, 22.7 mmol) was added to the mixture under N<sub>2</sub>, after 10 min, the dry ice bath was removed, and the resulting mixture was stirred at room temp overnight. The reaction was quenched by the addition of dry ice powder and MeOH, and then concentrated under reduced pressure. The residue was diluted with aqueous NaHCO<sub>3</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub> thrice. After workup, the crude product was purified by flash chromatography (silica, 30â60% EtOAc in hexanes) to afford the title compound as a colorless oil (0.68 g; yield, 52%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 268/270 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 7.89 (d, 1H, <i>J</i> = 6.2 Hz), 6.35 (d, 1H, <i>J</i> = 6.2 Hz), 5.82 (ddt, 1H, <i>J</i> = 17.2, 10.4, 5.6 Hz), 5.20 (ddt, 1H, <i>J</i> = 17.2, 1.7, 1.7 Hz), 5.10 (ddt, 1H, <i>J</i> = 10.4, 1.6, 1.5 Hz), 4.08 (b s, 2H), 3.88 (dm, 2H, <i>J</i> = 7.1 Hz), 3.29 (dd, 1H, <i>J</i> = 9.4, 5.0 Hz), 3.22 (dd, 1H, <i>J</i> = 9.3, 7.7 Hz), 3.05 (ddd, 1H, <i>J</i> = 13.1, 10.6, 3.0 Hz), 2.86 (dd, 1H, <i>J</i> = 13.0, 9.7 Hz), 1.86â1.74 (m, 2H), 1.72â1.64 (m, 1H), 1.51â1.39 (m, 1H), 1.36â1.13 (m, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) Î´ 162.4, 160.6, 156.9, 134.7, 116.9, 101.3, 72.1, 72.0, 47.8, 44.8, 36.2, 27.3, 24.1.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 1-Allyl-6-(2-chloro-pyrimidin-4-yl)-1<i>H</i>-indole (<b>5c</b>)</h4><div class="NLM_p">A solution of <b>4b</b> (115 mg, 0.5 mmol) and NaH (73 mg, 60% in mineral oil, 0.9 mmol) in 2 mL of dried DMF was stirred at room temperature for 30 min. Allyl bromide (121 mg, 1.0 mmol) in 1 mL of dried DMF was added to the solution. The mixture was stirred at room temperature overnight. The reaction was quenched by adding water slowly. The mixture was extracted with EtOAc thrice, and the combined extracts were washed with water 3 times and then washed with brine once. The product <b>5c</b> (112 mg; yield, 83%) was obtained by flash column chromatography. (EtOAc/hexanes from 1:10 to 1:4) LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 270 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 8.54 (d, 1H), 8.21 (s, 1H), 7.75 (d, 1H), 7.71 (d, 1H), 7.66 (d, 1H), 7.25 (d, 1H), 6.56 (d, 1H), 6.02 (m, 1H), 5.25 (d, 1H), 5.12 (d, 1H), 4.83 (d, 2H).</div><div class="NLM_p last">Following a procedure similar to that of <b>5c</b>, the following intermediates were synthesized.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 1-But-3-enyl-6-(2-chloro-pyrimidin-4-yl)-1H-indole (<b>5b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4b</b> and 4-bromo-1-butene (yield, 62%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 284 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 1-Allyl-6-(2-chloro-5-methyl-pyrimidin-4-yl)-1<i>H</i>-indole (<b>5j</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4q</b> and allyl bromide (yield, 77%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 284 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-(5-Allyloxymethyl-furan-2-yl)-2-chloro-pyrimidine (<b>5d</b>)</h4><div class="NLM_p">A mixture of <b>4d</b> (10 g, 47.5 mmol), KOH (5.3 g, 94.6 mmol), and tetrabutyl ammonium hydrogen sulfate [TBAHSO<sub>4</sub>] (0.79 g, 2.38 mmol) in allyl bromide (40 mL, 4 vol) was stirred at rt for 12 h. The reaction mixture was quenched with water and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 Ã 20 mL). The combined organic extracts were washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure to obtain the crude residue, which was purified by column chromatography (using 15% EtOAc/hexanes) to furnish <b>5d</b> (10.0 g; yield, 84%) as a pale yellow oil. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 251 ([M + H]<sup>+</sup>).</div><div class="NLM_p last">Following a procedure similar to that of <b>5d</b>, the following intermediates were synthesized.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-(5-Allyloxymethyl-pyridin-3-yl)-2-chloro-pyrimidine (<b>5e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4g</b> and allyl bromide (yield, 46%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 262 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-(5-Allyloxymethyl-thiophen-2-yl)-2-chloro-pyrimidine (<b>5f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4i</b> and allyl bromide (yield, 80%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 267 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-(5-Allyloxymethyl-thiophen-3-yl)-2-chloro-pyrimidine (<b>5g</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4k</b> and allyl bromide (yield, 80%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 267 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-(5-Allyloxymethyl-furan-3-yl)-2-chloro-pyrimidine (<b>5h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4m</b> and allyl bromide (yield, 82%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 251 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4-(4-Allyloxymethyl-furan-2-yl)-2-chloro-pyrimidine (<b>5i</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4o</b> and allyl bromide (yield, 74%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 251 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 1-Allyloxymethyl-3-nitro-benzene (<b>9a</b>)</h4><div class="NLM_p last">The title compound was synthesized from 3-nitrobenzyl alcohol <b>7a</b> and allyl bromide (yield, 78%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 194 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>): Î´ 8.27 (s, 1H), 8.18 (dd, 1H), 7.73 (dd, 1H), 7.57 (t, 1H), 6.01 (m, 1H), 5.38 (m, 1H), 5.29 (m, 1H), 4.65 (s, 2H), 4.13 (dt, 2H).</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-(3-Allyloxymethyl phenyl)-2-chloro pyrimidine (<b>9b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>7b</b> and allyl bromide (yield, 55%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 261 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 8.62 (d, 1H), 8.06 (br, 1H), 8.00 (dt, 1H), 7.66 (d, 1H), 7.54â7.46 (m, 2H), 6.02 â 5.93 (m, 1H), 5.27 (ddq, 2H), 4.60 (s, 2H), 4.08 (dq, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) Î´ 167.1, 161.9, 159.9, 139.7, 135.3, 134.6, 131.2, 129.7, 129.3, 126.6, 117.5, 115.4, 71.7, 71.6. Anal. Calcd. for C<sub>12</sub>H1<sub>4C</sub>lNO4: C, 53.05; H, 5.19; N, 5.16; Cl: 13.05. Found: C, 53.09; H, 5.30; N, 5.14; Cl, 13.37. IR (KBr pellet): 1568, 1535, 1344, 1186, 1079 cm<sup>â1</sup>.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 2-(2-Methoxyâethoxy)-5-nitro-benzaldehyde (<b>6c</b>)</h4><div class="NLM_p last">To a mixture of 2-hydroxy-5-nitrobenzaldehyde <b>6b</b> (5 g, 29.9 mmol) and 1-bromo-2-methoxyethane (5.6 mL, 59.8 mmol) in DMF (50 mL, 10 vol)) was added K<sub>2</sub>CO<sub>3</sub> (6.25 g, 45.0 mmol), and the resulting mixture was stirred at 100â105 Â°C for 6 h. The reaction mixture was cooled to 0 Â°C and quenched with water. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> thrice, and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to furnish an oil, which was purified by column chromatography (EtOAc/Hexane) to obtain 5.8 g of <b>6c</b> (yield, 86%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 226 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2-(2-Chloro ethoxy)-5-nitro-benzaldehyde (<b>6d</b>) and [2-(2-Chloro-ethoxy)-5-nitro-phenyl]-methanol (<b>7b</b>)</h4><div class="NLM_p last">The title compounds were synthesized according to a literature procedure.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Allyl Methyl-(3 nitro benzyl) Amine (<b>8a</b>)</h4><div class="NLM_p">To a solution of 3-nitrobenzaldehyde <b>6a</b> (20 g, 132.4 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (500 mL) was added <i>N</i>-allyl methyl amine (18.8 mL, 198.6 mmol), and the resulting mixture was stirred at rt for 12 h, after which Na(OAc)<sub>3</sub>BH (56.13 g, 265 mmol) was added portion wise and stirred for additional 4 h. The reaction mixture was then quenched with sat. NH<sub>4</sub>Cl solution and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 Ã 150 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give the crude material, which was purified by column chromatography (EtOAc/hexane 1:19) to afford <b>8a</b> (25.9 g; yield, 95%) as a pale yellow syrup. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 207 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 8.20 (s, 1H), 8.11 (dd, 1H), 7.68 (dd, 1H), 7.48 (t, 1H), 5.85â5.94 (m, 1H), 5.20 (t, 1H), 3.60 (s, 2H), 3.07 (dd, 1H), 2.22 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) Î´ 148.4, 141.5, 135.20, 134.9, 129.1, 123.7, 122.1, 118.1, 60.52, 60.50. Anal. Calcd. for C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>: C, 64.06; H, 6.84; N, 13.58. Found: C, 62.31; H, 6.69; N, 13.25. IR (KBr pellet): 2787, 1528, 1349, 924, 733 cm<sup>â1</sup>.</div><div class="NLM_p last">Following a procedure similar to that of <b>8a</b>, the following intermediates were synthesized:</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Allyl-[2-(2-methoxyâethoxy)-5-nitro-benzyl]-methyl-amine (<b>8b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6c</b> and <i>N</i>-allyl methyl amine (yield, 92%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 281 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Allyl-[2-(2-chloro-ethoxy)-5-nitro-benzyl]-methyl-amine (<b>8c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6d</b> and <i>N</i>-allyl methyl amine (yield, 85%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 285 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> [5-(2-Chloro-pyrimidin-4-yl)-furan-3-yl]-methanol (<b>8d</b>)</h4><div class="NLM_p last">To a solution of <b>8c</b> (2 g, 7.02 mmol) in <i>N</i>,<i>N</i>-dimethylacetamide (DMA, 10 mL) was added pyrrolidine (4 mL, 2 vol), and the resulting mixture was stirred at 90 Â°C for 20 h. The reaction mixture was brought to rt and quenched with water (20 mL) and extracted in ethyl acetate (3 Ã 20 mL). The combined organic extracts were washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure to afford the crude <b>8d</b> (1.68 g; yield, 75%) as thick syrup. This intermediate was taken forward for the next step without any purification. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 320 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-[2-(2-Allyloxymethyl-4-nitro phenoxy] pyrrolidine (<b>9c</b>)</h4><div class="NLM_p last">Following a procedure similar to that of <b>8d</b>, the title compound was synthesized from <b>9b</b> and pyrrolidine (yield, 78%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 307 ([M + H]<sup>+</sup>). Theoretical HRMS ([M + H]<sup>+</sup>) 307.1652, found 307.1653; <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 8.33 (d, 1H), 8.17 (dd, 1H), 6.91 (d, 1H), 6.03â5.93 (m, 1H), 5.37â5.23 (m, 2H), 4.56 (s, 2H), 4.26 (t, 2H), 4.12 (dt, 2H), 2.99 (t, 2H), 2.71â2.68 (m, 4H), 1.90â1.86 (m, 4H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) Î´ 23.8, 54.7, 55.1, 66.3, 68.5, 72.2, 110.7, 117.6, 124.3, 125.0, 128.6, 134.6, 141.7, 161.0.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 3-[(Allylmethylamino) methyl] Phenyl Amine (<b>10a</b>)</h4><div class="NLM_p">To a solution of <b>8a</b> (6.9 g, 33.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, 100 mL), cooled to 0 Â°C, SnCl<sub>2</sub>Â·2H<sub>2</sub>O (25.4 g, 134 mmol) was added. The reaction mixture was gradually raised to rt and stirred for 12 h. After completion of the reaction, the solvent from the reaction mixture was removed under reduced pressure, and the residue was taken into aqueous Na<sub>2</sub>CO<sub>3</sub> and CH<sub>2</sub>Cl<sub>2</sub> (100 mL). The reaction mixture was filtered through filter paper. The organic layer was separated out from the filtrate, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 Ã 50 mL). The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure to afford <b>7</b> (5.8 g; yield, 98%) as a thick syrup, which was used for the next step without further purification. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 177 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 7.09 (t, 1H), 6.57â6.69 (m, 2H), 6.55 (dd, 1H), 5.85â5.95 (m, 1H), 5.12â5.17 (m, 2H), 3.67 (br, 1H), 3.39 (s, 2H), 3.02 (d, 2H), 2.18 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) Î´ 146.4, 140.3, 136.0, 129.1, 119.4, 117.4, 115.7, 113.8, 61.7, 60.6, 42.2. Anal. Calcd. for C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>: C, 74.96; H, 9.15; N, 15.89. Found: 74.34; H, 9.04; N, 15.68. IR (KBr pellet): 3346, 3210, 2782, 1605, 1460, 1294, 921, 785, 696 cm<sup>â1</sup>.</div><div class="NLM_p last">Following a procedure similar to that of <b>10a</b>, the following intermediates were synthesized.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 3-[(Allyl-methyl-amino)-methyl]-4-(2-methoxyâethoxy)-phenylamine (<b>10b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>8b</b> (yield, 64%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 251 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 3-[(Allyl-methyl-amino)-methyl]-4-(2-pyrrolidin-1-yl-ethoxy)-phenylamine (<b>10c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>8d</b> (yield, 88%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 290 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 3-Allyloxymethyl-phenylamine (<b>10d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>9a</b> (yield, 91%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 164 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 3-Allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)phenylamine (<b>10e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>9c</b> (yield, 89%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 277 ([M + H]<sup>+</sup>). Theoretical HRMS [M + H]<sup>+</sup> 277.1911, found 277.1916; <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 6.82â6.78 (m, 2H), 6.69 (dd, 1H), 5.93â5.83 (m, 1H), 5.26â5.11 (m, 2H), 4.45 (s, 2H), 4.20 (t, 2H), 3.97 (dt, 2H), 3.56 (t, 2H); <sup>13</sup>C NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 149.4, 140.2, 134.7, 127.6, 118.2, 116.5, 116.2, 113.9, 70.8, 67.3, 64.6, 54.5, 54.1, 22.6; IR (KBr pellet): 1626, 1502, 1225, 1084, 798 cm<sup>â1</sup>.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> {3-[(Allyl-methyl-amino)-methyl]-phenyl}-[4-(5-allyloxymethyl-furan-2-yl)-pyrimidin-2-yl]-amine (<b>11c</b>)</h4><div class="NLM_p">To a solution of <b>5d</b> (80 mg, 0.319 mmol) and <b>10a</b> (60 mg, 0.340 mmol) in <i>n</i>-butanol (2 mL) was added 4 M HCl (0.2 mL), and the resulting mixture was heated to 80â100 Â°C for 12 h. The reaction mixture was brought to rt, and the solvent was removed under reduced pressure. The residue was dissolved in minimum amount of MeOH and purified by preparative rpHPLC to furnish <b>11c</b> as a TFA salt (112 mg; yield, 90%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 391 ([M + H]<sup>+</sup>).</div><div class="NLM_p last">Following a procedure similar to that of <b>11c</b>, the following intermediates were synthesized.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> {3-[(Allyl-methyl-amino)-methyl]-phenyl}-[4-(3-allyloxymethyl-piperidin-1-yl)-pyrimidin-2-yl]-amine (<b>11a</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5a</b> and <b>10a</b> and was obtained as a crude yellow residue (HPLC purity = 94% at 254 nm), which was used for the next step of the reaction without further purification. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 408 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> {3-[(Allyl-methyl-amino)-methyl]-phenyl}-[4-(1-but-3-enyl-1<i>H</i>-indol-6-yl)-pyrimidin-2-yl]-amine (<b>11b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5b</b> and <b>10a</b> (yield, 94%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 424 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> {3-[(Allyl-methyl-amino)-methyl]-phenyl}-[4-(2-fluoro-pyridin-4-yl)-pyrimidin-2-yl]-amine (<b>11d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4e</b> and <b>10a</b> (yield, 86%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 350 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> {3-[(Allyl-methyl-amino)-methyl]-phenyl}-[4-(5-allyloxymethyl-pyridin-3-yl)-pyrimidin-2-yl]-amine (<b>11f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5e</b> and <b>10a</b> (yield, 84%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 402 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> [4-(5-Allyloxymethyl-furan-2-yl)-pyrimidin-2-yl]-(3-allyloxymethyl-phenyl)-amine (<b>11g</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5d</b> and <b>10d</b> (yield, 93%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 478 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> [4-(1-Allyl-1<i>H</i>-indol-6-yl)-pyrimidin-2-yl]-(3-allyloxymethyl-phenyl)-amine (<b>11h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5c</b> and <b>10d</b> (yield, 79%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 397 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (3-Allyloxymethyl-phenyl)-[4-(5-allyloxymethyl-pyridin-3-yl)-pyrimidin-2-yl]-amine (<b>11i</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5e</b> and <b>10d</b> (yield, 92%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 389 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> [3-[(Allyl-methyl-amino)-methyl]-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-[4-(5-allyloxymethyl-furan-2-yl)-pyrimidin-2-yl]-amine (<b>12a</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5d</b> and <b>10c</b> (yield, 72%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 504 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> [3-[(Allyl-methyl-amino)-methyl]-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-[4-(5-allyloxymethyl-thiophen-2-yl)-pyrimidin-2-yl]-amine (<b>12b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5f</b> and <b>10c</b> (yield, 62%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 520 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> [3-[(Allyl-methyl-amino)-methyl]-4-(2-methoxyâethoxy)-phenyl]-[4-(5-allyloxymethyl-thiophen-2-yl)-pyrimidin-2-yl]-amine (<b>12c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5f</b> and <b>10b</b> (yield, 72%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 481 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> [3-[(Allyl-methyl-amino)-methyl]-4-(2-methoxyâethoxy)-phenyl]-[4-(5-allyloxymethyl-furan-2-yl)-pyrimidin-2-yl]-amine (<b>12d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5d</b> and <b>10b</b> (yield, 68%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 465 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> [4-(1-Allyl-1<i>H</i>-indol-6-yl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (<b>12e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5c</b> and <b>10e</b> (yield, 71%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 510 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 8.20 (s, 1H), 8.15 (d, 1H), 7.81 (d, 1H), 7.64 (d, 1H), 7.43 (d, 1H), 7.33 (m, 1H), 7.02 (d, 1H), 6.43 (d, 1H), 5.85 (m, 2H), 5.15 (d, 1H), 5.06 (m, 2H), 4.95 (d, 1H), 4.79 (m, 2H), 4.55 (s, 2H), 4.30 (m, 2H), 4.00 (m, 2H), 3.68 (m, 2H), 3.60 (m, 2H), 3.18 (m, 2H), 2.10 (m, 2H), 1.91 (m, 2H).</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> [3-Allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-[4-(5-allyloxymethyl-thiophen-2-yl)-pyrimidin-2-yl]-amine (<b>12f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5f</b> and <b>10e</b> (yield, 87%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 507 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> [3-Allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-[4-(5-allyloxymethyl-thiophen-3-yl)-pyrimidin-2-yl]-amine (<b>12g</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5g</b> and <b>10e</b> (yield, 88%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 507 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> [4-(5-Allyloxymethyl-furan-3-yl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (<b>12h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5h</b> and <b>10e</b> (yield, 92%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 491 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> [4-(5-Allyloxymethyl-furan-2-yl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (<b>12i</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5d</b> and <b>10e</b> (yield, 96%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 491 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> [4-(4-Allyloxymethyl-furan-2-yl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (<b>12j</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5i</b> and <b>10e</b> (yield, 63%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 491 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> [4-(5-Allyloxymethyl-pyridin-3-yl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (<b>12k</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5e</b> and <b>10e</b> (yield, 68%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 502 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> [3-Allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-[4-(2-fluoro-pyridin-4-yl)-pyrimidin-2-yl]-amine (<b>12l</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4e</b> and <b>10e</b> (yield, 81%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 450 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 8.47â8.35 (m, 3H), 7.81 (d, 1H), 7.62 (dd, 1H), 7.50 (dd, 1H), 7.39 (s, 1H), 6.93 (d, 1H), 5.90â6.00 (dq, 1H), 5.33 (dd, 1H), 5.17 (dd, 1H), 4.58 (s, 2H), 4.45 (s, 2H), 4.10 (d, 2H), 4.04 (s, 2H), 3.65 (br s, 2H), 3.10 (m, 2H), 2.21â2.10 (m, 4H).</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> [3-Allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-[4-(2-fluoro-pyridin-4-yl)-5-methyl-pyrimidin-2-yl]-amine; compound with methane (<b>12n</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>4p</b> and <b>10e</b> (yield, 83%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 479 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> [4-(1-Allyl-1<i>H</i>-indol-6-yl)-5-methyl-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (<b>12p</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5c</b> and <b>10e</b> (yield, 86%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 524 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> {3-[(Allyl-methyl-amino)-methyl]-phenyl}-[4-(2-but-3-enyloxy-pyridin-4-yl)-pyrimidin-2-yl]-amine (<b>11d</b>)</h4><div class="NLM_p">To a solution of 3-buten-1-ol (30 Î¼L, 0.349 mmol), in anhydrous THF (2 mL), was added 60% sodium hydride in mineral oil (16 mg, 0.400 mmol) at 0 Â°C. The solution was stirred at 0 Â°C was 0.5 h and then slowly allowed to warm to rt. To this solution of sodium salt of 3-buten-1-ol was added a solution of <b>11c</b> (TFA salt, 120 mg, 0.269 mmol) in anhydrous THF (2 mL). The resulting mixture was heated at 70 Â°C for 12 h, quenched with water, and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation and purification by preparative HPLC afforded the title compound in 40% yield. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 402 ([M + H]<sup>+</sup>).</div><div class="NLM_p last">Following a procedure similar to that of <b>11d</b>, the following intermediates were synthesized.</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> [3-Allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-[4-(2-but-3-enyloxy-pyridin-4-yl)-pyrimidin-2-yl]-amine (<b>12m</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12l</b> and 3-buten-1-ol (yield, 48%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 502([M + H]<sup>+</sup>).</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> [3-Allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-[4-(2-but-3-enyloxy-pyridin-4-yl)-5-methyl-pyrimidin-2-yl]-amine (<b>12o</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12n</b> and 3-buten-1-ol (yield, 36%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 516 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 15-(2-Methoxyethoxy)-12-methyl-7-oxa-25-thia-12,19,21,24-tetraaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (<b>14i</b>)</h4><div class="NLM_p">To <b>12i</b> (TFA salt, 100 mg, 0.170 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) at ambient temperature was added 4 M HCl until the pH reached 2.0â2.2. The solution was degassed (N<sub>2</sub>), and Grubbs second generation catalyst (14 mg, 0.017 mmol) was added in two portions (7 mg each) at 1 h intervals. The resulting mixture was stirred at 40â45 Â°C for 4 h. The reaction mixture was cooled and concentrated under reduced pressure to furnish an oil, which was purified by preparative rpHPLC to obtain 63 mg of <b>14i</b> as a TFA salt (yield, 66%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 463 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>): Î´ 8.56 (d, 1H), 8.38 (d, 1H), 8.29 (br s, 1H), 7.17 (d, 1H), 7.11â7.06 (m, 2H), 7.03â7.01 (m, 1H), 5.99 (dt, 1H), 5.84 (dt, 1H), 4.66 (s, 2H<sub>2</sub>), 4.57 (s, 2H), 4.37 (t, 2H), 4.18 (d, 2H), 4.09 (d, 2H), 3.79 (br s, 2H), 3.69 (t, 2H), 3.35â3.34 (m, 2H), 2.21â2.07 (m, 4H).</div><div class="NLM_p last">Following a procedure similar to that of <b>14i</b>, the following compounds were synthesized.</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 14-Methyl-19-oxa-1,5,7,14,26-pentaaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-2(26),3,5,8(27), 9,11,16-heptaene (<b>13a</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11a</b> and isolated as freebase (33 mg, 15% from <b>5a</b> in two steps; mixture of cis/trans 1:9 by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 380 ([M + H]<sup>+</sup>). For the major trans isomer: <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 8.33 (t, 1H, <i>J</i> = 1.6 Hz), 7.92 (d, 1H, <i>J</i> = 6.1), 7.57 (b s, 1H), 7.16 (t, 1H, <i>J</i> = 7.7 Hz), 6.85 (d, 1H, <i>J</i> = 7.5 Hz), 6.75 (dd, 1H, <i>J</i> = 7.9, 1.3 Hz), 5.98 (d, 1H, <i>J</i> = 6.2 Hz), 5.92 (dm, 1H, <i>J</i> = 15.6 Hz), 5.61 (ddd, 1H, <i>J</i> = 15.7, 4.5, 3.7 Hz), 4.88 (dm, 1H, <i>J</i> = 13.0 Hz), 4.14 (dd, 1H, <i>J</i> = 15.1, 1.3 Hz), 3.91 (dd, 1H, <i>J</i> = 14.9, 4.6 Hz), 3.80 (d, 1H, <i>J</i> = 13.3 Hz), 3.58 (d, 1H, <i>J</i> = 12.4 Hz), 3.47 (m, 2H), 3.22 (d, 1H, <i>J</i> = 12.4 Hz), 3.20 (t, 1H, <i>J</i> = 5.4 Hz), 3.05 (dd, 1H, <i>J</i> = 13.1, 7.4 Hz), 2.93 (m, 1H), 2.87 (m, 1H), 2.16 (s, 3H), 1.95 (m, 1H), 1.83â1.75 (m, 2H), 1.65â1.49 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) Î´ 161.9, 159.6, 156.5, 140.6, 140.1, 129.9, 129.3, 128.1, 122.9, 119.6, 117.9, 94.2, 71.2, 68.5, 60.43, 60.38, 46.7, 45.4, 42.9, 36.1, 27.9, 25.2.</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 20,22-Etheno-14-methyl-5,7,14,20,26-pentaaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>13b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11b</b> (yield, 69%; mixture of cis/trans 13:87 by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 396 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 8.27 (m, 1H), 8.10â8.16 (m, 2H), 7.53â7.59 (m, 2H), 7.25â7.40 (m, 3H), 7.03 (m, 2H), 6.42 (m, 1H), 5.50â5.80 (m, 2H), 5.05 (m, 1H), 4.80 (m, 1H), 4.59 (m, 1H), 4.42 (m, 1H), 4.15 (m, 1H), 3.95 (m, 1H).</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 19,21-Etheno-14-oxa-5,7,19,25-tetraaza-tetracyclo[18.3.1.1(2,6).1(8,12)]hexacosa-1(24),2(25),3,5,8(26),9,11,16,20,22-decaene (<b>13c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11c</b> (yield, 76%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 363 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 9.04â9.03 (m, 1H), 8.42 (d, 1H) 7.33 (d, 1H) 7.23â7.15 (m, 4H), 6.69 (d, 1H), 6.28 (dt, 1H), 6.20â6.09 (m, 1H), 4.66 (s, 2H), 4.52â4.47 (m, 1H), 4.20 (br d, 2H), 4.11â4.04 (m, 1H), 3.92â3.81 (m, 2H), 2.90â2.84 (m, 3H).</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 14-Methyl-20-oxa-5,7,14,22,26-pentaaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>13d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11e</b> (yield, 52%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 374 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 9.08 (m, 1H), 8.64 (d, 1H), 8.31 (m, 1H), 7.84 (m, 1H), 7.53â7.52 (dd, 1H), 7.48â7.43 (m, 2H), 7.29â7.27 (m, 1H), 7.18 (m,1H), 6.29â6.21 (m, 1H), 5.90â5.82 (m, 1H), 4.39â3.72 (m, 6H), 2.68 (s, 5H).</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 14-Methyl-19-oxa-5,7,14,23,26-pentaaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>13e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11f</b> (yield, 44%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 374 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´ 10.04 (s, 1H), 9.30 (s, 1H), 8.78 (s, 1H), 8.72 (s, 1H), 8.67 (d, 1H), 8.61 (s, 1H), 7.67 (d, 1H), 7.39 (t, 1H), 7.31 (d, 1H), 7.15 (d, 1H), 6.24â6.18 (m, 1H), 5.96â5.88 (m, 1H), 4.75â4.62 (m, 2H), 4.50 (d, 1H), 4.15 (d, 2H), 4.05â3.93 (m, 2H), 3.84â3.76 (m, 1H), 2.68 (s, 1H).</div></div><div id="sec4_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 14,19-Dioxa-5,7,23,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>13f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11g</b> (yield, 73%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 350 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ 10.91(s, 1H), 8.67â8.66 (m, 1H), 8.17â8.14 (m, 1H), 7.37â7.32 (m, 1H), 7.28â7.27 (m, 1H), 7.18â7.16 (m, 2H), 6.97 (d, 1H), 6.65 (d, 1H), 6.00 (dt, 1H), 5.89 (dt, 1H), 4.61 (s, 2H), 4.58 (s, 2H), 4.15 (d, 2H), 4.08 (d, 2H).</div></div><div id="sec4_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 12-Methyl-7,25-dioxa-12,19,21,24-tetraaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (<b>13g</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11h</b> (yield, 51%; mixture of cis/trans 15:85 by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 369 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 8.68 (m, 1H), 8.37 (m, 1H), 8.40 (m, 1H), 8.21 (m, 1H), 7.71 (m, 2H), 7.48 (m, 2H), 7.30 (m, 2H), 6.62 (m, 1H), 5.75 (m, 2H), 4.46 (m, 2H), 4.25 (m, 2H), 3.75â3.95 (m, 2H), 2.87 (s, 3H), 2.75 (m, 2H).</div></div><div id="sec4_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (<b>13h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11i</b> (yield, 46%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 361 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´ 9.29 (s, 1H), 8.78 (s, 1H), 8.63 (d, 1H), 8.57 (s, 1H), 8.52 (s, 1H), 7.62 (d, 1H), 7.28 (t, 1H), 7.14 (d, 1H), 6.98 (d, 1H), 5.90â5.81 (m, 2H), 4.62 (s, 2H), 4.49 (s, 2H), 4.09â4.05 (m, 4H).</div></div><div id="sec4_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 19,21-Etheno-11-(2-(pyrrolidin-1-yl)ethoxy)-14-oxa-5,7,19,25-tetraaza-tetracyclo[18.3.1.1(2,6).1(8,12)]hexacosa-1(24),2(25),3,5,8(26),9,11,16,20,22-decaene (<b>14a</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12a</b> (yield, 65%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 476 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 9.02 (d, 1H), 8.40 (d, 1H), 7.31â7.25 (m, 2H), 7.22â7.14 (m, 2H), 6.69 (d, 1H, CH), 6.28 (dt, 1H), 6.20â6.11 (m, 1H), 4.66 (s, 2H), 4.49â4.39 (m, 4H), 4.25â4.15 (m, 2H), 3.88â3.76 (m, 6H), 2.89â2.84 (m, 4H), 2.31â2.04 (m, 5H).</div></div><div id="sec4_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 19,21-Etheno-3-methyl-11-(2-(pyrrolidin-1-yl)ethoxy)-14-oxa-5,7,19,25-tetraaza-tetracyclo[18.3.1.1(2,6).1(8,12)]hexacosa-1(24),2(25),3,5,8(26),9,11,16,20,22-decaene (<b>14b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12b</b> (yield, 44%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 492 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 8.80 (d, 1H), 8.32 (d, 1H), 7.83 (d, 1H), 7.31â7.28 (m, 2H), 7.18 (d, 1H), 7.07 (d, 1H), 6.31â6.17 (m, 2H), 4.56â4.47 (m, 4H), 4.36â4.24 (m, 4H), 4.04â3.95 (m, 2H), 3.82â3.77 (m, 5H), 2.71 (s, 3H), 2.21â2.13 (m, 5H).</div></div><div id="sec4_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 11-(2-(Pyrrolidin-1-yl)ethoxy)-14,19-dioxa-5,7,23,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>14c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12c</b> (yield, 48%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 453 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´ 9.78 (s, 1H), 9.54 (br s 1H), 8.73 (d, 1H), 8.48 (d, 1H), 7.90 (d, 1H), 7.35 (d, 1H), 7.15 (s, 1H), 7.10â7.14 (m, 1H), 6.23 (dt, 1H), 6.10 (dt, 1H), 4.90 (d, 2H), 4.11â4.35 (m, 11H), 3.70â3.74 (m, 2H), 2.63 (brs, 3H).</div></div><div id="sec4_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 11-(2-(Pyrrolidin-1-yl)ethoxy)-14,20-dioxa-5,7,22,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>14d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12d</b> (yield, 39%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 437 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´ 9.40 (s, 1H), 8.48 (d, 1H), 8.40 (d, 1H), 7.46 (d, 1H), 7.16 (d, 1H), 7.0 (dd, 1H), 6.90 (d, 1H), 6.67 (d, 1H), 5.93 (dt, 1H,), 5.69 (dt, 1H), 4.52 (s, 2H), 4.04â4.07 (m, 2H), 3.97 (d, 2H), 3.62â3.90 (m, 2H), 3.44 (s, 2H), 3.33 (s, 3H), 3.06 (d, 2H), 2.08 (s, 3H).</div></div><div id="sec4_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 3-Methyl-11-(2-(pyrrolidin-1-yl)ethoxy)-14,20-dioxa-5,7,22,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (<b>14e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12e</b> (yield, 65%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 482 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´ 9.58 (s, 1H), 8.69 (m, 1H), 8.47 (m, 1H), 8.17 (s, 1H), 7.68 (m, 1H), 7.49â7.53 (m, 2H), 7.20 (m, 2H), 7.01 (m, 1H), 6.52 (m, 1H), 6.17 (m, 1H), 5.66 (m, 1H), 4.97 (m, 2H), 4.49 (m, 2H), 4.26 (m, 2H), 3.97 (m, 2H), 3.59â3.67 (m, 4H), 3.18 (m, 2H), 2.05 (m, 2H), 1.90 (m, 2H).</div></div><div id="sec4_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 12-Methyl-15-(2-(pyrrolidin-1-yl)ethoxy)-7,25-dioxa-12,19,21,24-tetraaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (<b>14f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12f</b> (yield, 55%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 479 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 8.66 (d, 1H), 8.32 (d, 1H), 7.81 (d, 1H), 7.27 (d, 1H), 7.12 (dd, 1H), 7.07â7.02 (m, 2H), 6.08 (dt, 1H), 5.98 (dt, 1H), 4.61 (s, 2H), 4.38 (t, 2H), 4.18 (d, 4H), 3.81 (br s, 2H), 3.69 (t, 2H), 3.37â3.35 (m, 2H), 2.22â2.08 (m, 6H).</div></div><div id="sec4_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 12-Methyl-15-(2-(pyrrolidin-1-yl)ethoxy)-7-oxa-25-thia-12,19,21,24-tetraaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (<b>14g</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12g</b> (yield, 70%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 479 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 9.03 (d, 1H), 8.86 (d, 1H), 8.81 (d, 1H), 8.26 (s, 1H), 7.81 (d, 1H), 7.59 (dd, 1H), 7.56â7.51 (m, 1H), 6.38 (dt, 1H), 6.31 (dt, 1H), 5.24 (s, 2H), 5.14 (s, 2H), 4.86 (t, 2H), 4.65 (d, 2H), 4.54 (d, 2H), 4.29 (br s, 2H), 4.18 (t, 2H), 3.84â3.83 (m, 1H), 2.80â2.48 (m, 5H).</div></div><div id="sec4_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 15-(2-Methoxyethoxy)-12-methyl-7,25-dioxa-12,19,21,24-tetraaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (<b>14h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12h</b> (yield, 54%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 463 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 8.56 (d, 1H), 8.38 (d, 1H), 8.29 (br s, 1H), 7.17 (d, 1H), 7.11â7.06 (m, 2H), 7.03â7.01 (m, 1H), 5.99 (dt, 1H), 5.84 (dt, 1H), 4.66 (s, 2H<sub>2</sub>), 4.57 (s, 2H), 4.37 (t, 2H), 4.18 (d, 2H), 4.09 (d, 2H), 3.79 (brs, 2H), 3.69 (t, 2H), 3.35â3.34 (m, 2H), 2.21â2.07 (m, 4H).</div></div><div id="sec4_1_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> 15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12-dioxa-25-thia-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (<b>14j</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12j</b> (yield, 52%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 463 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 8.51 (bs, 1H), 8.34 (bd, 1H), 7.75 (s, 1H), 7.49 (s, 1H), 7.11â7.06 (m, 2H), 7.00 (d, 1H), 6.07 (dt, 1H), 5.92 (dt, 1H), 4.63 (s, 2H), 4.47 (s, 2H), 4.36 (t, 2H), 4.19 (d, 2H), 4.08 (d, 2H), 3.79 (bs, 2H), 3.69 (t, 2H), 3.27â3.25 (m, 2H), 2.21â2.08 (m, 4H).</div></div><div id="sec4_1_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> 15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12-dioxa-4-thia-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,5(25),9,14(26),15,17,20,22-nonaene (<b>14k</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12k</b> (yield, 34%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 474 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 9.26 (brs, 1H), 8.90â8.87 (m, 2H), 8.61â8.58 (m, 2H), 7.44 (d, 1H), 7.15â7.12 (m, 1H), 7.06 (d, 1H), 5.96 (dt, 1H), 5.88 (dt, 1H), 4.77 (s, 2H), 4.64 (s, 2H), 4.38 (t, 2H), 4.15 (q, 4H), 3.81 (brs, 2H), 3.70 (t, 2H), 3.27â3.25 (m, 2H), 2.23â1.99 (m, 5H).</div></div><div id="sec4_1_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> (9<i>E</i>)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26), 15,17,20,22-nonaene (<b>14l</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12n</b> (yield, 46%; mixture of cis/trans 33:67 by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 474 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 8.91 (d, 1H), 8.57â8.54 (m, 1H), 8.28 (d, 1H), 7.70 (s, 1H), 7.51â7.46 (m, 1H), 7.38â7.32 (m, 1H), 7.14â7.12 (m, 1H), 7.05 (s, 1H), 5.93â5.85 (m, 1H), 5.68â5.62 (m, 1H), 4.46 (s, 2H), 4.58 (m, 2H), 4.46â4.34 (m, 2H), 4.12 (d, 2H), 3.82 (m, 2H), 3.72 (m, 2H), 3.37 (m, 2H), 2.52 (m, 2H), 2.25 (m, 2H), 2.10 (m, 2H).</div></div><div id="sec4_1_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> 15-(2-(Pyrrolidin-1-yl)ethoxy)-4,7,12-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,5(25),9,14(26),15,17,20,22-nonaene (<b>14m</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12p</b> (yield, 58%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 488 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´ 8.82 (d, 1H), 8.38 (s, 1H), 8.25 (d, 1H); 7.24â7.30 (m, 2H); 7.07â7.11 (m, 2H); 6.99â7.03 (m, 2H), 5.81â5.92 (m, 1H); 5.54â5.64 (m, 1H), 4.55â4.60 (m, 2H); 4.33â4.36 (m, 2H); 4.07 (d, 2H); 3.75â3.85 (m, 2H); 3.65â3.71 (m, 2H); 3.22â3.29 (m, 4H); 2.54â2.60 (m, 2H); 2.35 (s, 3H); 2.18â2.28 (m, 2H); 2.04â2.12 (m, 2H).</div></div><div id="sec4_1_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 15-(2-(Pyrrolidin-1-yl)ethoxy)-3,7,12-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2(25),4,9,14(26),15,17,20,22-nonaene (<b>14n</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12q</b> (yield, 49%; >95% trans by <sup>1</sup>H NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 496 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>) Î´ 8.54 (brs, 1H), 8.24 (s, 1H), 7.72 (s, 1H), 7.55 (d, 1H), 7.26 (d, 1H), 7.15 (d, 1H), 6.98 (dd, 1H), 6.88 (d, 1H), 6.44 (d, 1H), 5.96â6.01 (m, 1H), 5.37â5.43 (m, 1H), 4.85 (s, 2H), 4.39 (s, 2H), 4.20 (d, 2H), 3.90 (d, 2H), 3.65 (brs, 2H), 3.51 (d, 2H), 3.03â3.15 (m, 2H), 2.19 (s, 3H), 2.07 (brs, 2H), 1.92 (brs, 2H).</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> Biology</h3><div class="NLM_p last">Enzyme assays (JAK1, JAK2, JAK3, TYK2, CDK2, and FLT3), cell proliferation, and computational algorithms were carried out as per the previously reported methods.<a onclick="showRef(event, 'ref22 ref34'); return false;" href="javascript:void(0);" class="ref ref22 ref34">(22, 34)</a> hERG activity was determined by MDS Pharma Services (<a href="http://www.mdsps.com" class="extLink">www.mdsps.com</a>). CYP induction and phenotyping was carried out at Cyprotex (<a href="http://www.cyprotex.com" class="extLink">www.cyprotex.com</a>).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> Metabolic Stability in Liver Microsomes</h3><div class="NLM_p last">Reactions were carried out in a 96 well microtiter plate. Compound <b>14l</b> (5 Î¼M) was incubated with HLM/MLM/DLM (at 0.87 mg/mL) or RLM and MoLM (at 1 mg/mL) in a reaction mix containing 50 mM potassium phosphate buffer (pH 7.4) and an NADPH regeneration system. The plate was incubated in an incubator shaker set at 37 Â°C. At predetermined time points, 0 min, 5,15, 30, 45, and 60 min, reactions (50 Î¼L aliquots) were terminated by the addition of 100 Î¼L of an ice-cold mixture of acetonitrile and DMSO (80:20, v/v).The terminated reaction mixtures were centrifuged and the supernatants analyzed by LC-MS. Stability was assessed by plotting the percent of parent compound remaining against time on a logâlinear scale and estimating the half-life from the linear portion of the logâlinear curve using the first order equation <i>t</i><sub>1/2</sub> = 0.693/<i>k</i>, where <i>k</i> = slope of the curve (equal to the first order elimination rate constant).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> Human in Vitro CYP450 Inhibition Assay</h3><div class="NLM_p last">Compounds were incubated (at concentrations of 0.001, 0.01, 0.1, 1.0, 5, 10, and 25 Î¼M) with human liver microsomes (0.25 mg/mL for CYP3A4 and 0.5 mg/mL for CYP1A2, CYP2C9, CYP2C19, and CYP2D6) and NADPH (1 mM) in the presence of the probe substrates testosterone for CYP3A4, phenacetin (CYP1A2), diclofenac (CYP2C9), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) at 37 Â°C. The selective inhibitors ketoconazole, furafylline, sulphaphenazole, ticlopidine, and quinidine were used as positive controls for CYP3A4, 1A2, CYP2C9, CYP2C19, and CYP2D6, respectively. For all CYP enzymes, the reactions were terminated by the addition of a mixture of acetonitrile and DMSO (8:2). The samples were centrifuged, and the supernatants were analyzed for respective metabolites 6-Î²-hydroxytestosterone (CYP3A4), acetaminophen (CYP1A2), 4-hydroxydiclofenac (CYP2C9), 5-hydroxyomeprazole (CYP2C19), and dextrorphan (CYP2D6) by LC-MS/MS. Formic A decrease in the formation of the metabolites compared to the vehicle control was used to calculate an IC<sub>50</sub> value (test compound concentration which produces 50% inhibition).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> Caco-2 Bidirectional Permeability Assay</h3><div class="NLM_p last">Caco-2 cells obtained from ATCC were used between passage numbers 40â60. Cells were seeded on to Millipore Multiscreen Caco-2 plates at 1 Ã 10<sup>5</sup> cells/cm<sup>2</sup>. The permeability study was performed on day 20. The incubation medium used was Hanks Balanced Salt Solution (HBSS) at pH 7.4, with 25 mM HEPES and 4.45 mM glucose at 37 Â°C. Incubations were carried out for 120 min in an atmosphere of 5% CO<sub>2</sub> with a relative humidity of 95% at 37 Â°C. The compound solutions were made by diluting 10 mM <b>14l</b> in DMSO with HBSS to give a final concentration of 10 Î¼M (final DMSO concentration 1%). The apical compartment inserts were placed into companion plates containing fresh HBSS. For basolateral to apical (BâA) permeability determination, the experiment was initiated by replacing the buffer in the inserts, then placing them in companion plates containing dosing solutions. After 120 min, the companion plate was removed, and apical and basolateral samples were diluted and analyzed by LC-MS/MS. The permeability of <b>14l</b> was assessed in duplicate. On each plate, reference compounds of known permeability characteristics were run as controls. The control compound and <b>14l</b> were quantified by LC-MS/MS. The integrity of the monolayers throughout the experiment was checked by monitoring lucifer yellow permeation using fluorimetric analysis.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> In Vitro Plasma Protein Binding</h3><div class="NLM_p last">Equilibrium dialysis was performed in a Micro-Equilibrium Dialyzer (Harvard Apparatus) with a chamber volume of 500 Î¼L (each compartment with a volume of 250 Î¼L). The semipermeable membrane used was rinsed with Milli-Q-water and soaked for 10 min in PBS. Compound <b>14l</b> was added to plasma (from mouse, rat, dog, monkey, and humans) to obtain a final concentration of 1000 ng/mL. The spiked plasma was vortexed, and 250 Î¼L was aliquoted into one chamber of the dialyzer cell. The other chamber was filled with 250 Î¼L of PBS buffer. The assembled cell was placed into a water-bath at 37 Â°C, and dialysis was performed for 4 h. Following dialysis, 50 Î¼L of PBS dialyzed samples containing free <b>14l</b> was transferred into 2 mL Eppendorf tubes in triplicate for extraction. Samples were extracted with 1250 Î¼L of MTBE (methyl tertiary-butyl ether) for 30 min and centrifuged at 4 Â°C for 10 min at 13,000 rpm in a microcentrifuge. The supernatants (1000 Î¼L) were transferred into fresh Eppendorf tubes and dried in a SpeedVac at 43 Â°C for 35 min. The dried samples were reconstituted with 100 Î¼L of acetonitrile/Milli-Q-water (60:40), vortexed, centrifuged for 2 min at 13,000 rpm, and analyzed by LC-MS/MS.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> Pharmacokinetics</h3><div class="NLM_p last">Female BALB/c nude mice (aged 8â10 weeks and weighing 18â22 g), male Wistar rats (aged 8â10 weeks, weighing 230â260 g), male Beagle dogs (â¼5â6 months of age, weighing â¼10 kg), and male rhesus monkeys (â¼4 years of age and weighing 6â7 kg) were used in the studies. All the animal studies were performed as per approved internal protocols for animal care and use. The oral doses for mice, rats, dogs, and monkeys were 50, 50, 5, and 20 mg/kg, respectively. The doses were administered, by gavage, as suspensions (0.5% methylcellulose and 0.1% Tween 80) to mice, rats, and monkeys and as gelatin capsules (SNAP-FIT, Capsugel) to dogs. Following oral dosing, serial blood samples were collected at different time points (0 to 24 h) in tubes containing K<sub>3</sub>EDTA as anticoagulant and centrifuged, and plasma was separated and stored at â70 Â°C until analysis. Plasma samples were processed and analyzed by LC/MS/MS. Pharmacokinetic parameters were estimated by noncompartmental methods using WinNonlin (ver 5.2, Pharsight, CA).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> High Throughput Solubility Assay</h3><div class="NLM_p last">This assay measures the solubility of a compound in PBS in a high throughput mode. The assay was done using 96-well semitransparent PP microplates with a V-shaped bottom (Greiner Bio-one) and 96-well UV transparent microplates (Greiner Bio-One). Compound solutions (250 Î¼M) were prepared in 10 mM phosphate buffer (pH 7.0) containing 20% DMSO in a total volume of 0.2 mL. Plates were placed on a shaker set at 600 rpm for 1.5 h, following which the plates were allowed to stand for 2 h at room temperature. The plates were centrifuged at 1500g for 15 min. The supernatants were transferred to a UV transparent microplate and analyzed by UV-spectrophotometry at the appropriate absorption maxima. The concentration of the compound in the supernatant was quantified using a calibration curve.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> Thermodynamic Solubility Assay</h3><div class="NLM_p last">This assay measures the solubility of a compound in pH buffered solutions in a low throughput mode with HPLC quantification. Approximately 5 mg of <b>14l</b> (citrate) was weighed into individual 4 mL glass vials. Appropriate volumes of buffers of pH 1, 3, 5, 7, and 9 were added to corresponding vials containing the compound to make 5 mg/mL (w/v) stock of <b>14l</b>. Each sample was made in triplicate. Prior to the addition of buffers, their initial pH was recorded. Following addition of the buffers, the vials were capped tightly with screw caps, transferred to the shaking platform, and allowed to shake for 24 h at 600 rpm at room temperature. After 24 h of shaking, each sample was filtered using a syringe filter (0.4 Î¼m) into clean Eppendorf tubes, and final pH of the filtrate was measured. The filtrates were appropriately diluted using acetonitrile/water (1:1), vortexed for 3 min, and centrifuged at 13200 rpm for 3 min. The resultant supernatant was transferred into HPLC vials and analyzed by HPLC-UV.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> Cell Lines</h3><div class="NLM_p last">SET2 cells were obtained from DSMZ (Braunschweig, Germany), while HL60, MDA-MB-231, HEK293, and 32D cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA). These cells were cultured as described previously.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Human CD4<sup>+</sup> T cells, isolated from peripheral blood mononuclear cells with >95% purity, were purchased from AllCells (Emeryville, CA) and maintained in X-VIVO 20 media (Lonza, Basel, Switzerland).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> Western Blot Analyses</h3><div class="NLM_p last">Cells were lysed and proteins immunoprecipitated as previously described.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Following SDSâpolyacrylamide gel electrophoresis, proteins were transferred to PVDF membranes. Western blots were performed according to standard methods. pJAK2 (Y1007/8) (Cat #3776), pSTAT3 (Y705), antimouse IgG (Cat #7074), and antirabbit IgG, HRP-linked (Cat #7076) antibodies were purchased from Cell Signaling Technology (Beverly, MA). pSTAT4 (Y693) (Cat# AF4319) was from R&D systems (Minneapolis, MN). pSTAT5 (Y694, Cat #611965) was obtained from BD Biosciences (San Jose, CA), tubulin (Cat #65â829) from Millipore (Billerica, MA), and actin (Cat #A2066) from Sigma (St Louis, MO). After the final wash, membranes were incubated for 5 min in ECL from GE-Healthcare (Singapore). The images were captured digitally using the LAS-3000 Life Science Imager from Fujifilm (Tokyo, Japan). Densitometric analysis was performed using MultiGauge software (v3.1) from Fujifilm.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> Collagen-Induced Arthritis (CIA)<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a></h3><div class="NLM_p last">The mouse CIA study was performed at Bolder BioPATH (Boulder, CO) and was approved by the Bolder BioPATHâs Institutional Animal Care and Use Committee (IACUC). Six to eight week old male B10/RIII mice were obtained from Jackson Laboratories (Bar Harbor, ME). The mice were immunized by injecting 300 Î¼g of bovine type II collagen (Elastin Products, Owensville, MO) emulsified in Freundâs Complete Adjuvant (Sigma) at the base of the tail on day 0 and again on day 15. The mice were randomized into treatment groups, and oral treatment with <b>14l</b> was initiated after the onset of arthritis (usually between days 18â22) identified by establishment of swelling in at least one paw. Treatment was continued twice daily (b.i.d) for 10 days. Arthritis severity was evaluated on a scale of 0â5 based on the number of joints affected, swelling of the joints, and the severity of erythema. The sum of scores for all four paws from each mouse was used as the total clinical score. The data for paw scores (mean for animal) was analyzed by determining the area under the dosing curve (AUC). The daily mouse scores were obtained, and the area under the curve between the treatment days and the final day was computed. Means for each group were determined, and percentage inhibition from arthritis controls was calculated by comparing values for treated and normal animals.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i117"><a href="/doi/suppl/10.1021/jm201454n">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23812" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23812" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Explanation for CDK2 selectivity of <b>14i</b> versus <b>14h</b> and explanation for the CDK2 potency of 13 h. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm201454n/suppl_file/jm201454n_si_001.pdf">jm201454n_si_001.pdf (150.88 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm201454n" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony D. William</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a8dfc9c6dcc0c7c6d19999e8d1c9c0c7c786cbc7c5"><span class="__cf_email__" data-cfemail="a8dfc9c6dcc0c7c6d19999e8d1c9c0c7c786cbc7c5">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angeline C.-H. Lee</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anders Poulsen</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kee Chuan Goh</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Babita Madan</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Hart</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Evelyn Tan</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haishan Wang</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harish Nagaraj</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dizhong Chen</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chai Ping Lee</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric T. Sun</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ramesh Jayaraman</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mohammad Khalid Pasha</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kantharaj Ethirajulu</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeanette M. Wood</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian W. Dymock</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science
Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore
117528</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d1327e5077-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i118">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26862" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26862" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Changyong Hu, Bee Kheng Ng, and Yong Cheng Tan for the generation of screening data, Venkatesh Reddy for PK sample analysis, Zahid Bonday and Miah Kiat for protein preparation work, Sam Ramanujulu Murugappan for NMR, and Dr. Simon Campbell for helpful discussions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i119" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i119"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i120" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i120"> Abbreviations Used</h2><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen induced arthritis</p></td></tr><tr><td class="NLM_term">CDKs</td><td class="NLM_def"><p class="first last">cyclin-dependent kinases</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">fms-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">janus kinase 2</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">RCM</td><td class="NLM_def"><p class="first last">ring closing metathesis</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20255" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20255" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Walsh, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gravallese, E. M.</span><span> </span><span class="NLM_article-title">Bone remodeling in rheumatic disease: a question of balance</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">233</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">â</span> <span class="NLM_lpage">312</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1111%2Fj.0105-2896.2009.00857.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=20193007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslaqsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=233&publication_year=2010&pages=301-312&author=N.+C.+Walshauthor=E.+M.+Gravallese&title=Bone+remodeling+in+rheumatic+disease%3A+a+question+of+balance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Bone remodeling in rheumatic disease: a question of balance</span></div><div class="casAuthors">Walsh, Nicole C.; Gravallese, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">233</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">301-312</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The past decade has obsd. an explosion of new information regarding the impact of inflammation on bone.  In rheumatic diseases, several factors that act as both immune modulators and regulators of bone homeostasis have been shown to mediate an imbalance in bone resorption and bone formation resulting in joint degeneration.  In rheumatoid arthritis (RA), focal bone loss is due to excess bone resorption by osteoclasts.  Resorption is mediated in part by increased local expression of the cytokine receptor activator of nuclear factor-ÎºB ligand (RANKL) compared with expression of its decoy receptor osteoprotegerin (OPG).  Bone formation by osteoblasts is also impaired at erosion sites in RA, and inhibitors of the canonical Wingless (Wnt) signaling pathway, including DKK1, have been implicated in the suppression of normal osteoblast function at these sites.  Inhibition of DKK1 in an animal model of RA attenuated bone erosion by increasing OPG expression as well as promoting bone formation.  In contrast to RA, inflammation in the spondyloarthropathies often results in excess periosteal bone formation, highlighting that the net impact of inflammation on bone is specific to the site at which inflammation occurs, and the cell types, cytokines, and factors present within the local bone microenvironment.  This fertile area of research bears watching for the identification of novel targets for the prevention of abnormal bone remodeling in inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmiN-GD2MZWLVg90H21EOLACvtfcHk0lgqm0FBGrsvgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslaqsrk%253D&md5=2575f9b46c28f7f1c01d5328cfe40f4a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.0105-2896.2009.00857.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.0105-2896.2009.00857.x%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DN.%2BC.%26aulast%3DGravallese%26aufirst%3DE.%2BM.%26atitle%3DBone%2520remodeling%2520in%2520rheumatic%2520disease%253A%2520a%2520question%2520of%2520balance%26jtitle%3DImmunol.%2520Rev.%26date%3D2010%26volume%3D233%26spage%3D301%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Machold, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nell, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolen, J. S.</span><span> </span><span class="NLM_article-title">Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1186%2Far1966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=16719936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A280%3ADC%252BD28zos1yitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=211&author=K.+P.+Macholdauthor=V.+P.+Nellauthor=T.+A.+Stammauthor=J.+S.+Smolen&title=Aspects+of+early+arthritis.+Traditional+DMARD+therapy%3A+is+it+sufficient%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?</span></div><div class="casAuthors">Machold Klaus P; Nell Valerie P K; Stamm Tanja A; Smolen Josef S</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis research & therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is increasing evidence for beneficial effects of early DMARD (disease-modifying antirheumatic drug) therapy over delayed treatment in patients who present with arthritis of recent onset.  However, no universal consensus exists concerning the choice of initial drug or whether single drugs or combinations should be given as initial treatments.  Recent studies have focused on the benefits of various strategies in which treatments were tailored to achieve low levels of disease activity, as assessed using validated response criteria.  These studies demonstrated superiority of 'aggressive' over 'conventional' approaches.  Whether the inclusion of tumour necrosis factor antagonists or other biologic targeted therapies in such strategies confers additional benefits in terms of improved long-term outcomes must be clarified by further studies.  Assessment of risks in the individual patient, allowing individual 'tailoring' of the initial treatment, would be desirable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQk1qViHPdTfRLDWw4HIq2sfW6udTcc2eaC8Fqwb8haLrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zos1yitw%253D%253D&md5=311a2350bfd460023abef30231e5682f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2Far1966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far1966%26sid%3Dliteratum%253Aachs%26aulast%3DMachold%26aufirst%3DK.%2BP.%26aulast%3DNell%26aufirst%3DV.%2BP.%26aulast%3DStamm%26aufirst%3DT.%2BA.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26atitle%3DAspects%2520of%2520early%2520arthritis.%2520Traditional%2520DMARD%2520therapy%253A%2520is%2520it%2520sufficient%253F%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2006%26volume%3D8%26spage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziring, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gjertson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R. R.</span><span> </span><span class="NLM_article-title">TNFalpha blockade in human diseases: mechanisms and future directions</span> <span class="citation_source-journal">Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">â</span> <span class="NLM_lpage">136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1016%2Fj.clim.2007.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=17916444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsFKntQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2008&pages=121-136&author=M.+Wongauthor=D.+Ziringauthor=Y.+Korinauthor=S.+Desaiauthor=S.+Kimauthor=J.+Linauthor=D.+Gjertsonauthor=J.+Braunauthor=E.+Reedauthor=R.+R.+Singh&title=TNFalpha+blockade+in+human+diseases%3A+mechanisms+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">TNFÎ± blockade in human diseases: Mechanisms and future directions</span></div><div class="casAuthors">Wong, Maida; Ziring, David; Korin, Yael; Desai, Sheetal; Kim, Sungjin; Lin, Jan; Gjertson, David; Braun, Jonathan; Reed, Elaine; Singh, Ram Raj</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-136</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Tumor necrosis factor-Î± (TNFÎ±) antagonists have shown remarkable efficacy in a variety of immune-mediated inflammatory diseases (IMIDs).  In spite of their therapeutic popularity, little is known about their modes of action in vivo and factors that limit their scope of therapeutic use.  Intriguingly, while all TNFÎ± antagonists including blocking antibodies and sol. receptors are effective in certain IMIDs, only anti-TNFÎ± antibodies are effective in other IMIDs.  Early efforts at understanding how TNFÎ± antagonists act in IMIDs centered on their ability to neutralize sol. TNFÎ± or to block TNF receptors from binding to their ligands.  Subsequent studies suggested a role of complement-mediated lysis or antibody-dependent cell cytotoxicity in their therapeutic effects.  More recent models postulate that TNFÎ± blockers may act by affecting intracellular signaling, with the end result being a hastened cell cycle arrest, apoptosis, suppression of cytokine prodn., or improved Treg cell function.  TNFÎ± antagonists can also modulate the functions of myofibroblasts and osteoclasts, which might explain how TNFÎ± antagonists reduce tissue damage in chronic IMIDs.  Focusing on the human therapeutic experience, this anal. review will review the biol. of mechanisms of action, the limiting factors contributing to disease restriction in therapeutic efficacy, and the mechanism and frequency of treatment-limiting adverse responses of TNFÎ± antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplPPg145r58rVg90H21EOLACvtfcHk0lgqm0FBGrsvgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsFKntQ%253D%253D&md5=08302c72cf62eead8f33fb31a22fa0dd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2007.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2007.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DM.%26aulast%3DZiring%26aufirst%3DD.%26aulast%3DKorin%26aufirst%3DY.%26aulast%3DDesai%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DGjertson%26aufirst%3DD.%26aulast%3DBraun%26aufirst%3DJ.%26aulast%3DReed%26aufirst%3DE.%26aulast%3DSingh%26aufirst%3DR.%2BR.%26atitle%3DTNFalpha%2520blockade%2520in%2520human%2520diseases%253A%2520mechanisms%2520and%2520future%2520directions%26jtitle%3DClin.%2520Immunol.%26date%3D2008%26volume%3D126%26spage%3D121%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Khraishi, M.</span><span> </span><span class="NLM_article-title">Comparative overview of safety of the biologics in rheumatoid arthritis</span> <span class="citation_source-journal">J. Rheumatol. Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">â</span> <span class="NLM_lpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.3899%2Fjrheum.090128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=19509327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotlSjur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2009&pages=25-32&author=M.+Khraishi&title=Comparative+overview+of+safety+of+the+biologics+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative overview of safety of the biologics in rheumatoid arthritis</span></div><div class="casAuthors">Khraishi, Majed</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology, Supplement</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">Biologic Therapies for the Management of Rheumatoid Arthritis</span>),
    <span class="NLM_cas:pages">25-32</span>CODEN:
                <span class="NLM_cas:coden">JRSUDX</span>;
        ISSN:<span class="NLM_cas:issn">0380-0903</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">A review.  Six biol. agents are currently available in Canada for the treatment of rheumatoid arthritis (RA): abatacept, adalimumab, anakinra, etanercept, infliximab, and rituximab.  Although they are generally considered to be safe and well tolerated, concerns have been raised regarding the use of biol. therapies in the treatment of RA.  The new biol. agents abatacept and rituximab have novel mechanisms of action, and may therefore offer different safety profiles.  The most important safety concerns with the biol. therapies remain the increased risk of infection.  An increased risk of malignancies, including lymphoma and skin cancer, has been noted in RA trials, but the extent to which each of the biol. therapies contributes to the risk of malignancy has not been clearly defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl8cpgp1o50rVg90H21EOLACvtfcHk0ljKHJ8mB0TauQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotlSjur4%253D&md5=ff5af7b4459e0de202a8ad74349400f3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.090128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.090128%26sid%3Dliteratum%253Aachs%26aulast%3DKhraishi%26aufirst%3DM.%26atitle%3DComparative%2520overview%2520of%2520safety%2520of%2520the%2520biologics%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Rheumatol.%2520Suppl.%26date%3D2009%26volume%3D82%26spage%3D25%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Buch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, P.</span><span> </span><span class="NLM_article-title">New therapies in the management of rheumatoid arthritis</span> <span class="citation_source-journal">Curr. Opin. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">â</span> <span class="NLM_lpage">251</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1097%2FBOR.0b013e3283454124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=21427579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFKls7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=245-251&author=M.+H.+Buchauthor=P.+Emery&title=New+therapies+in+the+management+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New therapies in the management of rheumatoid arthritis</span></div><div class="casAuthors">Buch, Maya H.; Emery, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Rheumatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">245-251</span>CODEN:
                <span class="NLM_cas:coden">CORHES</span>;
        ISSN:<span class="NLM_cas:issn">1040-8711</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The therapeutic landscape in the management of rheumatoid arthritis (RA) has witnessed significant changes over the past decade.  The ambition to improve outcomes further, minimize safety concerns and provide more convenient means of administration are all factors that continue to drive continued drug development.  This review summarizes novel therapies that have been most recently under investigation.  Recent findings: More refined drug technol. has seen the development of s.c. forms of existing therapies (abatacept, tocilizumab), as well as newer-generation monoclonal antibodies (e.g. B-cell-depleting agents, ocrelizumab and ofatumumab and the TNF-inhibitors certolizumab and golimumab).  Alternative methods of targeting crit. pathways, for example Blys inhibition (atacicept) and IL-6 as opposed to IL-6 receptor antagonism, have also been evaluated.  Finally, small mols. are receiving increasing attention, with some of the protein kinases inhibitors particularly promising.  Summary: The new emerging therapies for the management of RA illustrate much diversity, in terms of both drug technol. as well as the immunol. target.  Although not all may succeed in reaching the market, important insights can still be gained.  Challenging and exciting times lie ahead as these new technologies are embraced and efforts are made to det. how best to implement in practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTPD1rxbWFNbVg90H21EOLACvtfcHk0ljKHJ8mB0TauQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFKls7k%253D&md5=c3190617b11ca7cb36325cd493f98ee6</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2FBOR.0b013e3283454124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FBOR.0b013e3283454124%26sid%3Dliteratum%253Aachs%26aulast%3DBuch%26aufirst%3DM.%2BH.%26aulast%3DEmery%26aufirst%3DP.%26atitle%3DNew%2520therapies%2520in%2520the%2520management%2520of%2520rheumatoid%2520arthritis%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2011%26volume%3D23%26spage%3D245%26epage%3D251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Walker, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. D.</span><span> </span><span class="NLM_article-title">The Jak-STAT pathway in rheumatoid arthritis</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1650</span><span class="NLM_x">â</span> <span class="NLM_lpage">1653</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=16142855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFSktLfI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2005&pages=1650-1653&author=J.+G.+Walkerauthor=M.+D.+Smith&title=The+Jak-STAT+pathway+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The Jak-STAT pathway in rheumatoid arthritis</span></div><div class="casAuthors">Walker, Jennifer G.; Smith, Malcolm D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1650-1653</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">A review discusses several studies evaluating the role of Jak-STAT pathway in rheumatoid arthritis.  The Jak-STAT signal transduction pathway is differentially regulated in inflammatory arthritis, with changes already documented in STAT1, STAT3, STAT4, and STAT6 expression.  There is growing evidence that modulation of the Jak-STAT pathway may represent a viable alternative therapeutic target in the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpeL2mM7Gh27Vg90H21EOLACvtfcHk0ljKHJ8mB0TauQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFSktLfI&md5=21c28d6a026a89dcea963cb5aa569d6d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DJ.%2BG.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26atitle%3DThe%2520Jak-STAT%2520pathway%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Rheumatol.%26date%3D2005%26volume%3D32%26spage%3D1650%26epage%3D1653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Yamaoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saharinen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, V. E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">The Janus kinases (Jaks)</span> <span class="citation_source-journal">Genome Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">253.1</span><span class="NLM_x">â</span> <span class="NLM_lpage">253.6</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=253.1-253.6&author=K.+Yamaokaauthor=P.+Saharinenauthor=M.+Pesuauthor=V.+E.+T.+Holtauthor=O.+Silvennoinenauthor=J.+J.+O%E2%80%99Shea&title=The+Janus+kinases+%28Jaks%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DHolt%26aufirst%3DV.%2BE.%2BT.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Janus%2520kinases%2520%2528Jaks%2529%26jtitle%3DGenome%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D253.1%26epage%3D253.6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuccola, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jepson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shlyakter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoock, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furey, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frantz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauffenbach, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennani, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledeboer, M. W.</span><span> </span><span class="NLM_article-title">Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7938</span><span class="NLM_x">â</span> <span class="NLM_lpage">7941</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901383u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7938-7941&author=T.+Wangauthor=J.+P.+Duffyauthor=J.+Wangauthor=S.+Halasauthor=F.+G.+Salituroauthor=A.+C.+Pierceauthor=H.+J.+Zuccolaauthor=J.+R.+Blackauthor=J.+K.+Hoganauthor=S.+Jepsonauthor=D.+Shlyakterauthor=S.+Mahajanauthor=Y.+Guauthor=T.+Hoockauthor=M.+Woodauthor=B.+F.+Fureyauthor=J.+D.+Frantzauthor=L.+M.+Dauffenbachauthor=U.+A.+Germannauthor=B.+Fanauthor=M.+Namchukauthor=Y.+L.+Bennaniauthor=M.+W.+Ledeboer&title=Janus+kinase+2+inhibitors.+Synthesis+and+characterization+of+a+novel+polycyclic+azaindole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm901383u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901383u%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DDuffy%26aufirst%3DJ.%2BP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHalas%26aufirst%3DS.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DZuccola%26aufirst%3DH.%2BJ.%26aulast%3DBlack%26aufirst%3DJ.%2BR.%26aulast%3DHogan%26aufirst%3DJ.%2BK.%26aulast%3DJepson%26aufirst%3DS.%26aulast%3DShlyakter%26aufirst%3DD.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHoock%26aufirst%3DT.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DFurey%26aufirst%3DB.%2BF.%26aulast%3DFrantz%26aufirst%3DJ.%2BD.%26aulast%3DDauffenbach%26aufirst%3DL.%2BM.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DFan%26aufirst%3DB.%26aulast%3DNamchuk%26aufirst%3DM.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26aulast%3DLedeboer%26aufirst%3DM.%2BW.%26atitle%3DJanus%2520kinase%25202%2520inhibitors.%2520Synthesis%2520and%2520characterization%2520of%2520a%2520novel%2520polycyclic%2520azaindole%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7938%26epage%3D7941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Chen, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prchal, J. T.</span><span> </span><span class="NLM_article-title">JAK2 kinase inhibitors and myeloproliferative disorders</span> <span class="citation_source-journal">Curr Opin Hematol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">â</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1097%2FMOH.0b013e3283366b91" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=20087176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1yns7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=110-116&author=A.+T.+Chenauthor=J.+T.+Prchal&title=JAK2+kinase+inhibitors+and+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2 kinase inhibitors and myeloproliferative disorders</span></div><div class="casAuthors">Chen, Andrew T.; Prchal, Josef T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">110-116</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: The pathophysiol. of Philadelphia-chromosome neg. myeloproliferative disorders has significantly advanced with the discovery of JAK2V617F.  The prevalence of JAK2V617F mutation has made it a much anticipated target for inhibition; this review will update and assess progress.  Recent findings: Many agents have been studied in preclin. trials, of which few have entered clin. trials.  Data from the clin. trials are limited and mostly in the form of abstrs. and reviews.  Summary: The prevalence of the JAK2V617F mutation in the classic Philadelphia-chromosome neg. myeloproliferative disorders has made it a much anticipated target for inhibition.  Present in greater than 90% of patients with polycythemia vera and approx. 50% of patients with essential thrombocythemia and primary myelofibrosis, it has been hoped that targeted inhibition of JAK2V617F would achieve similar disease control as imatinib mesylate has produced in chronic myeloid leukemia.  However, JAK2V617F in the Philadelphia-chromosome neg. myeloproliferative disorders, unlike bcr/abl tyrosine kinase in chronic myeloid leukemia, is not a causative but rather a secondary somatic mutation.  As the JAK2 inhibitors move into phase III clin. trials, their efficacy and role in therapy is becoming clearer; however, there are still many questions needing answers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa5ZWxfhCU7rVg90H21EOLACvtfcHk0lgrdD8pmoMBMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1yns7Y%253D&md5=a03760b25eb1630429ab40137fb179c9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2FMOH.0b013e3283366b91&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMOH.0b013e3283366b91%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DA.%2BT.%26aulast%3DPrchal%26aufirst%3DJ.%2BT.%26atitle%3DJAK2%2520kinase%2520inhibitors%2520and%2520myeloproliferative%2520disorders%26jtitle%3DCurr%2520Opin%2520Hematol%26date%3D2010%26volume%3D17%26spage%3D110%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">â</span> <span class="NLM_lpage">8484</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=S.-P.+Changauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+A+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lgrdD8pmoMBMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DS.-P.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520A%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favata, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">5298</span><span class="NLM_x">â</span> <span class="NLM_lpage">5307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-5307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shiauthor=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0ljcDbXkd8noVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D5307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Kiss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sayeski, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">KeserÅ©, G. M.</span><span> </span><span class="NLM_article-title">Recent developments on JAK2 inhibitors: a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">â</span> <span class="NLM_lpage">495</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1517%2F13543771003639436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=20205617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslalsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=471-495&author=R.+Kissauthor=P.+P.+Sayeskiauthor=G.+M.+Keser%C5%A9&title=Recent+developments+on+JAK2+inhibitors%3A+a+patent+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments on JAK2 inhibitors: a patent review</span></div><div class="casAuthors">Kiss, Robert; Sayeski, Peter P.; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-495</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: JAK2 is one of the most promising targets against neoplastic growth.  A somatic mutation (V617F) resulting in enhanced JAK2 kinase activity can be frequently found in patients with serious myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia and primary myelofibrosis.  Preclin. results strongly support that JAK2 inhibitors could be effectively used in these indications.  Pharmaceutical companies and academic groups have developed a no. of potent JAK2 inhibitors during the last decade.  Tolerability and effectiveness of the most promising compds. are currently being investigated in clin. trials.  Areas covered in this review: In this paper, we aim to give a comprehensive review of the currently available patent literature of JAK2 inhibitors.  What the reader will gain: We tried to collect the published core structures possessing JAK2 inhibitory potency including compds. developed by academic and industrial research groups.  We review the currently available patent literature as well as the key papers contg. addnl. information about the described JAK2 inhibitors.  Clin. status data were collected by searching the Prous Integrity and Pharmaprojects databases.  Take home message: The significant no. of JAK2 inhibitors published and numerous clin. trials involving these compds. suggest that some of them might be approved in the next few years and can serve as novel drugs for the treatment of JAK2-dependent pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJQgQopptoVrVg90H21EOLACvtfcHk0ljcDbXkd8noVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslalsrY%253D&md5=2531795d8c66c3b7173a0c1a3b2738e1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1517%2F13543771003639436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543771003639436%26sid%3Dliteratum%253Aachs%26aulast%3DKiss%26aufirst%3DR.%26aulast%3DSayeski%26aufirst%3DP.%2BP.%26aulast%3DKeser%25C5%25A9%26aufirst%3DG.%2BM.%26atitle%3DRecent%2520developments%2520on%2520JAK2%2520inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D471%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Mesa, R. A.</span><span> </span><span class="NLM_article-title">Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">â</span> <span class="NLM_lpage">403</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=20506062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1yltr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=394-403&author=R.+A.+Mesa&title=Ruxolitinib%2C+a+selective+JAK1+and+JAK2+inhibitor+for+the+treatment+of+myeloproliferative+neoplasms+and+psoriasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis</span></div><div class="casAuthors">Mesa, Ruben A.</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-403</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, being developed by Incyte Corp and Novartis AG.  Ruxolitinib was initially developed to target the constitutive activation of the JAK-STAT pathway in patients with myeloproliferative neoplasms (MPNs).  Meaningful redns. in spleen size and constitutional symptoms have been noted in patients with myelofibrosis (both primary and post-essential thrombocythemia/polycythemia vera).  Data from a phase I/II clin. trial led to ongoing registration trials in the US and Europe.  Toxicity (primarily decreased erythropoiesis and thrombocytopoiesis) has been managed by close control of dosing.  The inhibition of inflammatory cytokine signaling through JAK1 inhibition has led to intriguing results in patients with rheumatoid arthritis and psoriasis (using a topical cream formulation).  Ruxolitinib is a well tolerated, first-in-class JAK2 inhibitor with various potential clin. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5yUMfeRYwE7Vg90H21EOLACvtfcHk0ljcDbXkd8noVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1yltr0%253D&md5=9f89b13c71527c112b797375c93ccbff</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26atitle%3DRuxolitinib%252C%2520a%2520selective%2520JAK1%2520and%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%2520and%2520psoriasis%26jtitle%3DIDrugs%26date%3D2010%26volume%3D13%26spage%3D394%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Passamonti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maffioli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caramazza, D.</span><span> </span><span class="NLM_article-title">New generation small-molecule inhibitors in myeloproliferative neoplasms</span> <span class="citation_source-journal">Curr. Opin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">â</span> <span class="NLM_lpage">123</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1097%2FMOH.0b013e32834ff575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=22227528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFanur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=117-123&author=F.+Passamontiauthor=M.+Maffioliauthor=D.+Caramazza&title=New+generation+small-molecule+inhibitors+in+myeloproliferative+neoplasms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">New generation small-molecule inhibitors in myeloproliferative neoplasms</span></div><div class="casAuthors">Passamonti, Francesco; Maffioli, Margherita; Caramazza, Domenica</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-123</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Myeloproliferative neoplasms (MPNs) are diseases that carry the JAK2 (V617F) mutation in about 70% of the patients.  The purpose of this review is to describe the recent advances in the therapy of MPNs with JAK2 inhibitors.  Recent findings: Many drugs are now under investigations targeting different pathways crit. for MPN development, such as the JAK-STAT (JAK2 inhibitors: INCB018424 or ruxolitinib, TG101348 or SAR302503, CYT387, SB1518, CEP701 and LY2784544) and the PI3K/AKT/mTOR (everolimus) pathways, or act through remodeling of chromatin with a key role in epigenetics (givinostat, panobinostat and vorinostat).  The most relevant effects were spleen size redn. and relief of constitutional symptoms.  Summary: Patients who might benefit from JAK2 inhibitors in clin. practice are mostly those with splenomegaly or with constitutional symptoms.  We should alert patients with lower Hb levels that these therapies might, although temporarily, favor the need for red blood cell transfusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_BM7nBQTO8LVg90H21EOLACvtfcHk0li0RicuN3E9nQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFanur4%253D&md5=2684c66d8b79d201a2a17d43bfed53b5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1097%2FMOH.0b013e32834ff575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMOH.0b013e32834ff575%26sid%3Dliteratum%253Aachs%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DMaffioli%26aufirst%3DM.%26aulast%3DCaramazza%26aufirst%3DD.%26atitle%3DNew%2520generation%2520small-molecule%2520inhibitors%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2012%26volume%3D19%26spage%3D117%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Santos, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">JAK2 inhibitors: Whatâs the true therapeutic potential?</span> <span class="citation_source-journal">Blood Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">â</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1016%2Fj.blre.2010.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=21095048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitFKjsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=53-63&author=F.+P.+Santosauthor=S.+Verstovsek&title=JAK2+inhibitors%3A+What%E2%80%99s+the+true+therapeutic+potential%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2 inhibitors: What's the true therapeutic potential?</span></div><div class="casAuthors">Santos, Fabio P. S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">53-63</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Physicians treating patients with the classic Philadelphia-neg. myeloproliferative neoplasms (Ph-neg. MPNs) (polycythemia vera [PV], essential thrombocythemia [ET] and primary myelofibrosis [PMF]) traditionally had few therapeutic drugs available.  Spurred by the discovery of activating mutation of the JAK2 tyrosine kinase (JAK2 V617F mutation) in patients with Ph-neg. MPNs several years ago, several JAK2 inhibitors were synthesized and are currently undergoing clin. trials in patients with PMF, PV and ET.  Initial results from these studies have shown that these drugs can markedly reduce spleen size and alleviate constitutional symptoms, increase wt. and improve exercise capacity in MF patients, thus improve quality of their life, which is significant clin. benefit.  In ET and PV JAK2 inhibitor therapy may efficiently control blood cell count, as well as improve splenomegaly and control disease related symptoms.  JAK2 inhibitors are a novel class of agents with promising results for treating patients with MF, PV and ET.  In this article we will review the current evidence regarding the role of JAK2 mutations in the pathogenesis of Ph-neg. MPNs and summarize results from the most recent clin. trials with JAK2 inhibitors in these disorders.  JAK2 inhibitors are a novel class of agents with promising results for treating patients with MF, PV and ET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZb8q4WeXPbVg90H21EOLACvtfcHk0li0RicuN3E9nQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitFKjsbw%253D&md5=5e99d696b87a7523af5d1fb7c540f386</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2010.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2010.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DF.%2BP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DJAK2%2520inhibitors%253A%2520What%25E2%2580%2599s%2520the%2520true%2520therapeutic%2520potential%253F%26jtitle%3DBlood%2520Rev.%26date%3D2011%26volume%3D25%26spage%3D53%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">140</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=127-140&author=A.+Quintas-Cardamaauthor=H.+Kantarjianauthor=J.+Cortesauthor=S.+Verstovsek&title=Janus+kinase+inhibitors+for+the+treatment+of+myeloproliferative+neoplasias+and+beyond"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DJanus%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasias%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D127%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Ioannidis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almeida, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollard, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alimzhanov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebernitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huszar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinda, M.</span><span> </span><span class="NLM_article-title">Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol â3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">â</span> <span class="NLM_lpage">276</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1011319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=262-276&author=S.+Ioannidisauthor=M.+L.+Lambauthor=T.+Wangauthor=L.+Almeidaauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=B.+Pengauthor=M.+Suauthor=H.+J.+Zhangauthor=E.+Hoffmannauthor=C.+Rivardauthor=I.+Greenauthor=T.+Howardauthor=H.+Pollardauthor=J.+Readauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Yeauthor=D.+Huszarauthor=M.+Zinda&title=Discovery+of+5-chloro-N2-%5B%281S%29-1-%285-fluoropyrimidin-2-yl%29ethyl%5D-N4-%285-methyl-1H-pyrazol+%E2%88%923-yl%29pyrimidine-2%2C4-diamine+%28AZD1480%29+as+a+novel+inhibitor+of+the+Jak%2FStat+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm1011319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1011319%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DGreen%26aufirst%3DI.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DPollard%26aufirst%3DH.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25205-chloro-N2-%255B%25281S%2529-1-%25285-fluoropyrimidin-2-yl%2529ethyl%255D-N4-%25285-methyl-1H-pyrazol%2520%25E2%2588%25923-yl%2529pyrimidine-2%252C4-diamine%2520%2528AZD1480%2529%2520as%2520a%2520novel%2520inhibitor%2520of%2520the%2520Jak%252FStat%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D262%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Paunovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenbroeck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span> </span><span class="NLM_article-title">Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL)-12, â17, â23 and â27 in autoimmunity</span> <span class="citation_source-journal">Rheumatology (Oxford)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">771</span><span class="NLM_x">â</span> <span class="NLM_lpage">776</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1093%2Frheumatology%2Fkem352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=18238793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtlentrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=771-776&author=V.+Paunovicauthor=H.+P.+Carrollauthor=K.+Vandenbroeckauthor=M.+Gadina&title=Signalling%2C+inflammation+and+arthritis%3A+crossed+signals%3A+the+role+of+interleukin+%28IL%29-12%2C+%E2%88%9217%2C+%E2%88%9223+and+%E2%88%9227+in+autoimmunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling, inflammation and arthritis</span></div><div class="casAuthors">Paunovic, V.; Carroll, H. P.; Vandenbroeck, K.; Gadina, M.</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">771-776</span>CODEN:
                <span class="NLM_cas:coden">RUMAFK</span>;
        ISSN:<span class="NLM_cas:issn">1462-0324</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Autoimmune diseases such as rheumatoid arthritis are the consequence of a persistent imbalance between pro- and anti-inflammatory immune mechanisms leading to chronic inflammation.  The action of several cytokines is at the basis of this complex process.  This review is focused on the signalling events triggered by two major groups of cytokines, namely the IL-12 and IL-17 families, which in the past few years have been shown to have a prominent role in the pathogenesis of such diseases.  In particular, we will focus on the signalling cascades set in motion by such cytokines and how this may relate to the pathogenesis of human immune and inflammatory disorders as knowledge of such cascades may help in the development of novel therapeutic approaches for such diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8fu5A_UnbnbVg90H21EOLACvtfcHk0li0RicuN3E9nQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtlentrs%253D&md5=993ceb0f2b339360afdca135de4abb79</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fkem352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fkem352%26sid%3Dliteratum%253Aachs%26aulast%3DPaunovic%26aufirst%3DV.%26aulast%3DCarroll%26aufirst%3DH.%2BP.%26aulast%3DVandenbroeck%26aufirst%3DK.%26aulast%3DGadina%26aufirst%3DM.%26atitle%3DSignalling%252C%2520inflammation%2520and%2520arthritis%253A%2520crossed%2520signals%253A%2520the%2520role%2520of%2520interleukin%2520%2528IL%2529-12%252C%2520%25E2%2588%259217%252C%2520%25E2%2588%259223%2520and%2520%25E2%2588%259227%2520in%2520autoimmunity%26jtitle%3DRheumatology%2520%2528Oxford%2529%26date%3D2008%26volume%3D47%26spage%3D771%26epage%3D776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ishizaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muromoto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohshiro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekine, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimoda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oritani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, T.</span><span> </span><span class="NLM_article-title">Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice</span> <span class="citation_source-journal">Int. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">â</span> <span class="NLM_lpage">582</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1093%2Fintimm%2Fdxr057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=21765170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGlu77M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=575-582&author=M.+Ishizakiauthor=R.+Muromotoauthor=T.+Akimotoauthor=Y.+Ohshiroauthor=M.+Takahashiauthor=Y.+Sekineauthor=H.+Maedaauthor=K.+Shimodaauthor=K.+Oritaniauthor=T.+Matsuda&title=Tyk2+deficiency+protects+joints+against+destruction+in+anti-type+II+collagen+antibody-induced+arthritis+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice</span></div><div class="casAuthors">Ishizaki, Masayuki; Muromoto, Ryuta; Akimoto, Toshihiko; Ohshiro, Yuya; Takahashi, Miki; Sekine, Yuichi; Maeda, Hiroaki; Shimoda, Kazuya; Oritani, Kenji; Matsuda, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">575-582</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Tyrosine kinase-2 (Tyk2) participates in the signaling pathways of multiple cytokines in innate and acquired immunity.  In the present study, we investigated the in vivo involvement of Tyk2 in anti-type II collagen antibody-induced arthritis (CAIA) using Tyk2-deficient mice.  Hind paws of wild-type mice showed massive swelling and erythema by arthritogenic antibody injection, whereas Tyk2-deficient mice did not show any signs of arthritis.  Indeed, neither the infiltration of inflammatory cells nor the fibrillation of articular cartilages was obsd. in Tyk2-deficient mice.  Tyk2 deficiency also reduced the prodn. of Th1/Th17-related cytokines, the other proinflammatory cytokines and matrix metalloproteases, which are induced in the CAIA paw.  Our results demonstrate a crit. contribution of Tyk2 in the development of arthritis, and we propose that Tyk2 might be an important candidate for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKbV7yONzwx7Vg90H21EOLACvtfcHk0liITfB-Uhlqwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGlu77M&md5=852ac0d9133c8eb5423a186b0040dbb7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxr057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxr057%26sid%3Dliteratum%253Aachs%26aulast%3DIshizaki%26aufirst%3DM.%26aulast%3DMuromoto%26aufirst%3DR.%26aulast%3DAkimoto%26aufirst%3DT.%26aulast%3DOhshiro%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSekine%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DShimoda%26aufirst%3DK.%26aulast%3DOritani%26aufirst%3DK.%26aulast%3DMatsuda%26aufirst%3DT.%26atitle%3DTyk2%2520deficiency%2520protects%2520joints%2520against%2520destruction%2520in%2520anti-type%2520II%2520collagen%2520antibody-induced%2520arthritis%2520in%2520mice%26jtitle%3DInt.%2520Immunol.%26date%3D2011%26volume%3D23%26spage%3D575%26epage%3D582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Dehlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokarewa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottapel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnusson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlberg, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarkowski, A.</span><span> </span><span class="NLM_article-title">Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">e3633</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=e3633&author=M.+Dehlinauthor=M.+Bokarewaauthor=R.+Rottapelauthor=S.+J.+Fosterauthor=M.+Magnussonauthor=L.+E.+Dahlbergauthor=A.+Tarkowski&title=Intra-articular+fms-like+tyrosine+kinase+3+ligand+expression+is+a+driving+force+in+induction+and+progression+of+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDehlin%26aufirst%3DM.%26aulast%3DBokarewa%26aufirst%3DM.%26aulast%3DRottapel%26aufirst%3DR.%26aulast%3DFoster%26aufirst%3DS.%2BJ.%26aulast%3DMagnusson%26aufirst%3DM.%26aulast%3DDahlberg%26aufirst%3DL.%2BE.%26aulast%3DTarkowski%26aufirst%3DA.%26atitle%3DIntra-articular%2520fms-like%2520tyrosine%2520kinase%25203%2520ligand%2520expression%2520is%2520a%2520driving%2520force%2520in%2520induction%2520and%2520progression%2520of%2520arthritis%26jtitle%3DPLoS%2520One%26date%3D2008%26volume%3D3%26spage%3De3633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Dehlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlandsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brisslert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokarewa, M.</span><span> </span><span class="NLM_article-title">Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">â</span> <span class="NLM_lpage">817</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1189%2Fjlb.1110640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=21771900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlWitLrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2011&pages=811-817&author=M.+Dehlinauthor=S.+Anderssonauthor=M.+Erlandssonauthor=M.+Brisslertauthor=M.+Bokarewa&title=Inhibition+of+fms-like+tyrosine+kinase+3+alleviates+experimental+arthritis+by+reducing+formation+of+dendritic+cells+and+antigen+presentation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation</span></div><div class="casAuthors">Dehlin, Mats; Andersson, Sofia; Erlandsson, Malin; Brisslert, Mikael; Bokarewa, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">811-817</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Society for Leucocyte Biology</span>)
        </div><div class="casAbstract">TKs are intracellular signaling mols. essential for cell homeostasis.  Inhibition of TKs is used in treatment of malignancies and diabetes mellitus.  The present study evaluated the role of Flt3 in antigen-induced arthritis.  Mice were immunized with mBSA, and arthritis was induced by an i.a. injection of mBSA.  Treatment with the Flt3 inhibitor sunitinib was started together with mBSA immunization or together with the induction of arthritis.  The mBSA-injected joints were evaluated morphol. for signs of synovitis and bone/cartilage destruction.  Markers of bone metab. and antibody responses were measured by ELISA.  Maturation of DCs in the bone marrow and spleen was evaluated by flow cytometry.  Sunitinib treatment reduced the intensity of synovitis and the incidence of bone destruction.  The redn. in bone destruction was seen when the treatment was started at the time of immunization or at the time of arthritis induction.  The antiarthritic effect was achieved by inhibition of DCs, redn. of antibody prodn., and bone metab.  Inhibition of Flt3 is a potent antiarthritic mechanism reducing antigen presentation, synovial inflammation, and bone resorption.  Down-regulation of TKs may be a useful tool in the treatment of human RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqccTBQDx10d7Vg90H21EOLACvtfcHk0liEWiBMhYstyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlWitLrF&md5=6e2339d9127229cf00760beec828b211</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1189%2Fjlb.1110640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.1110640%26sid%3Dliteratum%253Aachs%26aulast%3DDehlin%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DS.%26aulast%3DErlandsson%26aufirst%3DM.%26aulast%3DBrisslert%26aufirst%3DM.%26aulast%3DBokarewa%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520fms-like%2520tyrosine%2520kinase%25203%2520alleviates%2520experimental%2520arthritis%2520by%2520reducing%2520formation%2520of%2520dendritic%2520cells%2520and%2520antigen%2520presentation%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2011%26volume%3D90%26spage%3D811%26epage%3D817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1. 1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">â</span> <span class="NLM_lpage">4658</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.+1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.%25201%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of kinase spectrum selective macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2) and Fms-liketyrosine kinase-3 (FLT3) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">â</span> <span class="NLM_lpage">196</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201112g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=169-196&author=A.+D.+Williamauthor=A.+Leeauthor=K.+C.+Gohauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+Teoauthor=H.+Nagarajauthor=C.+P.+Leeauthor=H.+Wangauthor=M.+Williamsauthor=E.+T.+Sunauthor=C.+Huauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+Woodauthor=B.+W.+Dymock&title=Discovery+of+kinase+spectrum+selective+macrocycle+%2816E%29-14-Methyl-20-oxa-5%2C7%2C14%2C26-tetraaza-tetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2827%29%2C9%2C11%2C16%2C21%2C23-decaene+%28SB1317%2FTG02%29%2C+a+potent+inhibitor+of+cyclin+dependant+kinases+%28CDKs%29%2C+Janus+kinase+2+%28JAK2%29+and+Fms-liketyrosine+kinase-3+%28FLT3%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm201112g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201112g%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DC.%2BP.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520kinase%2520spectrum%2520selective%2520macrocycle%2520%252816E%2529-14-Methyl-20-oxa-5%252C7%252C14%252C26-tetraaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252827%2529%252C9%252C11%252C16%252C21%252C23-decaene%2520%2528SB1317%252FTG02%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520cyclin%2520dependant%2520kinases%2520%2528CDKs%2529%252C%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520Fms-liketyrosine%2520kinase-3%2520%2528FLT3%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D169%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, S.-L.</span><span> </span><span class="NLM_article-title">Asymmetric construction of polycyclic indoles through olefin cross- metathesis/intramolecular FriedelâCrafts alkylation under sequential catalysis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7428</span><span class="NLM_x">â</span> <span class="NLM_lpage">7431</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=7428-7431&author=Q.+Caiauthor=Z.-A.+Zhaoauthor=S.-L.+You&title=Asymmetric+construction+of+polycyclic+indoles+through+olefin+cross-+metathesis%2Fintramolecular+Friedel%E2%80%93Crafts+alkylation+under+sequential+catalysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DZ.-A.%26aulast%3DYou%26aufirst%3DS.-L.%26atitle%3DAsymmetric%2520construction%2520of%2520polycyclic%2520indoles%2520through%2520olefin%2520cross-%2520metathesis%252Fintramolecular%2520Friedel%25E2%2580%2593Crafts%2520alkylation%2520under%2520sequential%2520catalysis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D7428%26epage%3D7431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Schmidt, B.</span><span> </span><span class="NLM_article-title">Ruthenium-catalyzed cyclizations: more than just olefin metathesis!</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">4996</span><span class="NLM_x">â</span> <span class="NLM_lpage">4999</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=4996-4999&author=B.+Schmidt&title=Ruthenium-catalyzed+cyclizations%3A+more+than+just+olefin+metathesis%21"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DB.%26atitle%3DRuthenium-catalyzed%2520cyclizations%253A%2520more%2520than%2520just%2520olefin%2520metathesis%2521%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D4996%26epage%3D4999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Chen, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRose, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burka, L. T.</span><span> </span><span class="NLM_article-title">Metabolism of furans in vitro: ipomeanine and 4-ipomeanol</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1320</span><span class="NLM_x">â</span> <span class="NLM_lpage">1329</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx060128f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVylu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=1320-1329&author=L.+J.+Chenauthor=E.+F.+DeRoseauthor=L.+T.+Burka&title=Metabolism+of+furans+in+vitro%3A+ipomeanine+and+4-ipomeanol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of Furans in Vitro: Ipomeanine and 4-Ipomeanol</span></div><div class="casAuthors">Chen, Ling-Jen; DeRose, Eugene F.; Burka, Leo T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1320-1329</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ipomeanine (IPN), 4-ipomeanol (4-IPO), 1-ipomeanol (1-IPO), and 1,4-ipomeadiol (DIOL) are toxic 3-substituted furans found in mold-damaged sweet potatoes.  IPN and 4-IPO are the most toxic, but all produce pulmonary toxicity in cattle and rodents, and 4-IPO induces hepatotoxicity in humans.  These furans require metabolic activation to elicit toxicity, but the limited information obtained from previous metab. studies prompted us to initiate the investigation reported here.  Our initial studies of 4-IPO metab. by rat liver microsomes demonstrated that the oxidn. of 4-IPO to IPN and redn. to DIOL occurred and that more IPN was metabolized to a reactive species than 4-IPO or DIOL.  Incubation of IPN and Gly produced a 2'-pyrrolin-5'-one adduct establishing that IPN was metabolized to an enedial.  N-Acetylcysteine reacted with the 5'-aldehyde of the enedial to give two 2',5'-dihydro-2'-hydroxyfurans stabilized by H bonding between the 2'-OH and 3'-keto group.  Reaction of the enedial metabolite of IPN with one GSH gave several adducts including a pyrrole derived from the 1,2-addn. of GSH to the 5'-aldehyde as well as two tricyclic 2'-pyrrolines derived from the 1,4-addn. of GSH at the 4'-position.  The identities of the pyrrole and 2'-pyrroline GSH adducts were confirmed by observation of structurally similar adducts from Cys conjugation with the enedial metabolite of IPN.  Several minor adducts from the conjugation of the enedial metabolite of IPN with two GSH were also detected.  Mono-GSH and bis-GSH adducts were derived from both the 1,2-and 1,4-addn. of GSH to the enedial metabolite of 4-IPO in rat liver microsomal incubations of 4-IPO and GSH.  Sequential oxidn. of 4-IPO to IPN and then to the enedial metabolite followed by GSH conjugation also occurred in the 4-IPO incubations.  The complex structures of the reaction products of the enedial with biol. nucleophiles may explain why the many attempts to identify 4-IPO adducts to protein have not been successful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVFkIl0mq48rVg90H21EOLACvtfcHk0lhxISPdvIA2pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVylu7s%253D&md5=5735edaa74c5cbce8735c23db0eb4daf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Ftx060128f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx060128f%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%2BJ.%26aulast%3DDeRose%26aufirst%3DE.%2BF.%26aulast%3DBurka%26aufirst%3DL.%2BT.%26atitle%3DMetabolism%2520of%2520furans%2520in%2520vitro%253A%2520ipomeanine%2520and%25204-ipomeanol%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2006%26volume%3D19%26spage%3D1320%26epage%3D1329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. A.</span><span> </span><span class="NLM_article-title">Identification of furan metabolites derived from cysteine-cis-2-butene-1,4-dial-lysine cross-links</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">â</span> <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx9003215" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=142-151&author=D.+Luauthor=L.+A.+Peterson&title=Identification+of+furan+metabolites+derived+from+cysteine-cis-2-butene-1%2C4-dial-lysine+cross-links"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Ftx9003215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx9003215%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DPeterson%26aufirst%3DL.%2BA.%26atitle%3DIdentification%2520of%2520furan%2520metabolites%2520derived%2520from%2520cysteine-cis-2-butene-1%252C4-dial-lysine%2520cross-links%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D142%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Lant, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxford, J.</span><span> </span><span class="NLM_article-title">Qualitative and quantitative analysis of ranitidine and its metabolites by high-performance liquid chromatography-mass spectrometry</span> <span class="citation_source-journal">J. Chromatogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">â</span> <span class="NLM_lpage">152</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1016%2FS0021-9673%2801%2990379-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=4008551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADyaL2MXhvFOns7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=1985&pages=143-152&author=M.+S.+Lantauthor=L.+E.+Martinauthor=J.+Oxford&title=Qualitative+and+quantitative+analysis+of+ranitidine+and+its+metabolites+by+high-performance+liquid+chromatography-mass+spectrometry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Qualitative and quantitative analysis of ranitidine and its metabolites by high-performance liquid chromatography-mass spectrometry</span></div><div class="casAuthors">Lant, M. S.; Martin, L. E.; Oxford, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">143-52</span>CODEN:
                <span class="NLM_cas:coden">JOCRAM</span>;
        ISSN:<span class="NLM_cas:issn">0021-9673</span>.
    </div><div class="casAbstract">Reversed-phase HPLC systems for the sepn. of ranitidine  [66357-35-5] and its metabolites ranitidine N-oxide  [73857-20-2], ranitidine S-oxide  [73851-70-4], and desmethylranitidine  [66357-25-3] were developed for use in HPLC-mass spectrometry.  A direct liq. introduction-HPLC-mass spectrometry system to analyze qual. and quant. solns. contg. ranitidine and its metabolites by reversed-phase chromatog. is described.  A sample of urine collected from a subject given an oral dose of 75 mg ranitidine and 75 mg [2H3]ranitidine was analyzed by this system.  Ranitidine and its metabolites were identified by the ion doublets in the mass spectra which were 3 amu apart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9sEXPH9K0dbVg90H21EOLACvtfcHk0lhxISPdvIA2pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXhvFOns7s%253D&md5=4486fc5859d208e8d8230e88a5959658</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0021-9673%2801%2990379-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9673%252801%252990379-6%26sid%3Dliteratum%253Aachs%26aulast%3DLant%26aufirst%3DM.%2BS.%26aulast%3DMartin%26aufirst%3DL.%2BE.%26aulast%3DOxford%26aufirst%3DJ.%26atitle%3DQualitative%2520and%2520quantitative%2520analysis%2520of%2520ranitidine%2520and%2520its%2520metabolites%2520by%2520high-performance%2520liquid%2520chromatography-mass%2520spectrometry%26jtitle%3DJ.%2520Chromatogr.%26date%3D1985%26volume%3D323%26spage%3D143%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Madan, B.; Goh, K. C.; Hart, S.; William, A. D.; Jayaraman, R.; Ethirajulu, K.; Dymock, B. W.; Wood, J. M.</span>, unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Madan%2C+B.%3B+Goh%2C+K.+C.%3B+Hart%2C+S.%3B+William%2C+A.+D.%3B+Jayaraman%2C+R.%3B+Ethirajulu%2C+K.%3B+Dymock%2C+B.+W.%3B+Wood%2C+J.+M.%2C+unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DMadan%26aufirst%3DB." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">302</span><span class="NLM_x">â</span> <span class="NLM_lpage">13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=302-13&author=S.+Wangauthor=P.+M.+Fischer&title=Cyclin-dependent+kinase+9%3A+a+key+transcriptional+regulator+and+potential+drug+target+in+oncology%2C+virology+and+cardiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DCyclin-dependent%2520kinase%25209%253A%2520a%2520key%2520transcriptional%2520regulator%2520and%2520potential%2520drug%2520target%2520in%2520oncology%252C%2520virology%2520and%2520cardiology%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26spage%3D302%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Quentmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLeod, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaborski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H. G.</span><span> </span><span class="NLM_article-title">JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">â</span> <span class="NLM_lpage">476</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=471-476&author=H.+Quentmeierauthor=R.+A.+MacLeodauthor=M.+Zaborskiauthor=H.+G.+Drexler&title=JAK2+V617F+tyrosine+kinase+mutation+in+cell+lines+derived+from+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DMacLeod%26aufirst%3DR.%2BA.%26aulast%3DZaborski%26aufirst%3DM.%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26atitle%3DJAK2%2520V617F%2520tyrosine%2520kinase%2520mutation%2520in%2520cell%2520lines%2520derived%2520from%2520myeloproliferative%2520disorders%26jtitle%3DLeukemia%26date%3D2006%26volume%3D20%26spage%3D471%26epage%3D476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Holmdahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldschmidt, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MalmstrÃ¶m, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, J.</span><span> </span><span class="NLM_article-title">Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity</span> <span class="citation_source-journal">APMIS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">â</span> <span class="NLM_lpage">584</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1111%2Fj.1699-0463.1989.tb00446.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=2665798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A280%3ADyaL1Mzit12htA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=1989&pages=575-584&author=R.+Holmdahlauthor=M.+E.+Anderssonauthor=T.+J.+Goldschmidtauthor=L.+Janssonauthor=M.+Karlssonauthor=V.+Malmstr%C3%B6mauthor=J.+Mo&title=Collagen+induced+arthritis+as+an+experimental+model+for+rheumatoid+arthritis.+Immunogenetics%2C+pathogenesis+and+autoimmunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity</span></div><div class="casAuthors">Holmdahl R; Andersson M E; Goldschmidt T J; Jansson L; Karlsson M; Malmstrom V; Mo J</div><div class="citationInfo"><span class="NLM_cas:title">APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">575-84</span>
        ISSN:<span class="NLM_cas:issn">0903-4641</span>.
    </div><div class="casAbstract">The type II collagen (CII) induced arthritis animal model (CIA) provides opportunities to study the nature of autoimmune reactions leading to arthritis and may be used as a model for rheumatoid arthritis (RA).  Thus, in similarity with RA, the CIA model, when induced with autologous CII, shows a chronic and progressive disease course.  The susceptibility to both RA and CIA are correlated to the expression of certain MHC class II allotype genes.  In both diseases are autoantibodies to CII and rheumatoid factors produced.  Immunohistopathology of affected joints show in both diseases a dominance of activated macrophages/fibroblasts with a significant infiltration of activated T cells and an infiltration of granulocytes.  We do here suggest that both RA and CIA are dependent on a synergy between delayed type hypersensitivity and immune complex mediated inflammatory mechanisms and that CIA provides opportunities for studies of immunospecific reactions leading to arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThpC-SSrvRQ_9pSBfyDvp7fW6udTcc2eag70T7xBUa3Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1Mzit12htA%253D%253D&md5=30ef4460b144242f27184a74ce55b624</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fj.1699-0463.1989.tb00446.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1699-0463.1989.tb00446.x%26sid%3Dliteratum%253Aachs%26aulast%3DHolmdahl%26aufirst%3DR.%26aulast%3DAndersson%26aufirst%3DM.%2BE.%26aulast%3DGoldschmidt%26aufirst%3DT.%2BJ.%26aulast%3DJansson%26aufirst%3DL.%26aulast%3DKarlsson%26aufirst%3DM.%26aulast%3DMalmstr%25C3%25B6m%26aufirst%3DV.%26aulast%3DMo%26aufirst%3DJ.%26atitle%3DCollagen%2520induced%2520arthritis%2520as%2520an%2520experimental%2520model%2520for%2520rheumatoid%2520arthritis.%2520Immunogenetics%252C%2520pathogenesis%2520and%2520autoimmunity%26jtitle%3DAPMIS%26date%3D1989%26volume%3D97%26spage%3D575%26epage%3D584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Williams, R. O.</span><span> </span><span class="NLM_article-title">Collagen-induced arthritis as a model for rheumatoid arthritis</span> <span class="citation_source-journal">Methods Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">â</span> <span class="NLM_lpage">216</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=15064442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslGktbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2004&pages=207-216&author=R.+O.+Williams&title=Collagen-induced+arthritis+as+a+model+for+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Collagen-induced arthritis as a model for rheumatoid arthritis</span></div><div class="casAuthors">Williams, Richard O.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">Tumor Necrosis Factor</span>),
    <span class="NLM_cas:pages">207-216</span>CODEN:
                <span class="NLM_cas:coden">MMMEFN</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Collagen-induced arthritis (CIA) is an animal model of rheumatoid arthritis (RA) that is widely used to address questions of disease pathogenesis and to validate therapeutic targets.  Arthritis is normally induced in mice or rats by immunization with autologous or heterologous type II collagen in adjuvant.  Susceptibility to collagen-induced arthritis is strongly assocd. with major histocompatibility complex class II genes, and the development of arthritis is accompanied by a robust T- and B-cell response to type II collagen.  The chief pathol. features of CIA include a proliferative synovitis with infiltration of polymorphonuclear and mononuclear cells, pannus formation, cartilage degrdn., erosion of bone, and fibrosis.  As in RA, pro-inflammatory cytokines, such as tumor necrosis factor Î± (TNFÎ±) and interleukin (IL)-1Î², are abundantly expressed in the arthritic joints of mice with CIA, and blockade of these mols. results in a redn. of disease severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrFCOnX7gRn7Vg90H21EOLACvtfcHk0liaPF60H-hVjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslGktbs%253D&md5=c99965592d21a3aff8667aa1576a2c70</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DR.%2BO.%26atitle%3DCollagen-induced%2520arthritis%2520as%2520a%2520model%2520for%2520rheumatoid%2520arthritis%26jtitle%3DMethods%2520Mol.%2520Med.%26date%3D2004%26volume%3D98%26spage%3D207%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny-Diermayr, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hentze, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amalini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. W.</span><span> </span><span class="NLM_article-title">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1751</span><span class="NLM_x">â</span> <span class="NLM_lpage">1759</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1751-1759&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=C.+Y.+Huauthor=H.+Hentzeauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=Y.+K.+Lohauthor=L.+C.+Ongauthor=A.+D.+Williamauthor=A.+Leeauthor=A.+Poulsenauthor=R.+Jayaramanauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+W.+Wood&title=SB1518%2C+a+novel+macrocyclic+pyrimidine-based+JAK2+inhibitor+for+the+treatment+of+myeloid+and+lymphoid+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHu%26aufirst%3DC.%2BY.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BW.%26atitle%3DSB1518%252C%2520a%2520novel%2520macrocyclic%2520pyrimidine-based%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloid%2520and%2520lymphoid%2520malignancies%26jtitle%3DLeukemia%26date%3D2011%26volume%3D25%26spage%3D1751%26epage%3D1759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 29 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jennifer Alisa Amrhein, Stefan Knapp, <span class="NLM_string-name hlFld-ContribAuthor">Thomas Hanke</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7991-8009. <a href="https://doi.org/10.1021/acs.jmedchem.1c00217" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00217</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00217%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BOpportunities%252Band%252BChallenges%252Bfor%252BMacrocyclic%252BKinase%252BInhibitors%26aulast%3DAmrhein%26aufirst%3DJennifer%2BAlisa%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D04022021%26date%3D02062021%26volume%3D64%26issue%3D12%26spage%3D7991%26epage%3D8009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mohammed
I. El-Gamal, Shahad K. Al-Ameen, Dania M. Al-Koumi, Mawadda G. Hamad, Nouran A. Jalal, <span class="NLM_string-name hlFld-ContribAuthor">Chang-Hyun Oh</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances of Colony-Stimulating Factor-1 Receptor (CSF-1R) Kinase and Its Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (13)
                                     , 5450-5466. <a href="https://doi.org/10.1021/acs.jmedchem.7b00873" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00873</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00873%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BAdvances%252Bof%252BColony-Stimulating%252BFactor-1%252BReceptor%252B%252528CSF-1R%252529%252BKinase%252Band%252BIts%252BInhibitors%26aulast%3DEl-Gamal%26aufirst%3DMohammed%2BI.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D14062017%26date%3D17012018%26date%3D02012018%26volume%3D61%26issue%3D13%26spage%3D5450%26epage%3D5466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xing  Che</span>, <span class="hlFld-ContribAuthor ">Jun  Zhang</span>, <span class="hlFld-ContribAuthor ">Hui  Quan</span>, <span class="hlFld-ContribAuthor ">Lijiang  Yang</span>, and <span class="hlFld-ContribAuthor ">Yi Qin  Gao</span>  . </span><span class="cited-content_cbyCitation_article-title">CDNsâSTING Interaction Mechanism Investigations and Instructions on Design of CDN-Derivatives. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry B</span><span> <strong>2018,</strong> <em>122 </em>
                                    (6)
                                     , 1862-1868. <a href="https://doi.org/10.1021/acs.jpcb.7b12276" title="DOI URL">https://doi.org/10.1021/acs.jpcb.7b12276</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpcb.7b12276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpcb.7b12276%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520B%26atitle%3DCDNs%2525E2%252580%252593STING%252BInteraction%252BMechanism%252BInvestigations%252Band%252BInstructions%252Bon%252BDesign%252Bof%252BCDN-Derivatives%26aulast%3DChe%26aufirst%3DXing%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D2018%26date%3D13122017%26date%3D17012018%26date%3D02022018%26date%3D15022018%26date%3D23012018%26volume%3D122%26issue%3D6%26spage%3D1862%26epage%3D1868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">DÃ¡vid  Bajusz</span>, <span class="hlFld-ContribAuthor ">GyÃ¶rgy G.  Ferenczy</span>, and <span class="hlFld-ContribAuthor ">GyÃ¶rgy M.  KeserÅ±</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (1)
                                     , 234-247. <a href="https://doi.org/10.1021/acs.jcim.5b00634" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00634%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDiscovery%252Bof%252BSubtype%252BSelective%252BJanus%252BKinase%252B%252528JAK%252529%252BInhibitors%252Bby%252BStructure-Based%252BVirtual%252BScreening%26aulast%3DBajusz%26aufirst%3DD%25C3%25A1vid%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D18102015%26date%3D31122015%26date%3D25012016%26date%3D18122015%26volume%3D56%26issue%3D1%26spage%3D234%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott E.  Allen</span>, <span class="hlFld-ContribAuthor ">Nikolay V.  Dokholyan</span>, and <span class="hlFld-ContribAuthor ">Albert A.  Bowers</span>  . </span><span class="cited-content_cbyCitation_article-title">Dynamic Docking of Conformationally Constrained Macrocycles: Methods and Applications. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2016,</strong> <em>11 </em>
                                    (1)
                                     , 10-24. <a href="https://doi.org/10.1021/acschembio.5b00663" title="DOI URL">https://doi.org/10.1021/acschembio.5b00663</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.5b00663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.5b00663%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDynamic%252BDocking%252Bof%252BConformationally%252BConstrained%252BMacrocycles%25253A%252BMethods%252Band%252BApplications%26aulast%3DAllen%26aufirst%3DScott%2BE.%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D19082015%26date%3D17112015%26date%3D04122015%26date%3D15012016%26date%3D17112015%26volume%3D11%26issue%3D1%26spage%3D10%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James D.  Clark</span>, <span class="hlFld-ContribAuthor ">Mark E.  Flanagan</span>, and <span class="hlFld-ContribAuthor ">Jean-Baptiste  Telliez</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (12)
                                     , 5023-5038. <a href="https://doi.org/10.1021/jm401490p" title="DOI URL">https://doi.org/10.1021/jm401490p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401490p%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BJanus%252BKinase%252B%252528JAK%252529%252BInhibitors%252Bfor%252BInflammatory%252BDiseases%26aulast%3DClark%26aufirst%3DJames%2BD.%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D25092013%26date%3D23012014%26date%3D26062014%26date%3D13012014%26volume%3D57%26issue%3D12%26spage%3D5023%26epage%3D5038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lexian  Tong</span>, <span class="hlFld-ContribAuthor ">Xuemei  Li</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in FLT3 inhibitors for acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 961-981. <a href="https://doi.org/10.4155/fmc-2019-0365" title="DOI URL">https://doi.org/10.4155/fmc-2019-0365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0365%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252BFLT3%252Binhibitors%252Bfor%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DTong%26aufirst%3DLexian%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D961%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reem Fawaz  Abutayeh</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2019,</strong> <em>88 </em>, 128-151. <a href="https://doi.org/10.1016/j.jmgm.2019.01.011" title="DOI URL">https://doi.org/10.1016/j.jmgm.2019.01.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2019.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2019.01.011%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DDiscovery%252Bof%252Bnovel%252BFlt3%252Binhibitory%252Bchemotypes%252Bthrough%252Bextensive%252Bligand-based%252Band%252Bnew%252Bstructure-based%252Bpharmacophore%252Bmodelling%252Bmethods%26aulast%3DAbutayeh%26aufirst%3DReem%2BFawaz%26date%3D2019%26volume%3D88%26spage%3D128%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Catalytic Metathesis Reactions: Nobel Prize Catalysis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 259-290. <a href="https://doi.org/10.1002/9783527807253.ch7" title="DOI URL">https://doi.org/10.1002/9783527807253.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527807253.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527807253.ch7%26sid%3Dliteratum%253Aachs%26atitle%3DCatalytic%252BMetathesis%252BReactions%25253A%252BNobel%252BPrize%252BCatalysis%26date%3D2018%26date%3D2018%26spage%3D259%26epage%3D290%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DActive%252BPharmaceutical%252BIngredients%252Bin%252BSynthesis%26aulast%3DBurke%26aufirst%3DAnthony%2BJ%26date%3D2018%26volume%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jack W.  Singer</span>, <span class="hlFld-ContribAuthor ">Angela  Fleischman</span>, <span class="hlFld-ContribAuthor ">Suliman  Al-Fayoumi</span>, <span class="hlFld-ContribAuthor ">John O.  Mascarenhas</span>, <span class="hlFld-ContribAuthor ">Qiang  Yu</span>, <span class="hlFld-ContribAuthor ">Anupriya  Agarwal</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (70)
                                     , 33416-33439. <a href="https://doi.org/10.18632/oncotarget.26058" title="DOI URL">https://doi.org/10.18632/oncotarget.26058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.26058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.26058%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DInhibition%252Bof%252Binterleukin-1%252Breceptor-associated%252Bkinase%252B1%252B%252528IRAK1%252529%252Bas%252Ba%252Btherapeutic%252Bstrategy%26aulast%3DSinger%26aufirst%3DJack%2BW.%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D70%26spage%3D33416%26epage%3D33439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">2-Aminopyrimidines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 237-283. <a href="https://doi.org/10.1002/9781118686263.ch7" title="DOI URL">https://doi.org/10.1002/9781118686263.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118686263.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118686263.ch7%26sid%3Dliteratum%253Aachs%26atitle%3D2-Aminopyrimidines%26date%3D2018%26date%3D2018%26spage%3D237%26epage%3D283%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPrivileged%252BStructures%252Bin%252BDrug%252BDiscovery%26aulast%3DYet%26aufirst%3DLarry%26date%3D2018%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniella M.  Schwartz</span>, <span class="hlFld-ContribAuthor ">Yuka  Kanno</span>, <span class="hlFld-ContribAuthor ">Alejandro  Villarino</span>, <span class="hlFld-ContribAuthor ">Michael  Ward</span>, <span class="hlFld-ContribAuthor ">Massimo  Gadina</span>, <span class="hlFld-ContribAuthor ">John J.  O'Shea</span>. </span><span class="cited-content_cbyCitation_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2017,</strong> <em>16 </em>
                                    (12)
                                     , 843-862. <a href="https://doi.org/10.1038/nrd.2017.201" title="DOI URL">https://doi.org/10.1038/nrd.2017.201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DJAK%252Binhibition%252Bas%252Ba%252Btherapeutic%252Bstrategy%252Bfor%252Bimmune%252Band%252Binflammatory%252Bdiseases%26aulast%3DSchwartz%26aufirst%3DDaniella%2BM.%26date%3D2017%26date%3D2017%26volume%3D16%26issue%3D12%26spage%3D843%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jongrock  Kong</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches Used in the Scale-Up of Macrocyclic Clinical Candidates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 377-409. <a href="https://doi.org/10.1002/9781119092599.ch15" title="DOI URL">https://doi.org/10.1002/9781119092599.ch15</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119092599.ch15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119092599.ch15%26sid%3Dliteratum%253Aachs%26atitle%3DSynthetic%252BApproaches%252BUsed%252Bin%252Bthe%252BScale-Up%252Bof%252BMacrocyclic%252BClinical%252BCandidates%26aulast%3DKong%26aufirst%3DJongrock%26date%3D2017%26date%3D2017%26spage%3D377%26epage%3D409%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPractical%252BMedicinal%252BChemistry%252Bwith%252BMacrocycles%26aulast%3DMarsault%26aufirst%3DEric%26date%3D2017%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Stotani</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Giordanetto</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of Macrocycles in Clinical Development and Clinically Used. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 411-499. <a href="https://doi.org/10.1002/9781119092599.ch16" title="DOI URL">https://doi.org/10.1002/9781119092599.ch16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119092599.ch16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119092599.ch16%26sid%3Dliteratum%253Aachs%26atitle%3DOverview%252Bof%252BMacrocycles%252Bin%252BClinical%252BDevelopment%252Band%252BClinically%252BUsed%26aulast%3DStotani%26aufirst%3DSilvia%26date%3D2017%26date%3D2017%26spage%3D411%26epage%3D499%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPractical%252BMedicinal%252BChemistry%252Bwith%252BMacrocycles%26aulast%3DMarsault%26aufirst%3DEric%26date%3D2017%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haifa Kathrin  Al-Ali</span>, <span class="hlFld-ContribAuthor ">Alessandro M.  Vannucchi</span>. </span><span class="cited-content_cbyCitation_article-title">Managing patients with myelofibrosis and low platelet counts. </span><span class="cited-content_cbyCitation_journal-name">Annals of Hematology</span><span> <strong>2017,</strong> <em>96 </em>
                                    (4)
                                     , 537-548. <a href="https://doi.org/10.1007/s00277-016-2697-8" title="DOI URL">https://doi.org/10.1007/s00277-016-2697-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00277-016-2697-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00277-016-2697-8%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Hematology%26atitle%3DManaging%252Bpatients%252Bwith%252Bmyelofibrosis%252Band%252Blow%252Bplatelet%252Bcounts%26aulast%3DAl-Ali%26aufirst%3DHaifa%2BKathrin%26date%3D2017%26date%3D2016%26volume%3D96%26issue%3D4%26spage%3D537%26epage%3D548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew L.  McIver</span>, <span class="hlFld-ContribAuthor ">Weihe  Zhang</span>, <span class="hlFld-ContribAuthor ">Qingyang  Liu</span>, <span class="hlFld-ContribAuthor ">Xinpeng  Jiang</span>, <span class="hlFld-ContribAuthor ">Michael A.  Stashko</span>, <span class="hlFld-ContribAuthor ">James  Nichols</span>, <span class="hlFld-ContribAuthor ">Michael J.  Miley</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Norris-Drouin</span>, <span class="hlFld-ContribAuthor ">Mischa  Machius</span>, <span class="hlFld-ContribAuthor ">Deborah  DeRyckere</span>, <span class="hlFld-ContribAuthor ">Edgar  Wood</span>, <span class="hlFld-ContribAuthor ">Douglas K.  Graham</span>, <span class="hlFld-ContribAuthor ">H. Shelton  Earp</span>, <span class="hlFld-ContribAuthor ">Dmitri  Kireev</span>, <span class="hlFld-ContribAuthor ">Stephen V.  Frye</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2017,</strong> <em>12 </em>
                                    (3)
                                     , 207-213. <a href="https://doi.org/10.1002/cmdc.201600589" title="DOI URL">https://doi.org/10.1002/cmdc.201600589</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201600589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201600589%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDiscovery%252Bof%252BMacrocyclic%252BPyrimidines%252Bas%252BMerTK-Specific%252BInhibitors%26aulast%3DMcIver%26aufirst%3DAndrew%2BL.%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D3%26spage%3D207%26epage%3D213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">DÃ¡vid  Bajusz</span>, <span class="hlFld-ContribAuthor ">GyÃ¶rgy G.  Ferenczy</span>, <span class="hlFld-ContribAuthor ">GyÃ¶rgy M.  KeserÅ±</span>. </span><span class="cited-content_cbyCitation_article-title">Ensemble docking-based virtual screening yields novel spirocyclic JAK1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2016,</strong> <em>70 </em>, 275-283. <a href="https://doi.org/10.1016/j.jmgm.2016.10.014" title="DOI URL">https://doi.org/10.1016/j.jmgm.2016.10.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2016.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2016.10.014%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DEnsemble%252Bdocking-based%252Bvirtual%252Bscreening%252Byields%252Bnovel%252Bspirocyclic%252BJAK1%252Binhibitors%26aulast%3DBajusz%26aufirst%3DD%25C3%25A1vid%26date%3D2016%26volume%3D70%26spage%3D275%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samra  Sardar</span>, <span class="hlFld-ContribAuthor ">Ãsa  Andersson</span>. </span><span class="cited-content_cbyCitation_article-title">Old and new therapeutics for Rheumatoid Arthritis:
              in vivo
              models and drug development. </span><span class="cited-content_cbyCitation_journal-name">Immunopharmacology and Immunotoxicology</span><span> <strong>2016,</strong> <em>38 </em>
                                    (1)
                                     , 2-13. <a href="https://doi.org/10.3109/08923973.2015.1125917" title="DOI URL">https://doi.org/10.3109/08923973.2015.1125917</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3109/08923973.2015.1125917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3109%2F08923973.2015.1125917%26sid%3Dliteratum%253Aachs%26jtitle%3DImmunopharmacology%2520and%2520Immunotoxicology%26atitle%3DOld%252Band%252Bnew%252Btherapeutics%252Bfor%252BRheumatoid%252BArthritis%25253A%252Bin%252Bvivo%252Bmodels%252Band%252Bdrug%252Bdevelopment%26aulast%3DSardar%26aufirst%3DSamra%26date%3D2016%26date%3D2016%26volume%3D38%26issue%3D1%26spage%3D2%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenwen  Chen</span>, <span class="hlFld-ContribAuthor ">Hailin  Bao</span>, <span class="hlFld-ContribAuthor ">Dingsheng  Wang</span>, <span class="hlFld-ContribAuthor ">Xinyan  Wang</span>, <span class="hlFld-ContribAuthor ">Yadong  Li</span>, <span class="hlFld-ContribAuthor ">Yuefei  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Chemoselective hydrogenation of nitrobenzyl ethers to aminobenzyl ethers catalyzed by palladiumânickel bimetallic nanoparticles. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2015,</strong> <em>71 </em>
                                    (49)
                                     , 9240-9244. <a href="https://doi.org/10.1016/j.tet.2015.10.037" title="DOI URL">https://doi.org/10.1016/j.tet.2015.10.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2015.10.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2015.10.037%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DChemoselective%252Bhydrogenation%252Bof%252Bnitrobenzyl%252Bethers%252Bto%252Baminobenzyl%252Bethers%252Bcatalyzed%252Bby%252Bpalladium%2525E2%252580%252593nickel%252Bbimetallic%252Bnanoparticles%26aulast%3DChen%26aufirst%3DWenwen%26date%3D2015%26volume%3D71%26issue%3D49%26spage%3D9240%26epage%3D9244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Song  Ling</span>, <span class="hlFld-ContribAuthor ">Ying  Liu</span>, <span class="hlFld-ContribAuthor ">Jiaqi  Fu</span>, <span class="hlFld-ContribAuthor ">Alessandro  Colletta</span>, <span class="hlFld-ContribAuthor ">Chaim  Gilon</span>, <span class="hlFld-ContribAuthor ">Joseph  Holoshitz</span>. </span><span class="cited-content_cbyCitation_article-title">Shared Epitope-Antagonistic Ligands: A New Therapeutic Strategy in Mice With Erosive Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Arthritis & Rheumatology</span><span> <strong>2015,</strong> <em>67 </em>
                                    (8)
                                     , 2061-2070. <a href="https://doi.org/10.1002/art.39158" title="DOI URL">https://doi.org/10.1002/art.39158</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/art.39158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fart.39158%26sid%3Dliteratum%253Aachs%26jtitle%3DArthritis%2520%2526%2520Rheumatology%26atitle%3DShared%252BEpitope-Antagonistic%252BLigands%25253A%252BA%252BNew%252BTherapeutic%252BStrategy%252Bin%252BMice%252BWith%252BErosive%252BArthritis%26aulast%3DLing%26aufirst%3DSong%26date%3D2015%26date%3D2015%26volume%3D67%26issue%3D8%26spage%3D2061%26epage%3D2070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashu  Chaudhary</span>, <span class="hlFld-ContribAuthor ">Ekta  Rawat</span>. </span><span class="cited-content_cbyCitation_article-title">Macrocyclic Assembly: A Dive into the Pecking Order and Applied Aspects of Multitalented Metallomacrocycles. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Inorganic Chemistry</span><span> <strong>2014,</strong> <em>2014 </em>, 1-30. <a href="https://doi.org/10.1155/2014/509151" title="DOI URL">https://doi.org/10.1155/2014/509151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2014/509151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2014%2F509151%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Inorganic%2520Chemistry%26atitle%3DMacrocyclic%252BAssembly%25253A%252BA%252BDive%252Binto%252Bthe%252BPecking%252BOrder%252Band%252BApplied%252BAspects%252Bof%252BMultitalented%252BMetallomacrocycles%26aulast%3DChaudhary%26aufirst%3DAshu%26date%3D2014%26volume%3D2014%26spage%3D1%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Norman</span>. </span><span class="cited-content_cbyCitation_article-title">Selective JAK inhibitors in development for rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2014,</strong> <em>23 </em>
                                    (8)
                                     , 1067-1077. <a href="https://doi.org/10.1517/13543784.2014.918604" title="DOI URL">https://doi.org/10.1517/13543784.2014.918604</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543784.2014.918604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543784.2014.918604%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DSelective%252BJAK%252Binhibitors%252Bin%252Bdevelopment%252Bfor%252Brheumatoid%252Barthritis%26aulast%3DNorman%26aufirst%3DPeter%26date%3D2014%26date%3D2014%26volume%3D23%26issue%3D8%26spage%3D1067%26epage%3D1077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian W  Dymock</span>, <span class="hlFld-ContribAuthor ">Eugene Guorong  Yang</span>, <span class="hlFld-ContribAuthor ">Yuyi  Chu-Farseeva</span>, <span class="hlFld-ContribAuthor ">Lianbin  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Selective JAK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2014,</strong> <em>6 </em>
                                    (12)
                                     , 1439-1471. <a href="https://doi.org/10.4155/fmc.14.92" title="DOI URL">https://doi.org/10.4155/fmc.14.92</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.14.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.14.92%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DSelective%252BJAK%252Binhibitors%26aulast%3DDymock%26aufirst%3DBrian%2BW%26date%3D2014%26volume%3D6%26issue%3D12%26spage%3D1439%26epage%3D1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian W  Dymock</span>, <span class="hlFld-ContribAuthor ">Cheng Shang  See</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 â 2012. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2013,</strong> <em>23 </em>
                                    (4)
                                     , 449-501. <a href="https://doi.org/10.1517/13543776.2013.765862" title="DOI URL">https://doi.org/10.1517/13543776.2013.765862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2013.765862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2013.765862%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DInhibitors%252Bof%252BJAK2%252Band%252BJAK3%25253A%252Ban%252Bupdate%252Bon%252Bthe%252Bpatent%252Bliterature%252B2010%252B%2525E2%252580%252593%252B2012%26aulast%3DDymock%26aufirst%3DBrian%2BW%26date%3D2013%26date%3D2013%26volume%3D23%26issue%3D4%26spage%3D449%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandrine  Vendeville</span>, <span class="hlFld-ContribAuthor ">Maxwell D.  Cummings</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Macrocycles in Small-Molecule Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 371-386. <a href="https://doi.org/10.1016/B978-0-12-417150-3.00023-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-417150-3.00023-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-417150-3.00023-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-417150-3.00023-5%26sid%3Dliteratum%253Aachs%26atitle%3DSynthetic%252BMacrocycles%252Bin%252BSmall-Molecule%252BDrug%252BDiscovery%26aulast%3DVendeville%26aufirst%3DSandrine%26date%3D2013%26spage%3D371%26epage%3D386%26pub%3DElsevier%26date%3D2013%26volume%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christel J.  Menet</span>, <span class="hlFld-ContribAuthor ">Luc Van  Rompaey</span>, <span class="hlFld-ContribAuthor ">RaphaÃ«l  Geney</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in the Discovery of Selective JAK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 153-223. <a href="https://doi.org/10.1016/B978-0-444-62652-3.00004-1" title="DOI URL">https://doi.org/10.1016/B978-0-444-62652-3.00004-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-444-62652-3.00004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-444-62652-3.00004-1%26sid%3Dliteratum%253Aachs%26atitle%3DAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BSelective%252BJAK%252BInhibitors%26aulast%3DMenet%26aufirst%3DChristel%2BJ.%26date%3D2013%26spage%3D153%26epage%3D223%26pub%3DElsevier%26date%3D2013%26volume%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raoul  Tibes</span>, <span class="hlFld-ContribAuthor ">James M  Bogenberger</span>, <span class="hlFld-ContribAuthor ">Holly L  Geyer</span>, <span class="hlFld-ContribAuthor ">Ruben A  Mesa</span>. </span><span class="cited-content_cbyCitation_article-title">JAK2 inhibitors in the treatment of myeloproliferative neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2012,</strong> <em>21 </em>
                                    (12)
                                     , 1755-1774. <a href="https://doi.org/10.1517/13543784.2012.721352" title="DOI URL">https://doi.org/10.1517/13543784.2012.721352</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543784.2012.721352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543784.2012.721352%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DJAK2%252Binhibitors%252Bin%252Bthe%252Btreatment%252Bof%252Bmyeloproliferative%252Bneoplasms%26aulast%3DTibes%26aufirst%3DRaoul%26date%3D2012%26date%3D2012%26volume%3D21%26issue%3D12%26spage%3D1755%26epage%3D1774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Babita  Madan</span>, <span class="hlFld-ContribAuthor ">Kee Chuan  Goh</span>, <span class="hlFld-ContribAuthor ">Stefan  Hart</span>, <span class="hlFld-ContribAuthor ">Anthony D.  William</span>, <span class="hlFld-ContribAuthor ">Ramesh  Jayaraman</span>, <span class="hlFld-ContribAuthor ">Kantharaj  Ethirajulu</span>, <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>, <span class="hlFld-ContribAuthor ">Jeanette M.  Wood</span>. </span><span class="cited-content_cbyCitation_article-title">SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Immunology</span><span> <strong>2012,</strong> <em>189 </em>
                                    (8)
                                     , 4123-4134. <a href="https://doi.org/10.4049/jimmunol.1200675" title="DOI URL">https://doi.org/10.4049/jimmunol.1200675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4049/jimmunol.1200675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4049%2Fjimmunol.1200675%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Immunology%26atitle%3DSB1578%25252C%252Ba%252BNovel%252BInhibitor%252Bof%252BJAK2%25252C%252BFLT3%25252C%252Band%252Bc-Fms%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DMadan%26aufirst%3DBabita%26date%3D2012%26date%3D2012%26volume%3D189%26issue%3D8%26spage%3D4123%26epage%3D4134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0013.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Modulating the macrocycle phenyl ring system.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0014.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) 3-piperidinemethanol, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 93%. (b) Allyl bromide, NaH (60% in mineral oil), â78 Â°Cârt, 52%. (c) Pd(dppf)Cl<sub>2</sub>Â·CH<sub>2</sub>Cl<sub>2</sub> (1:1), Na<sub>2</sub>CO<sub>3</sub>, 1,2-dimethoxyethane, water, 80 Â°C, 58â92%. (d) 4-Bromobut-1-ene/allyl bromide, NaH (60% in mineral oil), DMF, rt, 62â77%. (e) NaBH<sub>4</sub>, THF, MeOH, 0 Â°C, 70â94%. (f) Allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 46â84%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0001.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) <i>N</i>-Allylmethyl amine, Na(OAc)<sub>3</sub>BH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 75â95%. (b) SnCl<sub>2</sub>Â·2H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1), rt, 64â98%. (c) Allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 55â78%. (d) 2-Bromoethyl methyl ether, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 Â°C, 86%. (e) 1,2-Dichloroethane, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 Â°C, 72%. (f) NaBH<sub>4</sub>, THF, water, 0 Â°C, 94%. (g) Pyrrolidine, DMA, 90 Â°C, 75â78%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0002.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) 4 M HCl, <i>n</i>-butanol, 80â100 Â°C, 81â86%. (b) 3-Buten-1-ol, NaH (60% in mineral oil), THF, 0 Â°C, 36â48%. (c). Grubbs second generation or Zhan catalyst, HCl, CH<sub>2</sub>Cl<sub>2</sub>, 45 Â°C, 36â76%.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Compound <b>13c</b> docked into JAK2. Hydrogen bonds are shown in magenta dashed lines and close contacts in orange dashed lines. The only close contact between <b>13c</b> and JAK2 is between the backbone carbonyl of Glu930 and the free hydrogen next to the pyrimidine nitrogen of <b>13c</b>. This is an attractive interaction and may be described as a weak hydrogen bond. (B) Compound <b>13b</b> docked into JAK2. The macrocyclic linker of <b>13b</b> is more bulky than that of <b>13c</b>, and consequently <b>13b</b> has several close contacts to the protein. The reduced JAK2 activity of <b>13b</b> may be due to slight clashes with the protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Sitemap analysis of JAK2 with <b>13e</b> docked into the ATP-binding site. White dots indicate positions where it is favorable to place ligand atoms. The yellow, blue, and red grids are hydrophobic and hydrogen bond acceptor and donor areas of the binding site, respectively. The pyridine nitrogen falls into the hydrogen bond donor area around the carboxylic acid group of Asp994. The interaction with Asp994 will be repulsive (distance 3.7 Ã) unless the pyridine is protonated. The pyridine p<i>K</i><sub>a</sub> is calculated by Epik to be 3.6, which indicates it is not protonated; hence, the negative interaction of the pyridine forces the compound out of the binding site leading to a lower IC<sub>50</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>14d</b> docked into JAK2. There is room for a water molecule which may mediate a hydrogen bond between the pyridine nitrogen and the side chain of Asp981. This may explain the increased JAK2 activity of pyrimidine analogues like <b>14d</b> and <b>14e</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>14l</b> blocks JAK2 signaling pathways in multiple cellular contexts.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/medium/jm-2011-01454n_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>14l</b> attenuates clinical symptoms of arthritis in a mouse CIA model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201454n/production/images/large/jm-2011-01454n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201454n&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17178" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17178" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Walsh, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gravallese, E. M.</span><span> </span><span class="NLM_article-title">Bone remodeling in rheumatic disease: a question of balance</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">233</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">â</span> <span class="NLM_lpage">312</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1111%2Fj.0105-2896.2009.00857.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=20193007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslaqsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=233&publication_year=2010&pages=301-312&author=N.+C.+Walshauthor=E.+M.+Gravallese&title=Bone+remodeling+in+rheumatic+disease%3A+a+question+of+balance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Bone remodeling in rheumatic disease: a question of balance</span></div><div class="casAuthors">Walsh, Nicole C.; Gravallese, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">233</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">301-312</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The past decade has obsd. an explosion of new information regarding the impact of inflammation on bone.  In rheumatic diseases, several factors that act as both immune modulators and regulators of bone homeostasis have been shown to mediate an imbalance in bone resorption and bone formation resulting in joint degeneration.  In rheumatoid arthritis (RA), focal bone loss is due to excess bone resorption by osteoclasts.  Resorption is mediated in part by increased local expression of the cytokine receptor activator of nuclear factor-ÎºB ligand (RANKL) compared with expression of its decoy receptor osteoprotegerin (OPG).  Bone formation by osteoblasts is also impaired at erosion sites in RA, and inhibitors of the canonical Wingless (Wnt) signaling pathway, including DKK1, have been implicated in the suppression of normal osteoblast function at these sites.  Inhibition of DKK1 in an animal model of RA attenuated bone erosion by increasing OPG expression as well as promoting bone formation.  In contrast to RA, inflammation in the spondyloarthropathies often results in excess periosteal bone formation, highlighting that the net impact of inflammation on bone is specific to the site at which inflammation occurs, and the cell types, cytokines, and factors present within the local bone microenvironment.  This fertile area of research bears watching for the identification of novel targets for the prevention of abnormal bone remodeling in inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmiN-GD2MZWLVg90H21EOLACvtfcHk0ljsbyMlybaj0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslaqsrk%253D&md5=2575f9b46c28f7f1c01d5328cfe40f4a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.0105-2896.2009.00857.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.0105-2896.2009.00857.x%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DN.%2BC.%26aulast%3DGravallese%26aufirst%3DE.%2BM.%26atitle%3DBone%2520remodeling%2520in%2520rheumatic%2520disease%253A%2520a%2520question%2520of%2520balance%26jtitle%3DImmunol.%2520Rev.%26date%3D2010%26volume%3D233%26spage%3D301%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Machold, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nell, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolen, J. S.</span><span> </span><span class="NLM_article-title">Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1186%2Far1966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=16719936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A280%3ADC%252BD28zos1yitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=211&author=K.+P.+Macholdauthor=V.+P.+Nellauthor=T.+A.+Stammauthor=J.+S.+Smolen&title=Aspects+of+early+arthritis.+Traditional+DMARD+therapy%3A+is+it+sufficient%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?</span></div><div class="casAuthors">Machold Klaus P; Nell Valerie P K; Stamm Tanja A; Smolen Josef S</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis research & therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is increasing evidence for beneficial effects of early DMARD (disease-modifying antirheumatic drug) therapy over delayed treatment in patients who present with arthritis of recent onset.  However, no universal consensus exists concerning the choice of initial drug or whether single drugs or combinations should be given as initial treatments.  Recent studies have focused on the benefits of various strategies in which treatments were tailored to achieve low levels of disease activity, as assessed using validated response criteria.  These studies demonstrated superiority of 'aggressive' over 'conventional' approaches.  Whether the inclusion of tumour necrosis factor antagonists or other biologic targeted therapies in such strategies confers additional benefits in terms of improved long-term outcomes must be clarified by further studies.  Assessment of risks in the individual patient, allowing individual 'tailoring' of the initial treatment, would be desirable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQk1qViHPdTfRLDWw4HIq2sfW6udTcc2eZ2HPQ9hwVp67ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zos1yitw%253D%253D&md5=311a2350bfd460023abef30231e5682f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2Far1966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far1966%26sid%3Dliteratum%253Aachs%26aulast%3DMachold%26aufirst%3DK.%2BP.%26aulast%3DNell%26aufirst%3DV.%2BP.%26aulast%3DStamm%26aufirst%3DT.%2BA.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26atitle%3DAspects%2520of%2520early%2520arthritis.%2520Traditional%2520DMARD%2520therapy%253A%2520is%2520it%2520sufficient%253F%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2006%26volume%3D8%26spage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziring, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gjertson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R. R.</span><span> </span><span class="NLM_article-title">TNFalpha blockade in human diseases: mechanisms and future directions</span> <span class="citation_source-journal">Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">â</span> <span class="NLM_lpage">136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1016%2Fj.clim.2007.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=17916444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsFKntQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2008&pages=121-136&author=M.+Wongauthor=D.+Ziringauthor=Y.+Korinauthor=S.+Desaiauthor=S.+Kimauthor=J.+Linauthor=D.+Gjertsonauthor=J.+Braunauthor=E.+Reedauthor=R.+R.+Singh&title=TNFalpha+blockade+in+human+diseases%3A+mechanisms+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">TNFÎ± blockade in human diseases: Mechanisms and future directions</span></div><div class="casAuthors">Wong, Maida; Ziring, David; Korin, Yael; Desai, Sheetal; Kim, Sungjin; Lin, Jan; Gjertson, David; Braun, Jonathan; Reed, Elaine; Singh, Ram Raj</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-136</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Tumor necrosis factor-Î± (TNFÎ±) antagonists have shown remarkable efficacy in a variety of immune-mediated inflammatory diseases (IMIDs).  In spite of their therapeutic popularity, little is known about their modes of action in vivo and factors that limit their scope of therapeutic use.  Intriguingly, while all TNFÎ± antagonists including blocking antibodies and sol. receptors are effective in certain IMIDs, only anti-TNFÎ± antibodies are effective in other IMIDs.  Early efforts at understanding how TNFÎ± antagonists act in IMIDs centered on their ability to neutralize sol. TNFÎ± or to block TNF receptors from binding to their ligands.  Subsequent studies suggested a role of complement-mediated lysis or antibody-dependent cell cytotoxicity in their therapeutic effects.  More recent models postulate that TNFÎ± blockers may act by affecting intracellular signaling, with the end result being a hastened cell cycle arrest, apoptosis, suppression of cytokine prodn., or improved Treg cell function.  TNFÎ± antagonists can also modulate the functions of myofibroblasts and osteoclasts, which might explain how TNFÎ± antagonists reduce tissue damage in chronic IMIDs.  Focusing on the human therapeutic experience, this anal. review will review the biol. of mechanisms of action, the limiting factors contributing to disease restriction in therapeutic efficacy, and the mechanism and frequency of treatment-limiting adverse responses of TNFÎ± antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplPPg145r58rVg90H21EOLACvtfcHk0lhU2q8Fa84stg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsFKntQ%253D%253D&md5=08302c72cf62eead8f33fb31a22fa0dd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2007.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2007.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DM.%26aulast%3DZiring%26aufirst%3DD.%26aulast%3DKorin%26aufirst%3DY.%26aulast%3DDesai%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DGjertson%26aufirst%3DD.%26aulast%3DBraun%26aufirst%3DJ.%26aulast%3DReed%26aufirst%3DE.%26aulast%3DSingh%26aufirst%3DR.%2BR.%26atitle%3DTNFalpha%2520blockade%2520in%2520human%2520diseases%253A%2520mechanisms%2520and%2520future%2520directions%26jtitle%3DClin.%2520Immunol.%26date%3D2008%26volume%3D126%26spage%3D121%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Khraishi, M.</span><span> </span><span class="NLM_article-title">Comparative overview of safety of the biologics in rheumatoid arthritis</span> <span class="citation_source-journal">J. Rheumatol. Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">â</span> <span class="NLM_lpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.3899%2Fjrheum.090128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=19509327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotlSjur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2009&pages=25-32&author=M.+Khraishi&title=Comparative+overview+of+safety+of+the+biologics+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative overview of safety of the biologics in rheumatoid arthritis</span></div><div class="casAuthors">Khraishi, Majed</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology, Supplement</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">Biologic Therapies for the Management of Rheumatoid Arthritis</span>),
    <span class="NLM_cas:pages">25-32</span>CODEN:
                <span class="NLM_cas:coden">JRSUDX</span>;
        ISSN:<span class="NLM_cas:issn">0380-0903</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">A review.  Six biol. agents are currently available in Canada for the treatment of rheumatoid arthritis (RA): abatacept, adalimumab, anakinra, etanercept, infliximab, and rituximab.  Although they are generally considered to be safe and well tolerated, concerns have been raised regarding the use of biol. therapies in the treatment of RA.  The new biol. agents abatacept and rituximab have novel mechanisms of action, and may therefore offer different safety profiles.  The most important safety concerns with the biol. therapies remain the increased risk of infection.  An increased risk of malignancies, including lymphoma and skin cancer, has been noted in RA trials, but the extent to which each of the biol. therapies contributes to the risk of malignancy has not been clearly defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl8cpgp1o50rVg90H21EOLACvtfcHk0lhU2q8Fa84stg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotlSjur4%253D&md5=ff5af7b4459e0de202a8ad74349400f3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.090128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.090128%26sid%3Dliteratum%253Aachs%26aulast%3DKhraishi%26aufirst%3DM.%26atitle%3DComparative%2520overview%2520of%2520safety%2520of%2520the%2520biologics%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Rheumatol.%2520Suppl.%26date%3D2009%26volume%3D82%26spage%3D25%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Buch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, P.</span><span> </span><span class="NLM_article-title">New therapies in the management of rheumatoid arthritis</span> <span class="citation_source-journal">Curr. Opin. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">â</span> <span class="NLM_lpage">251</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1097%2FBOR.0b013e3283454124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=21427579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFKls7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=245-251&author=M.+H.+Buchauthor=P.+Emery&title=New+therapies+in+the+management+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New therapies in the management of rheumatoid arthritis</span></div><div class="casAuthors">Buch, Maya H.; Emery, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Rheumatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">245-251</span>CODEN:
                <span class="NLM_cas:coden">CORHES</span>;
        ISSN:<span class="NLM_cas:issn">1040-8711</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The therapeutic landscape in the management of rheumatoid arthritis (RA) has witnessed significant changes over the past decade.  The ambition to improve outcomes further, minimize safety concerns and provide more convenient means of administration are all factors that continue to drive continued drug development.  This review summarizes novel therapies that have been most recently under investigation.  Recent findings: More refined drug technol. has seen the development of s.c. forms of existing therapies (abatacept, tocilizumab), as well as newer-generation monoclonal antibodies (e.g. B-cell-depleting agents, ocrelizumab and ofatumumab and the TNF-inhibitors certolizumab and golimumab).  Alternative methods of targeting crit. pathways, for example Blys inhibition (atacicept) and IL-6 as opposed to IL-6 receptor antagonism, have also been evaluated.  Finally, small mols. are receiving increasing attention, with some of the protein kinases inhibitors particularly promising.  Summary: The new emerging therapies for the management of RA illustrate much diversity, in terms of both drug technol. as well as the immunol. target.  Although not all may succeed in reaching the market, important insights can still be gained.  Challenging and exciting times lie ahead as these new technologies are embraced and efforts are made to det. how best to implement in practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTPD1rxbWFNbVg90H21EOLACvtfcHk0lhU2q8Fa84stg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFKls7k%253D&md5=c3190617b11ca7cb36325cd493f98ee6</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2FBOR.0b013e3283454124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FBOR.0b013e3283454124%26sid%3Dliteratum%253Aachs%26aulast%3DBuch%26aufirst%3DM.%2BH.%26aulast%3DEmery%26aufirst%3DP.%26atitle%3DNew%2520therapies%2520in%2520the%2520management%2520of%2520rheumatoid%2520arthritis%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2011%26volume%3D23%26spage%3D245%26epage%3D251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Walker, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. D.</span><span> </span><span class="NLM_article-title">The Jak-STAT pathway in rheumatoid arthritis</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1650</span><span class="NLM_x">â</span> <span class="NLM_lpage">1653</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=16142855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFSktLfI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2005&pages=1650-1653&author=J.+G.+Walkerauthor=M.+D.+Smith&title=The+Jak-STAT+pathway+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The Jak-STAT pathway in rheumatoid arthritis</span></div><div class="casAuthors">Walker, Jennifer G.; Smith, Malcolm D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1650-1653</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">A review discusses several studies evaluating the role of Jak-STAT pathway in rheumatoid arthritis.  The Jak-STAT signal transduction pathway is differentially regulated in inflammatory arthritis, with changes already documented in STAT1, STAT3, STAT4, and STAT6 expression.  There is growing evidence that modulation of the Jak-STAT pathway may represent a viable alternative therapeutic target in the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpeL2mM7Gh27Vg90H21EOLACvtfcHk0lhABRa_xgobow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFSktLfI&md5=21c28d6a026a89dcea963cb5aa569d6d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DJ.%2BG.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26atitle%3DThe%2520Jak-STAT%2520pathway%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Rheumatol.%26date%3D2005%26volume%3D32%26spage%3D1650%26epage%3D1653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Yamaoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saharinen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, V. E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">The Janus kinases (Jaks)</span> <span class="citation_source-journal">Genome Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">253.1</span><span class="NLM_x">â</span> <span class="NLM_lpage">253.6</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=253.1-253.6&author=K.+Yamaokaauthor=P.+Saharinenauthor=M.+Pesuauthor=V.+E.+T.+Holtauthor=O.+Silvennoinenauthor=J.+J.+O%E2%80%99Shea&title=The+Janus+kinases+%28Jaks%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DHolt%26aufirst%3DV.%2BE.%2BT.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Janus%2520kinases%2520%2528Jaks%2529%26jtitle%3DGenome%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D253.1%26epage%3D253.6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuccola, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jepson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shlyakter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoock, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furey, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frantz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauffenbach, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennani, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledeboer, M. W.</span><span> </span><span class="NLM_article-title">Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7938</span><span class="NLM_x">â</span> <span class="NLM_lpage">7941</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901383u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7938-7941&author=T.+Wangauthor=J.+P.+Duffyauthor=J.+Wangauthor=S.+Halasauthor=F.+G.+Salituroauthor=A.+C.+Pierceauthor=H.+J.+Zuccolaauthor=J.+R.+Blackauthor=J.+K.+Hoganauthor=S.+Jepsonauthor=D.+Shlyakterauthor=S.+Mahajanauthor=Y.+Guauthor=T.+Hoockauthor=M.+Woodauthor=B.+F.+Fureyauthor=J.+D.+Frantzauthor=L.+M.+Dauffenbachauthor=U.+A.+Germannauthor=B.+Fanauthor=M.+Namchukauthor=Y.+L.+Bennaniauthor=M.+W.+Ledeboer&title=Janus+kinase+2+inhibitors.+Synthesis+and+characterization+of+a+novel+polycyclic+azaindole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm901383u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901383u%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DDuffy%26aufirst%3DJ.%2BP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHalas%26aufirst%3DS.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DZuccola%26aufirst%3DH.%2BJ.%26aulast%3DBlack%26aufirst%3DJ.%2BR.%26aulast%3DHogan%26aufirst%3DJ.%2BK.%26aulast%3DJepson%26aufirst%3DS.%26aulast%3DShlyakter%26aufirst%3DD.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHoock%26aufirst%3DT.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DFurey%26aufirst%3DB.%2BF.%26aulast%3DFrantz%26aufirst%3DJ.%2BD.%26aulast%3DDauffenbach%26aufirst%3DL.%2BM.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DFan%26aufirst%3DB.%26aulast%3DNamchuk%26aufirst%3DM.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26aulast%3DLedeboer%26aufirst%3DM.%2BW.%26atitle%3DJanus%2520kinase%25202%2520inhibitors.%2520Synthesis%2520and%2520characterization%2520of%2520a%2520novel%2520polycyclic%2520azaindole%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7938%26epage%3D7941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Chen, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prchal, J. T.</span><span> </span><span class="NLM_article-title">JAK2 kinase inhibitors and myeloproliferative disorders</span> <span class="citation_source-journal">Curr Opin Hematol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">â</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1097%2FMOH.0b013e3283366b91" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=20087176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1yns7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=110-116&author=A.+T.+Chenauthor=J.+T.+Prchal&title=JAK2+kinase+inhibitors+and+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2 kinase inhibitors and myeloproliferative disorders</span></div><div class="casAuthors">Chen, Andrew T.; Prchal, Josef T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">110-116</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: The pathophysiol. of Philadelphia-chromosome neg. myeloproliferative disorders has significantly advanced with the discovery of JAK2V617F.  The prevalence of JAK2V617F mutation has made it a much anticipated target for inhibition; this review will update and assess progress.  Recent findings: Many agents have been studied in preclin. trials, of which few have entered clin. trials.  Data from the clin. trials are limited and mostly in the form of abstrs. and reviews.  Summary: The prevalence of the JAK2V617F mutation in the classic Philadelphia-chromosome neg. myeloproliferative disorders has made it a much anticipated target for inhibition.  Present in greater than 90% of patients with polycythemia vera and approx. 50% of patients with essential thrombocythemia and primary myelofibrosis, it has been hoped that targeted inhibition of JAK2V617F would achieve similar disease control as imatinib mesylate has produced in chronic myeloid leukemia.  However, JAK2V617F in the Philadelphia-chromosome neg. myeloproliferative disorders, unlike bcr/abl tyrosine kinase in chronic myeloid leukemia, is not a causative but rather a secondary somatic mutation.  As the JAK2 inhibitors move into phase III clin. trials, their efficacy and role in therapy is becoming clearer; however, there are still many questions needing answers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa5ZWxfhCU7rVg90H21EOLACvtfcHk0lhABRa_xgobow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1yns7Y%253D&md5=a03760b25eb1630429ab40137fb179c9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2FMOH.0b013e3283366b91&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMOH.0b013e3283366b91%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DA.%2BT.%26aulast%3DPrchal%26aufirst%3DJ.%2BT.%26atitle%3DJAK2%2520kinase%2520inhibitors%2520and%2520myeloproliferative%2520disorders%26jtitle%3DCurr%2520Opin%2520Hematol%26date%3D2010%26volume%3D17%26spage%3D110%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">â</span> <span class="NLM_lpage">8484</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=S.-P.+Changauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+A+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lhhuh1OwOKFBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DS.-P.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520A%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favata, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">5298</span><span class="NLM_x">â</span> <span class="NLM_lpage">5307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-5307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shiauthor=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0lhhuh1OwOKFBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D5307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Kiss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sayeski, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">KeserÅ©, G. M.</span><span> </span><span class="NLM_article-title">Recent developments on JAK2 inhibitors: a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">â</span> <span class="NLM_lpage">495</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1517%2F13543771003639436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=20205617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslalsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=471-495&author=R.+Kissauthor=P.+P.+Sayeskiauthor=G.+M.+Keser%C5%A9&title=Recent+developments+on+JAK2+inhibitors%3A+a+patent+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments on JAK2 inhibitors: a patent review</span></div><div class="casAuthors">Kiss, Robert; Sayeski, Peter P.; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-495</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: JAK2 is one of the most promising targets against neoplastic growth.  A somatic mutation (V617F) resulting in enhanced JAK2 kinase activity can be frequently found in patients with serious myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia and primary myelofibrosis.  Preclin. results strongly support that JAK2 inhibitors could be effectively used in these indications.  Pharmaceutical companies and academic groups have developed a no. of potent JAK2 inhibitors during the last decade.  Tolerability and effectiveness of the most promising compds. are currently being investigated in clin. trials.  Areas covered in this review: In this paper, we aim to give a comprehensive review of the currently available patent literature of JAK2 inhibitors.  What the reader will gain: We tried to collect the published core structures possessing JAK2 inhibitory potency including compds. developed by academic and industrial research groups.  We review the currently available patent literature as well as the key papers contg. addnl. information about the described JAK2 inhibitors.  Clin. status data were collected by searching the Prous Integrity and Pharmaprojects databases.  Take home message: The significant no. of JAK2 inhibitors published and numerous clin. trials involving these compds. suggest that some of them might be approved in the next few years and can serve as novel drugs for the treatment of JAK2-dependent pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJQgQopptoVrVg90H21EOLACvtfcHk0lgaHeYP_wigoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslalsrY%253D&md5=2531795d8c66c3b7173a0c1a3b2738e1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1517%2F13543771003639436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543771003639436%26sid%3Dliteratum%253Aachs%26aulast%3DKiss%26aufirst%3DR.%26aulast%3DSayeski%26aufirst%3DP.%2BP.%26aulast%3DKeser%25C5%25A9%26aufirst%3DG.%2BM.%26atitle%3DRecent%2520developments%2520on%2520JAK2%2520inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D471%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Mesa, R. A.</span><span> </span><span class="NLM_article-title">Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">â</span> <span class="NLM_lpage">403</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=20506062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1yltr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=394-403&author=R.+A.+Mesa&title=Ruxolitinib%2C+a+selective+JAK1+and+JAK2+inhibitor+for+the+treatment+of+myeloproliferative+neoplasms+and+psoriasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis</span></div><div class="casAuthors">Mesa, Ruben A.</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-403</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, being developed by Incyte Corp and Novartis AG.  Ruxolitinib was initially developed to target the constitutive activation of the JAK-STAT pathway in patients with myeloproliferative neoplasms (MPNs).  Meaningful redns. in spleen size and constitutional symptoms have been noted in patients with myelofibrosis (both primary and post-essential thrombocythemia/polycythemia vera).  Data from a phase I/II clin. trial led to ongoing registration trials in the US and Europe.  Toxicity (primarily decreased erythropoiesis and thrombocytopoiesis) has been managed by close control of dosing.  The inhibition of inflammatory cytokine signaling through JAK1 inhibition has led to intriguing results in patients with rheumatoid arthritis and psoriasis (using a topical cream formulation).  Ruxolitinib is a well tolerated, first-in-class JAK2 inhibitor with various potential clin. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5yUMfeRYwE7Vg90H21EOLACvtfcHk0lgaHeYP_wigoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1yltr0%253D&md5=9f89b13c71527c112b797375c93ccbff</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26atitle%3DRuxolitinib%252C%2520a%2520selective%2520JAK1%2520and%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%2520and%2520psoriasis%26jtitle%3DIDrugs%26date%3D2010%26volume%3D13%26spage%3D394%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Passamonti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maffioli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caramazza, D.</span><span> </span><span class="NLM_article-title">New generation small-molecule inhibitors in myeloproliferative neoplasms</span> <span class="citation_source-journal">Curr. Opin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">â</span> <span class="NLM_lpage">123</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1097%2FMOH.0b013e32834ff575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=22227528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFanur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=117-123&author=F.+Passamontiauthor=M.+Maffioliauthor=D.+Caramazza&title=New+generation+small-molecule+inhibitors+in+myeloproliferative+neoplasms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">New generation small-molecule inhibitors in myeloproliferative neoplasms</span></div><div class="casAuthors">Passamonti, Francesco; Maffioli, Margherita; Caramazza, Domenica</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-123</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Myeloproliferative neoplasms (MPNs) are diseases that carry the JAK2 (V617F) mutation in about 70% of the patients.  The purpose of this review is to describe the recent advances in the therapy of MPNs with JAK2 inhibitors.  Recent findings: Many drugs are now under investigations targeting different pathways crit. for MPN development, such as the JAK-STAT (JAK2 inhibitors: INCB018424 or ruxolitinib, TG101348 or SAR302503, CYT387, SB1518, CEP701 and LY2784544) and the PI3K/AKT/mTOR (everolimus) pathways, or act through remodeling of chromatin with a key role in epigenetics (givinostat, panobinostat and vorinostat).  The most relevant effects were spleen size redn. and relief of constitutional symptoms.  Summary: Patients who might benefit from JAK2 inhibitors in clin. practice are mostly those with splenomegaly or with constitutional symptoms.  We should alert patients with lower Hb levels that these therapies might, although temporarily, favor the need for red blood cell transfusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_BM7nBQTO8LVg90H21EOLACvtfcHk0lgaHeYP_wigoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFanur4%253D&md5=2684c66d8b79d201a2a17d43bfed53b5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1097%2FMOH.0b013e32834ff575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMOH.0b013e32834ff575%26sid%3Dliteratum%253Aachs%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DMaffioli%26aufirst%3DM.%26aulast%3DCaramazza%26aufirst%3DD.%26atitle%3DNew%2520generation%2520small-molecule%2520inhibitors%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2012%26volume%3D19%26spage%3D117%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Santos, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">JAK2 inhibitors: Whatâs the true therapeutic potential?</span> <span class="citation_source-journal">Blood Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">â</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1016%2Fj.blre.2010.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=21095048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitFKjsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=53-63&author=F.+P.+Santosauthor=S.+Verstovsek&title=JAK2+inhibitors%3A+What%E2%80%99s+the+true+therapeutic+potential%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2 inhibitors: What's the true therapeutic potential?</span></div><div class="casAuthors">Santos, Fabio P. S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">53-63</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Physicians treating patients with the classic Philadelphia-neg. myeloproliferative neoplasms (Ph-neg. MPNs) (polycythemia vera [PV], essential thrombocythemia [ET] and primary myelofibrosis [PMF]) traditionally had few therapeutic drugs available.  Spurred by the discovery of activating mutation of the JAK2 tyrosine kinase (JAK2 V617F mutation) in patients with Ph-neg. MPNs several years ago, several JAK2 inhibitors were synthesized and are currently undergoing clin. trials in patients with PMF, PV and ET.  Initial results from these studies have shown that these drugs can markedly reduce spleen size and alleviate constitutional symptoms, increase wt. and improve exercise capacity in MF patients, thus improve quality of their life, which is significant clin. benefit.  In ET and PV JAK2 inhibitor therapy may efficiently control blood cell count, as well as improve splenomegaly and control disease related symptoms.  JAK2 inhibitors are a novel class of agents with promising results for treating patients with MF, PV and ET.  In this article we will review the current evidence regarding the role of JAK2 mutations in the pathogenesis of Ph-neg. MPNs and summarize results from the most recent clin. trials with JAK2 inhibitors in these disorders.  JAK2 inhibitors are a novel class of agents with promising results for treating patients with MF, PV and ET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZb8q4WeXPbVg90H21EOLACvtfcHk0lgaHeYP_wigoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitFKjsbw%253D&md5=5e99d696b87a7523af5d1fb7c540f386</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2010.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2010.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DF.%2BP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DJAK2%2520inhibitors%253A%2520What%25E2%2580%2599s%2520the%2520true%2520therapeutic%2520potential%253F%26jtitle%3DBlood%2520Rev.%26date%3D2011%26volume%3D25%26spage%3D53%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">140</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=127-140&author=A.+Quintas-Cardamaauthor=H.+Kantarjianauthor=J.+Cortesauthor=S.+Verstovsek&title=Janus+kinase+inhibitors+for+the+treatment+of+myeloproliferative+neoplasias+and+beyond"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DJanus%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasias%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D127%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Ioannidis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almeida, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollard, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alimzhanov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebernitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huszar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinda, M.</span><span> </span><span class="NLM_article-title">Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol â3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">â</span> <span class="NLM_lpage">276</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1011319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=262-276&author=S.+Ioannidisauthor=M.+L.+Lambauthor=T.+Wangauthor=L.+Almeidaauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=B.+Pengauthor=M.+Suauthor=H.+J.+Zhangauthor=E.+Hoffmannauthor=C.+Rivardauthor=I.+Greenauthor=T.+Howardauthor=H.+Pollardauthor=J.+Readauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Yeauthor=D.+Huszarauthor=M.+Zinda&title=Discovery+of+5-chloro-N2-%5B%281S%29-1-%285-fluoropyrimidin-2-yl%29ethyl%5D-N4-%285-methyl-1H-pyrazol+%E2%88%923-yl%29pyrimidine-2%2C4-diamine+%28AZD1480%29+as+a+novel+inhibitor+of+the+Jak%2FStat+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm1011319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1011319%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DGreen%26aufirst%3DI.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DPollard%26aufirst%3DH.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25205-chloro-N2-%255B%25281S%2529-1-%25285-fluoropyrimidin-2-yl%2529ethyl%255D-N4-%25285-methyl-1H-pyrazol%2520%25E2%2588%25923-yl%2529pyrimidine-2%252C4-diamine%2520%2528AZD1480%2529%2520as%2520a%2520novel%2520inhibitor%2520of%2520the%2520Jak%252FStat%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D262%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Paunovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenbroeck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span> </span><span class="NLM_article-title">Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL)-12, â17, â23 and â27 in autoimmunity</span> <span class="citation_source-journal">Rheumatology (Oxford)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">771</span><span class="NLM_x">â</span> <span class="NLM_lpage">776</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1093%2Frheumatology%2Fkem352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=18238793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtlentrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=771-776&author=V.+Paunovicauthor=H.+P.+Carrollauthor=K.+Vandenbroeckauthor=M.+Gadina&title=Signalling%2C+inflammation+and+arthritis%3A+crossed+signals%3A+the+role+of+interleukin+%28IL%29-12%2C+%E2%88%9217%2C+%E2%88%9223+and+%E2%88%9227+in+autoimmunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling, inflammation and arthritis</span></div><div class="casAuthors">Paunovic, V.; Carroll, H. P.; Vandenbroeck, K.; Gadina, M.</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">771-776</span>CODEN:
                <span class="NLM_cas:coden">RUMAFK</span>;
        ISSN:<span class="NLM_cas:issn">1462-0324</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Autoimmune diseases such as rheumatoid arthritis are the consequence of a persistent imbalance between pro- and anti-inflammatory immune mechanisms leading to chronic inflammation.  The action of several cytokines is at the basis of this complex process.  This review is focused on the signalling events triggered by two major groups of cytokines, namely the IL-12 and IL-17 families, which in the past few years have been shown to have a prominent role in the pathogenesis of such diseases.  In particular, we will focus on the signalling cascades set in motion by such cytokines and how this may relate to the pathogenesis of human immune and inflammatory disorders as knowledge of such cascades may help in the development of novel therapeutic approaches for such diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8fu5A_UnbnbVg90H21EOLACvtfcHk0liPAnPOh5NtCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtlentrs%253D&md5=993ceb0f2b339360afdca135de4abb79</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fkem352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fkem352%26sid%3Dliteratum%253Aachs%26aulast%3DPaunovic%26aufirst%3DV.%26aulast%3DCarroll%26aufirst%3DH.%2BP.%26aulast%3DVandenbroeck%26aufirst%3DK.%26aulast%3DGadina%26aufirst%3DM.%26atitle%3DSignalling%252C%2520inflammation%2520and%2520arthritis%253A%2520crossed%2520signals%253A%2520the%2520role%2520of%2520interleukin%2520%2528IL%2529-12%252C%2520%25E2%2588%259217%252C%2520%25E2%2588%259223%2520and%2520%25E2%2588%259227%2520in%2520autoimmunity%26jtitle%3DRheumatology%2520%2528Oxford%2529%26date%3D2008%26volume%3D47%26spage%3D771%26epage%3D776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ishizaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muromoto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohshiro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekine, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimoda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oritani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, T.</span><span> </span><span class="NLM_article-title">Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice</span> <span class="citation_source-journal">Int. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">â</span> <span class="NLM_lpage">582</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1093%2Fintimm%2Fdxr057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=21765170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGlu77M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=575-582&author=M.+Ishizakiauthor=R.+Muromotoauthor=T.+Akimotoauthor=Y.+Ohshiroauthor=M.+Takahashiauthor=Y.+Sekineauthor=H.+Maedaauthor=K.+Shimodaauthor=K.+Oritaniauthor=T.+Matsuda&title=Tyk2+deficiency+protects+joints+against+destruction+in+anti-type+II+collagen+antibody-induced+arthritis+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice</span></div><div class="casAuthors">Ishizaki, Masayuki; Muromoto, Ryuta; Akimoto, Toshihiko; Ohshiro, Yuya; Takahashi, Miki; Sekine, Yuichi; Maeda, Hiroaki; Shimoda, Kazuya; Oritani, Kenji; Matsuda, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">575-582</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Tyrosine kinase-2 (Tyk2) participates in the signaling pathways of multiple cytokines in innate and acquired immunity.  In the present study, we investigated the in vivo involvement of Tyk2 in anti-type II collagen antibody-induced arthritis (CAIA) using Tyk2-deficient mice.  Hind paws of wild-type mice showed massive swelling and erythema by arthritogenic antibody injection, whereas Tyk2-deficient mice did not show any signs of arthritis.  Indeed, neither the infiltration of inflammatory cells nor the fibrillation of articular cartilages was obsd. in Tyk2-deficient mice.  Tyk2 deficiency also reduced the prodn. of Th1/Th17-related cytokines, the other proinflammatory cytokines and matrix metalloproteases, which are induced in the CAIA paw.  Our results demonstrate a crit. contribution of Tyk2 in the development of arthritis, and we propose that Tyk2 might be an important candidate for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKbV7yONzwx7Vg90H21EOLACvtfcHk0liPAnPOh5NtCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGlu77M&md5=852ac0d9133c8eb5423a186b0040dbb7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxr057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxr057%26sid%3Dliteratum%253Aachs%26aulast%3DIshizaki%26aufirst%3DM.%26aulast%3DMuromoto%26aufirst%3DR.%26aulast%3DAkimoto%26aufirst%3DT.%26aulast%3DOhshiro%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSekine%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DShimoda%26aufirst%3DK.%26aulast%3DOritani%26aufirst%3DK.%26aulast%3DMatsuda%26aufirst%3DT.%26atitle%3DTyk2%2520deficiency%2520protects%2520joints%2520against%2520destruction%2520in%2520anti-type%2520II%2520collagen%2520antibody-induced%2520arthritis%2520in%2520mice%26jtitle%3DInt.%2520Immunol.%26date%3D2011%26volume%3D23%26spage%3D575%26epage%3D582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Dehlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokarewa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottapel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnusson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlberg, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarkowski, A.</span><span> </span><span class="NLM_article-title">Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">e3633</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=e3633&author=M.+Dehlinauthor=M.+Bokarewaauthor=R.+Rottapelauthor=S.+J.+Fosterauthor=M.+Magnussonauthor=L.+E.+Dahlbergauthor=A.+Tarkowski&title=Intra-articular+fms-like+tyrosine+kinase+3+ligand+expression+is+a+driving+force+in+induction+and+progression+of+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDehlin%26aufirst%3DM.%26aulast%3DBokarewa%26aufirst%3DM.%26aulast%3DRottapel%26aufirst%3DR.%26aulast%3DFoster%26aufirst%3DS.%2BJ.%26aulast%3DMagnusson%26aufirst%3DM.%26aulast%3DDahlberg%26aufirst%3DL.%2BE.%26aulast%3DTarkowski%26aufirst%3DA.%26atitle%3DIntra-articular%2520fms-like%2520tyrosine%2520kinase%25203%2520ligand%2520expression%2520is%2520a%2520driving%2520force%2520in%2520induction%2520and%2520progression%2520of%2520arthritis%26jtitle%3DPLoS%2520One%26date%3D2008%26volume%3D3%26spage%3De3633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Dehlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlandsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brisslert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokarewa, M.</span><span> </span><span class="NLM_article-title">Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">â</span> <span class="NLM_lpage">817</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1189%2Fjlb.1110640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=21771900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlWitLrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2011&pages=811-817&author=M.+Dehlinauthor=S.+Anderssonauthor=M.+Erlandssonauthor=M.+Brisslertauthor=M.+Bokarewa&title=Inhibition+of+fms-like+tyrosine+kinase+3+alleviates+experimental+arthritis+by+reducing+formation+of+dendritic+cells+and+antigen+presentation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation</span></div><div class="casAuthors">Dehlin, Mats; Andersson, Sofia; Erlandsson, Malin; Brisslert, Mikael; Bokarewa, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">811-817</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Society for Leucocyte Biology</span>)
        </div><div class="casAbstract">TKs are intracellular signaling mols. essential for cell homeostasis.  Inhibition of TKs is used in treatment of malignancies and diabetes mellitus.  The present study evaluated the role of Flt3 in antigen-induced arthritis.  Mice were immunized with mBSA, and arthritis was induced by an i.a. injection of mBSA.  Treatment with the Flt3 inhibitor sunitinib was started together with mBSA immunization or together with the induction of arthritis.  The mBSA-injected joints were evaluated morphol. for signs of synovitis and bone/cartilage destruction.  Markers of bone metab. and antibody responses were measured by ELISA.  Maturation of DCs in the bone marrow and spleen was evaluated by flow cytometry.  Sunitinib treatment reduced the intensity of synovitis and the incidence of bone destruction.  The redn. in bone destruction was seen when the treatment was started at the time of immunization or at the time of arthritis induction.  The antiarthritic effect was achieved by inhibition of DCs, redn. of antibody prodn., and bone metab.  Inhibition of Flt3 is a potent antiarthritic mechanism reducing antigen presentation, synovial inflammation, and bone resorption.  Down-regulation of TKs may be a useful tool in the treatment of human RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqccTBQDx10d7Vg90H21EOLACvtfcHk0lg2QaNIcRmY5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlWitLrF&md5=6e2339d9127229cf00760beec828b211</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1189%2Fjlb.1110640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.1110640%26sid%3Dliteratum%253Aachs%26aulast%3DDehlin%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DS.%26aulast%3DErlandsson%26aufirst%3DM.%26aulast%3DBrisslert%26aufirst%3DM.%26aulast%3DBokarewa%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520fms-like%2520tyrosine%2520kinase%25203%2520alleviates%2520experimental%2520arthritis%2520by%2520reducing%2520formation%2520of%2520dendritic%2520cells%2520and%2520antigen%2520presentation%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2011%26volume%3D90%26spage%3D811%26epage%3D817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1. 1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">â</span> <span class="NLM_lpage">4658</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.+1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.%25201%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of kinase spectrum selective macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2) and Fms-liketyrosine kinase-3 (FLT3) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">â</span> <span class="NLM_lpage">196</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201112g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=169-196&author=A.+D.+Williamauthor=A.+Leeauthor=K.+C.+Gohauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+Teoauthor=H.+Nagarajauthor=C.+P.+Leeauthor=H.+Wangauthor=M.+Williamsauthor=E.+T.+Sunauthor=C.+Huauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+Woodauthor=B.+W.+Dymock&title=Discovery+of+kinase+spectrum+selective+macrocycle+%2816E%29-14-Methyl-20-oxa-5%2C7%2C14%2C26-tetraaza-tetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2827%29%2C9%2C11%2C16%2C21%2C23-decaene+%28SB1317%2FTG02%29%2C+a+potent+inhibitor+of+cyclin+dependant+kinases+%28CDKs%29%2C+Janus+kinase+2+%28JAK2%29+and+Fms-liketyrosine+kinase-3+%28FLT3%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm201112g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201112g%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DC.%2BP.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520kinase%2520spectrum%2520selective%2520macrocycle%2520%252816E%2529-14-Methyl-20-oxa-5%252C7%252C14%252C26-tetraaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252827%2529%252C9%252C11%252C16%252C21%252C23-decaene%2520%2528SB1317%252FTG02%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520cyclin%2520dependant%2520kinases%2520%2528CDKs%2529%252C%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520Fms-liketyrosine%2520kinase-3%2520%2528FLT3%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D169%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, S.-L.</span><span> </span><span class="NLM_article-title">Asymmetric construction of polycyclic indoles through olefin cross- metathesis/intramolecular FriedelâCrafts alkylation under sequential catalysis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7428</span><span class="NLM_x">â</span> <span class="NLM_lpage">7431</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=7428-7431&author=Q.+Caiauthor=Z.-A.+Zhaoauthor=S.-L.+You&title=Asymmetric+construction+of+polycyclic+indoles+through+olefin+cross-+metathesis%2Fintramolecular+Friedel%E2%80%93Crafts+alkylation+under+sequential+catalysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DZ.-A.%26aulast%3DYou%26aufirst%3DS.-L.%26atitle%3DAsymmetric%2520construction%2520of%2520polycyclic%2520indoles%2520through%2520olefin%2520cross-%2520metathesis%252Fintramolecular%2520Friedel%25E2%2580%2593Crafts%2520alkylation%2520under%2520sequential%2520catalysis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D7428%26epage%3D7431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Schmidt, B.</span><span> </span><span class="NLM_article-title">Ruthenium-catalyzed cyclizations: more than just olefin metathesis!</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">4996</span><span class="NLM_x">â</span> <span class="NLM_lpage">4999</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=4996-4999&author=B.+Schmidt&title=Ruthenium-catalyzed+cyclizations%3A+more+than+just+olefin+metathesis%21"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DB.%26atitle%3DRuthenium-catalyzed%2520cyclizations%253A%2520more%2520than%2520just%2520olefin%2520metathesis%2521%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D4996%26epage%3D4999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Chen, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRose, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burka, L. T.</span><span> </span><span class="NLM_article-title">Metabolism of furans in vitro: ipomeanine and 4-ipomeanol</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1320</span><span class="NLM_x">â</span> <span class="NLM_lpage">1329</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx060128f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVylu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=1320-1329&author=L.+J.+Chenauthor=E.+F.+DeRoseauthor=L.+T.+Burka&title=Metabolism+of+furans+in+vitro%3A+ipomeanine+and+4-ipomeanol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of Furans in Vitro: Ipomeanine and 4-Ipomeanol</span></div><div class="casAuthors">Chen, Ling-Jen; DeRose, Eugene F.; Burka, Leo T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1320-1329</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ipomeanine (IPN), 4-ipomeanol (4-IPO), 1-ipomeanol (1-IPO), and 1,4-ipomeadiol (DIOL) are toxic 3-substituted furans found in mold-damaged sweet potatoes.  IPN and 4-IPO are the most toxic, but all produce pulmonary toxicity in cattle and rodents, and 4-IPO induces hepatotoxicity in humans.  These furans require metabolic activation to elicit toxicity, but the limited information obtained from previous metab. studies prompted us to initiate the investigation reported here.  Our initial studies of 4-IPO metab. by rat liver microsomes demonstrated that the oxidn. of 4-IPO to IPN and redn. to DIOL occurred and that more IPN was metabolized to a reactive species than 4-IPO or DIOL.  Incubation of IPN and Gly produced a 2'-pyrrolin-5'-one adduct establishing that IPN was metabolized to an enedial.  N-Acetylcysteine reacted with the 5'-aldehyde of the enedial to give two 2',5'-dihydro-2'-hydroxyfurans stabilized by H bonding between the 2'-OH and 3'-keto group.  Reaction of the enedial metabolite of IPN with one GSH gave several adducts including a pyrrole derived from the 1,2-addn. of GSH to the 5'-aldehyde as well as two tricyclic 2'-pyrrolines derived from the 1,4-addn. of GSH at the 4'-position.  The identities of the pyrrole and 2'-pyrroline GSH adducts were confirmed by observation of structurally similar adducts from Cys conjugation with the enedial metabolite of IPN.  Several minor adducts from the conjugation of the enedial metabolite of IPN with two GSH were also detected.  Mono-GSH and bis-GSH adducts were derived from both the 1,2-and 1,4-addn. of GSH to the enedial metabolite of 4-IPO in rat liver microsomal incubations of 4-IPO and GSH.  Sequential oxidn. of 4-IPO to IPN and then to the enedial metabolite followed by GSH conjugation also occurred in the 4-IPO incubations.  The complex structures of the reaction products of the enedial with biol. nucleophiles may explain why the many attempts to identify 4-IPO adducts to protein have not been successful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVFkIl0mq48rVg90H21EOLACvtfcHk0liK-UB1eDt99A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVylu7s%253D&md5=5735edaa74c5cbce8735c23db0eb4daf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Ftx060128f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx060128f%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%2BJ.%26aulast%3DDeRose%26aufirst%3DE.%2BF.%26aulast%3DBurka%26aufirst%3DL.%2BT.%26atitle%3DMetabolism%2520of%2520furans%2520in%2520vitro%253A%2520ipomeanine%2520and%25204-ipomeanol%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2006%26volume%3D19%26spage%3D1320%26epage%3D1329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. A.</span><span> </span><span class="NLM_article-title">Identification of furan metabolites derived from cysteine-cis-2-butene-1,4-dial-lysine cross-links</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">â</span> <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx9003215" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=142-151&author=D.+Luauthor=L.+A.+Peterson&title=Identification+of+furan+metabolites+derived+from+cysteine-cis-2-butene-1%2C4-dial-lysine+cross-links"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Ftx9003215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx9003215%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DPeterson%26aufirst%3DL.%2BA.%26atitle%3DIdentification%2520of%2520furan%2520metabolites%2520derived%2520from%2520cysteine-cis-2-butene-1%252C4-dial-lysine%2520cross-links%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D142%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Lant, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxford, J.</span><span> </span><span class="NLM_article-title">Qualitative and quantitative analysis of ranitidine and its metabolites by high-performance liquid chromatography-mass spectrometry</span> <span class="citation_source-journal">J. Chromatogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">â</span> <span class="NLM_lpage">152</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1016%2FS0021-9673%2801%2990379-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=4008551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADyaL2MXhvFOns7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=1985&pages=143-152&author=M.+S.+Lantauthor=L.+E.+Martinauthor=J.+Oxford&title=Qualitative+and+quantitative+analysis+of+ranitidine+and+its+metabolites+by+high-performance+liquid+chromatography-mass+spectrometry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Qualitative and quantitative analysis of ranitidine and its metabolites by high-performance liquid chromatography-mass spectrometry</span></div><div class="casAuthors">Lant, M. S.; Martin, L. E.; Oxford, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">143-52</span>CODEN:
                <span class="NLM_cas:coden">JOCRAM</span>;
        ISSN:<span class="NLM_cas:issn">0021-9673</span>.
    </div><div class="casAbstract">Reversed-phase HPLC systems for the sepn. of ranitidine  [66357-35-5] and its metabolites ranitidine N-oxide  [73857-20-2], ranitidine S-oxide  [73851-70-4], and desmethylranitidine  [66357-25-3] were developed for use in HPLC-mass spectrometry.  A direct liq. introduction-HPLC-mass spectrometry system to analyze qual. and quant. solns. contg. ranitidine and its metabolites by reversed-phase chromatog. is described.  A sample of urine collected from a subject given an oral dose of 75 mg ranitidine and 75 mg [2H3]ranitidine was analyzed by this system.  Ranitidine and its metabolites were identified by the ion doublets in the mass spectra which were 3 amu apart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9sEXPH9K0dbVg90H21EOLACvtfcHk0ljach4bSUhl9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXhvFOns7s%253D&md5=4486fc5859d208e8d8230e88a5959658</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0021-9673%2801%2990379-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9673%252801%252990379-6%26sid%3Dliteratum%253Aachs%26aulast%3DLant%26aufirst%3DM.%2BS.%26aulast%3DMartin%26aufirst%3DL.%2BE.%26aulast%3DOxford%26aufirst%3DJ.%26atitle%3DQualitative%2520and%2520quantitative%2520analysis%2520of%2520ranitidine%2520and%2520its%2520metabolites%2520by%2520high-performance%2520liquid%2520chromatography-mass%2520spectrometry%26jtitle%3DJ.%2520Chromatogr.%26date%3D1985%26volume%3D323%26spage%3D143%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Madan, B.; Goh, K. C.; Hart, S.; William, A. D.; Jayaraman, R.; Ethirajulu, K.; Dymock, B. W.; Wood, J. M.</span>, unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Madan%2C+B.%3B+Goh%2C+K.+C.%3B+Hart%2C+S.%3B+William%2C+A.+D.%3B+Jayaraman%2C+R.%3B+Ethirajulu%2C+K.%3B+Dymock%2C+B.+W.%3B+Wood%2C+J.+M.%2C+unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DMadan%26aufirst%3DB." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">302</span><span class="NLM_x">â</span> <span class="NLM_lpage">13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=302-13&author=S.+Wangauthor=P.+M.+Fischer&title=Cyclin-dependent+kinase+9%3A+a+key+transcriptional+regulator+and+potential+drug+target+in+oncology%2C+virology+and+cardiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DCyclin-dependent%2520kinase%25209%253A%2520a%2520key%2520transcriptional%2520regulator%2520and%2520potential%2520drug%2520target%2520in%2520oncology%252C%2520virology%2520and%2520cardiology%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26spage%3D302%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Quentmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLeod, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaborski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H. G.</span><span> </span><span class="NLM_article-title">JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">â</span> <span class="NLM_lpage">476</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=471-476&author=H.+Quentmeierauthor=R.+A.+MacLeodauthor=M.+Zaborskiauthor=H.+G.+Drexler&title=JAK2+V617F+tyrosine+kinase+mutation+in+cell+lines+derived+from+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DMacLeod%26aufirst%3DR.%2BA.%26aulast%3DZaborski%26aufirst%3DM.%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26atitle%3DJAK2%2520V617F%2520tyrosine%2520kinase%2520mutation%2520in%2520cell%2520lines%2520derived%2520from%2520myeloproliferative%2520disorders%26jtitle%3DLeukemia%26date%3D2006%26volume%3D20%26spage%3D471%26epage%3D476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Holmdahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldschmidt, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MalmstrÃ¶m, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, J.</span><span> </span><span class="NLM_article-title">Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity</span> <span class="citation_source-journal">APMIS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">â</span> <span class="NLM_lpage">584</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm201454n&amp;key=10.1111%2Fj.1699-0463.1989.tb00446.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=2665798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A280%3ADyaL1Mzit12htA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=1989&pages=575-584&author=R.+Holmdahlauthor=M.+E.+Anderssonauthor=T.+J.+Goldschmidtauthor=L.+Janssonauthor=M.+Karlssonauthor=V.+Malmstr%C3%B6mauthor=J.+Mo&title=Collagen+induced+arthritis+as+an+experimental+model+for+rheumatoid+arthritis.+Immunogenetics%2C+pathogenesis+and+autoimmunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity</span></div><div class="casAuthors">Holmdahl R; Andersson M E; Goldschmidt T J; Jansson L; Karlsson M; Malmstrom V; Mo J</div><div class="citationInfo"><span class="NLM_cas:title">APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">575-84</span>
        ISSN:<span class="NLM_cas:issn">0903-4641</span>.
    </div><div class="casAbstract">The type II collagen (CII) induced arthritis animal model (CIA) provides opportunities to study the nature of autoimmune reactions leading to arthritis and may be used as a model for rheumatoid arthritis (RA).  Thus, in similarity with RA, the CIA model, when induced with autologous CII, shows a chronic and progressive disease course.  The susceptibility to both RA and CIA are correlated to the expression of certain MHC class II allotype genes.  In both diseases are autoantibodies to CII and rheumatoid factors produced.  Immunohistopathology of affected joints show in both diseases a dominance of activated macrophages/fibroblasts with a significant infiltration of activated T cells and an infiltration of granulocytes.  We do here suggest that both RA and CIA are dependent on a synergy between delayed type hypersensitivity and immune complex mediated inflammatory mechanisms and that CIA provides opportunities for studies of immunospecific reactions leading to arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThpC-SSrvRQ_9pSBfyDvp7fW6udTcc2eb1ztt-iUwtzbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1Mzit12htA%253D%253D&md5=30ef4460b144242f27184a74ce55b624</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fj.1699-0463.1989.tb00446.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1699-0463.1989.tb00446.x%26sid%3Dliteratum%253Aachs%26aulast%3DHolmdahl%26aufirst%3DR.%26aulast%3DAndersson%26aufirst%3DM.%2BE.%26aulast%3DGoldschmidt%26aufirst%3DT.%2BJ.%26aulast%3DJansson%26aufirst%3DL.%26aulast%3DKarlsson%26aufirst%3DM.%26aulast%3DMalmstr%25C3%25B6m%26aufirst%3DV.%26aulast%3DMo%26aufirst%3DJ.%26atitle%3DCollagen%2520induced%2520arthritis%2520as%2520an%2520experimental%2520model%2520for%2520rheumatoid%2520arthritis.%2520Immunogenetics%252C%2520pathogenesis%2520and%2520autoimmunity%26jtitle%3DAPMIS%26date%3D1989%26volume%3D97%26spage%3D575%26epage%3D584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Williams, R. O.</span><span> </span><span class="NLM_article-title">Collagen-induced arthritis as a model for rheumatoid arthritis</span> <span class="citation_source-journal">Methods Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">â</span> <span class="NLM_lpage">216</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm201454n&amp;key=15064442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm201454n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslGktbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2004&pages=207-216&author=R.+O.+Williams&title=Collagen-induced+arthritis+as+a+model+for+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Collagen-induced arthritis as a model for rheumatoid arthritis</span></div><div class="casAuthors">Williams, Richard O.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">Tumor Necrosis Factor</span>),
    <span class="NLM_cas:pages">207-216</span>CODEN:
                <span class="NLM_cas:coden">MMMEFN</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Collagen-induced arthritis (CIA) is an animal model of rheumatoid arthritis (RA) that is widely used to address questions of disease pathogenesis and to validate therapeutic targets.  Arthritis is normally induced in mice or rats by immunization with autologous or heterologous type II collagen in adjuvant.  Susceptibility to collagen-induced arthritis is strongly assocd. with major histocompatibility complex class II genes, and the development of arthritis is accompanied by a robust T- and B-cell response to type II collagen.  The chief pathol. features of CIA include a proliferative synovitis with infiltration of polymorphonuclear and mononuclear cells, pannus formation, cartilage degrdn., erosion of bone, and fibrosis.  As in RA, pro-inflammatory cytokines, such as tumor necrosis factor Î± (TNFÎ±) and interleukin (IL)-1Î², are abundantly expressed in the arthritic joints of mice with CIA, and blockade of these mols. results in a redn. of disease severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrFCOnX7gRn7Vg90H21EOLACvtfcHk0liYM6uLqXigsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslGktbs%253D&md5=c99965592d21a3aff8667aa1576a2c70</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DR.%2BO.%26atitle%3DCollagen-induced%2520arthritis%2520as%2520a%2520model%2520for%2520rheumatoid%2520arthritis%26jtitle%3DMethods%2520Mol.%2520Med.%26date%3D2004%26volume%3D98%26spage%3D207%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny-Diermayr, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hentze, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amalini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. W.</span><span> </span><span class="NLM_article-title">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1751</span><span class="NLM_x">â</span> <span class="NLM_lpage">1759</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1751-1759&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=C.+Y.+Huauthor=H.+Hentzeauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=Y.+K.+Lohauthor=L.+C.+Ongauthor=A.+D.+Williamauthor=A.+Leeauthor=A.+Poulsenauthor=R.+Jayaramanauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+W.+Wood&title=SB1518%2C+a+novel+macrocyclic+pyrimidine-based+JAK2+inhibitor+for+the+treatment+of+myeloid+and+lymphoid+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHu%26aufirst%3DC.%2BY.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BW.%26atitle%3DSB1518%252C%2520a%2520novel%2520macrocyclic%2520pyrimidine-based%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloid%2520and%2520lymphoid%2520malignancies%26jtitle%3DLeukemia%26date%3D2011%26volume%3D25%26spage%3D1751%26epage%3D1759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i117"><a href="/doi/suppl/10.1021/jm201454n">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_13076"></div></div></div></div></div><hr /></hr><p class="last">Explanation for CDK2 selectivity of <b>14i</b> versus <b>14h</b> and explanation for the CDK2 potency of 13 h. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm201454n/suppl_file/jm201454n_si_001.pdf">jm201454n_si_001.pdf (150.88 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm201454n&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-6%3Barticle%3Aarticle%3A10.1021%2Fjm201454n" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm201454n" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797a967b66a2ca","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
